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ABSTRACT 
This study was undertaken as part of the efforts of the South African AIDS Vaccine Initiative 
(SAAVI) to develop a locally relevant HIV-1 vaccine for southern Africa. The use of recombinant 
bacille Calmette-Guerin (rBCG) as a vaccine vector was followed for this work. 
The first part of this project was the selection of an HIV-1 isolate for use in the development of 
HIV-1 Gag vaccines targeted for South Africa. This was done following a sequence survey of 
representative, recently transmitted isolates obtained from different sites in South Africa. After 
deriving a South African subtype C gag gene consensus sequence from the viral sequences, 
isolate Du422 was chosen because it was most closely related to this consensus sequence. 
Du422 was found to be 98.7% related to the South African consensus sequence. In addition, it 
was 96% similar to the derived ancestral sequence and 97% similar to the derived consensus 
sequences for the whole of subtype C. An updated analysis using a larger database of 
sequences and an updated consensus sequence did not alter the close relationship it has to the 
consensus. implying that the selection was still relevant. Immunologically. Du422 was also a good 
choice for vaccine strain since the amino acid sequence contains T-cell epitopes recognized by 
southern African individuals infected with subtype C HIV-1. These epitopes were in regions of the 
gag gene with a limited ability to change and thus important for inclusion in a vaccine. 
The rBCG model was chosen for this study because it is inexpensive to produce. is heat stable 
and can induce long lived Immunity. Shuttle vectors for use In rBCG were constructed using the 
Du422 gag gene and evaluated for stability and Gag expression in vitro to determine which 
candldate(s) would be best suited for immunogenicity testing in mice. The gag gene from isolate 
Du422 was amplified and cloned in 8 different E.colUMycobacterium shuttle vectors which were 
either integrated into the host cell genome or were maintained episomally. The shuttle vectors 
tested four promoters - hsp60. M. leprae 18kDa, mtrA and katG - for Gag expression in 
combination with either the a-antigen signal sequence or the 19kDa lipoprotein signal sequence. 
Since genetic stability and good expression levels are paramount for generating a good immune 
Iv 
response from rBCG vaccines, the genetic stability of the shuttle vectors and expression of Gag 
were studied in M.smegmatis. Southern blotting of genomic DNA demonstrated that recombinant 
M.smegmatis (rMS) carrying Integrative vectors pRT1 01, pRT102, pRT103 and pRT104 were 
highly stable over - 40 generations, with no shuttle vector rearrangements identified. Restriction 
enzyme mapping of the shuttle vectors from recombinants carrying the episomal vectors pRT1OS, 
pRT106, pRT107 and pRT108 revealed that they were less stable over the same time period. 
Shuttle vectors contained deletions in the promoter/signal sequence region and in the gag gene. 
rMS:RT108 was found to be the most stable, while rMS:RT106 displayed moderate stability. 
rMS:RT105 lost stability completely within the same time period while rMS:RT107 retained only 
40% integrity. 
The Gag expression levels In these rMS cultures were also tracked and the results indicated that 
the integrative constructs had a low level of expression that was maintained. Three patterns were 
observed for the episomal constructs: high initial expression followed by a rapid decline in the 
levels of Gag in the culture, a moderate expression which dropped more slowly and a low but 
fairly constant expression level. The higher genetic stability of the integrative constructs was 
associated with the low level of expression. In general, the higher expression levels in the 
episomal constructs were associated with a more rapid accumulation of deletions and low genetic 
stability. These results were supported by an indirect evaluation of the constructs investigating 
the metabolic load placed on the recombinants by the expression of Gag. A high metabolic 
loadlhigh expression levels yielded smaller colonies and allowed the bacteria to survive heat 
shock at 42°C compared to recombinants carrying an empty vector. The reverse was true for the 
low expression levels. Based on these studies, the medium stabilitylhigh-moderate expresser 
pRT106 (mtrA promoter + 19kDa signal sequence) and the high stability/low expresser pRT108 
(katG promoter + 19kDa signal sequence) were selected for rBCG studies. 
The pRT106 and pRT108 shuttle vectors were introduced into BCG and the expression of Gag 
from the recombinants was evaluated in culture and in infected macrophages. Gag levels formed 
v 
a small percentage of the total protein in culture but transport of Gag to the cell surface was 
demonstrated for both constructs. Expression of Gag from rBCG:AT106 and AT108 Tokyo in 
macrophages was also successfully demonstrated. 
The immunogenicity of both rBCG:AT106 and rBCG:AT108 were evaluated in the BALBlc mouse 
model. A single inoculation of rBCG:AT106 (Pasteur) at 103 or 1t1 cfu induced BCG-specific IFN-
y and IL-4 responses in vaccinated mice. However, no Gag-specific IFN-y or IL-4 production or 
anti-p24 antibodies were detected. 
A DNA:Gag prime followed by a rBCG (AT106 or H PV -16 L 1) boost at 103 or 1 05 cfu, also yielded 
BCG-specific IFN-y and IL-4 production. Anti-p24 antibodies were detected in all groups of mice 
but production of these antibodies was not enhanced by rBCG boosting. Although IFN-y and IL-4 
were produced after Gag-specific peptide stimulation in all groups of mice, no significant 
difference was seen when comparing rBCG:AT106 boosted mice to rBCG:119L1e boosted mice 
when measured in an ex vivo ELiSPOT assay. However, when the memory response in these 
mice was tested in a cytokine bead assay (CBA), both CD8 and CD4 peptides elicited Gag-
specific IFN-a and TNF-a production and IL-4 and IL-5 were produced on stimulation with CD4 
peptides. The rBCG:Gag vaccine was an effective CD8 and CD4-specific boost for the DNA 
prime, particularly at the 103cfu dose of rBCG:Gag. Also apparent from both the ELiSPOT assay 
and the CBA was that rBCG inoculation had a suppressive effect on the response. 
rBCG:AT106 or rBCG:AT108 (Tokyo) were also able to generate both a cellular and a humoral 
response in the BALB/c mice model. Mice receiving 5 Inoculations of these recombinants 
generated Gag-specific T cells that produced IFN-y when stimulated with rp24 or Gag VLPs. In 
addition, anti-p24 antibodies were detected in the mouse sera. 
The results presented here are the first to demonstrate antigen-specific cellular and humoral 
immune responses in mice to rBCG expressing a subtype C gag gene. In addition, they 
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PART A: HIV VACCINES 
1.A.1. BACKGROUND 
The virus that we now know as human immunodeficiency virus or HIV-1 was first identified in the 
early 1980s (Barre-Sinoussi et a/., 1983; Popovic et a/., 1984). HIV-1 exhibited morphological and 
genetic characteristics typical of the Lentivirus genus of the Retroviridae family. Clavel et a/. 
(1986) discovered a related but immunologically distinct human retrovirus in individuals residing 
in several West African countries. This virus was less pathogenic than HIV-1 and was named 
HIV-2. Other lentiviruses have been isolated from several nonhuman primates (Hirsch et a/., 
1993). These viruses do not produce disease in the natural host and have been designated 
simian immunodeficiency virus (SIV). This literature review will focus on HIV-1, the virus 
responsible for the global pandemic. 
1.A.2. CLASSIFICATION OF HIV-1 
HIV-1 belongs to the Lentivirus genus, of the Family Retroviridae. HIV-1 is further subdivided into 
3 groups: M (major), 0 (outlier) and N (non-M, non-O). The M group accounts for more than 95% 
of infections and consists of a number of genetic subtypes or clades (A, B, C, D, F, G, H, J and K) 
based on the sequence of complete viral genomes. Viruses from group 0 have been isolated 
from individuals in Cameroon, Gabon and Equatorial Guinea and their genomes share less than 
50% nucleotide identity with group M viruses (Subbarao and Schochetman, 1996). Group N 
viruses were more recently identified in Cameroonians in 1998 (Simon et a/., 1998). A significant 
portion of group M viruses consists of intersubtype recombinants. These circulating recombinant 
forms (CRFs) make a significant contribution to circulating HIV-1 strains and are commonly 
identified in areas with multiple subtypes circulating such as Kenya, Uganda and Tanzania 
(Janssens et a/., 1997) and are responsible for major epidemics in regions such as Thailand 
(CRF01_AE; Subbarao at al., 2000) and West African (CRF02_AG; Morison at al .• 2001). An M/O 
intergroup recombinant has also been identified (Peeters at al., 1999). 
1.A.3. ORIGIN OF HIV-1 
The oldest known case of HIV-1 infection was from a 1959 plasma sample from the Democratic 
Republic of Congo (ORC; Zhu at al., 1998). Phylogenetic analysis of the viral sequence placed 
this virus near the ancestral node of subtypes Band 0 in group M and indicates that these 
subtypes (and possibly all group M viruses) evolved from a common ancestor in Africa. Using 
comprehensive full-length sequence alignment of the anv gene. Korber et al. (2000) estimated 
that the last common ancestor of group M HIV-1 to be 1931 (range 1915-1941). HIV-1 and HIV-2 
have been identified as zoonotic infections (Gao et al .• 1999). The primate reservoir of HIV-2 has 
been identified as Carcocabus atys, the sooty mangabey (Hirsh at al .• 1989; Gao at al., 1992; 
Chen et al., 1996 and 1997). Gao at al. (1999) identified two SIVcpz infected chimpanzee 
subspecies (Pan troglodytas troglodytes and P. t. schwainfurthil) infected with highly divergent. 
subspecies-specific lineages. They also showed that all HIV-1 strains are phylogenetically closely 
related to the SIVcpz strains that infect P.t. troglodytas. Their results argue that P.t. troglodytes is 
the primary reservoir for HIV-1 Group M. There have been at least 3 introductions of SIVcpz into 
humans from chimpanzees to yield Group M, Nand O. 
1.A.4. VIRION STUCTURE AND REPLICATION 
HIV-1 virions are spherical and about 110nm in diameter (fig 1.1). In the mature capsid the outer 
lipid envelope and associated glycoproteins surround the conical core. the Mg2+ -dependent 
reverse transcriptase (RT) and the RNA genome. Retroviruses carry two copies of the single-
stranded RNA genome that are each approximately 9.2kb in size. The three major coding regions 
on the genome encode structural proteins that are synthesized as polyprotein precursors (fig 1.2). 
These are processed by proteases (viral or cellular) into mature proteins (Barre-Sinoussi. 1996). 
The matrix (MA). capsid (CA). nucleocapsid (NC) and p6 proteins are derived from the 55kOa 
2 
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1.A.S. THE HIV EPIDEMIC 
1.A.S.1. THE SOUTH AFRICAN HIV·1 EPIDEMIC 
The estimated number of people living with AIDS in 2003 was 38 million (UNAIDS, 2004). Sixty-
six percent of infected people reside in sub-Saharan Africa with the highest prevalence occurring 
in the southern African region. In 2003, there were 4.8 million new HIV infections worldwide and 
2.9 million AIDS deaths (UNAIDS, 2004). The global epidemic is not homogenous and each 
country has wide variations in infection levels between different regions. 
Sub-Saharan Africa accounts for only 10% of the world's population, however more than 600k of 
all the people living with HIV are from this region (AIDS epidemic update: http://www.unaids.org). 
South Africa has the highest number of people living with HIV. estimated at 5.3 million; 2.9 million 
of which are women (Department of Health, SA, 2004). From 1990 to 1998. there was an 
exponential Increase In the prevalence of HIV in the South African population, however, the 5 
years following that period has seen a stabilisation of the prevalence (figure 1.5; Department of 
Health, SA, 2004). In 2003, the results from the 14th annual survey of pregnant women attending 
government antenatal clinics showed that the prevalence of HIV in SA was 27.9%. This increase 
from 26.5% in 2002 was not statistically significant and the report concluded that although the 
Infection rates remain high, the epidemic is still in a stabilization phase and are therefore not 
declining. The UNAIDS report cautions that epidemics that appear to be stable or in a 
stabilisation phase may in fact be indicative of more or less equal numbers of newly Infected 
people and people dying of AIDS (one-third of AIDS deaths world-wide occur in southern Africa; 
AIDS epidemic update: http://www.unalds.org) 
There Is a regional variation In the prevalence of infection with three provinces having prevalence 
rates higher than 30% - KwaZulu-Natal (37.5%), Mpumalanga (32.6%) and Free State (30.1%). 
The rate was between 13 and 17.5% in the Western Cape, Limpopo and Northern Cape 
prOvinces and it was found that the rate had risen in all but two provinces (Free State at 27.1% 
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GLOBAL DISTRIBUTION OF HIV-1 
SUBTYPES AND RECOMBINANTS 
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Central Africa have both subtype A and subtype D foci. Although the western and western Central 
regions are mainly CRF02_AG, a number of other recombinants are also circulating at a lower 
level. Central Africa has the most complex epidemic with no clear predominant subtype in 
circulation. 
1.A5.3. THE SUBTYPE C EPIDEMIC 
The rapid emergence and escalation of HIV-1 subtype C infections means that it now accounts 
for more than 56% of all global HIV infections (Esparza and Bhamarapravati, 2000). The HIV 
epidemic in southern Africa is predominantly a subtype C epidemic, with some regions having 
prevalence rates as high as 40% in pregnant women (Department of Health, SA, 2004). Over 
95% of infections in South Africa are a result of subtype C (SA; see section 2.1.2) and this 
subtype has been associated with major epidemics in Botswana (Bredell et al., 1998; Novitsky et 
al., 1999 and Ndung'u et al., 2000), Zambia (Handema et al., 2001; Morison et al., 2001 and 
Trask et al., 2002). Zimbabwe (Obi et al., 1997a and 1997b and Batra et al .• 2000). Malawi 
(Candotti et al .• 2001 and McCormack et al., 2002). Swaziland (Bredell et al., 1998). Lesotho 
(Bredell et al., 1998) and Mozambique (Bredell et al., 1998; Engelbrecht et al., 1998 and Downing 
et al., 2000). Studies also suggest that subtype C has begun spreading further north into 
countries like the Congo, Tanzania, Burundi and Kenya (Zachar et al., 1996; Janssens et al .• 
1997 and Koch et al., 2001; Rodenburg etal., 2001). 
The epidemic in India is also predominantly subtype C (Shankarappa et al., 2001), while Brazil 
(Gao et al., 1998 and Soares et al., 2003a and 2003b) and China (Yu et al., 1998 and Rodenburg 
et al., 2001) are isolating subtype C viruses with increasing frequency. Intersubtype recombinants 
with subtype C have also been isolated in several countries: CID in Tanzania (Hoelscher et al., 
2001) and CIB in India (Rodenburg et al .• 2001) and China (Yang et al., 2002 and 2003). 
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Subtype C Epidemic in South Africa 
In the early 1980s the homosexual population was the group most affected by the AIDS epidemic 
with HIV moving into the heterosexual in the late 1980s (Sher, 1989; Kustner, at a/. 1994). In 
1995, Williamson at a/., found that the homosexual men recruited into their study were infected 
with mainly subtype B viruses (15 of 20), while the majority of heterosexual individuals were 
infected with subtype C viruses (28 of 33). This apparent association between mode of 
transmission and HIV-1 subtype was confirmed by van Harmalen at a/. (1997). 
Isolates from migrant workers in three SA gold mines were all shown to be subtype C but the 
heterogeneity of the sequences suggested that multiple introductions of subtype C occurred in 
this population (Bredell at a/., 1998). In a study using 107 samples from 4 different provinces in 
South Africa, it was concluded that subtype C was responsible for the vast majority of 
heterosexual infections and no evidence of a clonal epidemic could be detected (van Harmelen at 
a/., 1999). Full-length genome sequencing studies have also shown that there is little intersubtype 
recombination (van Harmelen, 2001; Papathanasopoulos, 2002). 
The predominance of subtype C in SA has been well established however non-subtype Cs have 
been identified, including some intersubtype recombinants. Among ten viruses studied in the gag 
and anv region, Bredell at a/. (2002) identified four recombinants of which one was unclassified 
env (CIA. C/D, G/A and D/un). There was evidence of a local recombination event since a 
subtype A and a subtype G fragment were shown to be in combination with subtype C. Also, 
three viruses containing subtype G sequences and a CRF02_AG-like virus not previously isolated 
in South Africa were Identified. Another virus contained a sequence fragment that could not be 
Identified. Papathanasopoulos at a/. (2002) identified a novel recombinant between subsubtype 
A2 and subtype C as well as a complex recombinant containing segments from subtypes A, C, 0, 
G and K. The novel A2/C recombinant was isolated from a female sex worker in Durban and thus 
requires careful monitoring since it is in a high transmission setting. 
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Dual infections with two phylogenetically distinct strains of HIV-1 subtype C have been identified 
in South Africa. Grobler et a/. (2004) showed that within 3 months of infection 19% of the women 
in the study were dually infected and that this dual Infection was associated with an increased 
viral load set pOint. 
Possible factors aiding the spread of HIV·1 subtype C 
The factors allowing for this devastating spread of subtype C are not completely understood but 
are thought to relate to the host, the virus and socioeconomic conditions in affected countries 
(Gordon at a/., 2003). Viral factors which have been suggested for the rapid spread of subtype C 
Include an extra NFkB binding site in the promoter region of the L TR which may represent an 
adaptive advantage for subtype C viruses since it represents an increased capacity for TNF-a. 
responsiveness (Montano at a/., 2000). TNF-a. is a proinflammatory cytokine that has been 
shown to enhance H IV-1 gene expression (Matsuyama et a/., 1991). Montano at a/. (2000) 
speculate that this TNF-a.-linked transcription may increase the viral load in transmission fluids 
and thereby increase the probability of transmission and the pathogenesis of subtype C viruses. 
Velazquez-Campoy at a/. (2001) have suggested that subtype C viruses are more viable since 
their proteases have greater catalytic efficiency than other subtypes. 
The ax vivo fitness of 9 subtype B strains with 6 subtype C strains were compared by measuring 
the infection rate/host cell entry in a number of cell types using a pairwise competition experiment 
(Ball at a/., 2003). The authors found that in PBMC, CD4+ lymphocytes and blood-derived 
mac rophages , subtype B isolates outcompeted the subtype C isolates. In skin-derived 
Langerhans cells, however, the rate of host cell entry was the same for both the C and B isolates. 
Infection of Langerhans cells provides a model for primary HIV-1 infection in the genital tract and 
thus virus transmission, while T cells and macrophages are cells that become infected in later 
stages of disease (Ball at a/., 2003). This implies that subtype C isolates may be transmitted as 
efficiently as subtype B isolates (Langerhans cell data) but that they are less fit during further 
disease progression (T-cell and macrophage data). 
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Another difference between subtype C and other subtypes is that subtype C isolates use the 
CCR5 coreceptor almost exclusively throughout infection and that CXCR4 coreceptor usage is 
rare (Abebe et al., 1999; Ping et al., 1999; Cecilia et al., 2000 and Morris et al., 2001 a). These 
reports implied that subtype C viruses may have envelope proteins that are atypical in structure 
or function compared to viruses of other subtypes and that these differences could provide an 
explanation as to why subtype C viruses are spreading so rapidly. However, it has been shown 
more recently that subtype C envelope proteins can accommodate the necessary amino acid 
changes to use CXCR4 as a coreceptor and, in patients with advanced AIDS, CXCR4-using 
subtype C viruses could be isolated (Cilliers et al., 2003). 
Subtype C viruses have other characteristics that differ from the non-C subtypes including a 
subtype-specific insertion in the transmembrane region of Vpu (McCormick-Davis et al., 2000), a 
prematurely truncated second exon in rev (Rodenburg et al., 2001) and increased natural amino 
acid variability in protease cleavage sites (de Oliveira et al., 2003). 
Immune response to HIV-1 subtype C In southern African Individuals 
The genetic background of the local population, as well as the immunogen, can impact the 
immune response to the virus and to a vaccine candidate. It is thus important for vaccine design 
to characterize the Circulating viruses on an epidemiological level and to investigate the immune 
responses to these viruses in infected individuals. Many of the early studies investigating the 
immune response to HIV-1 have been in individuals infected with subtype B viruses. However, 
there have been a number of recent reports from groups working on subtype C in southern Africa 
that have shed light on the immune response to subtype C viruses. 
Goulder et al. (2000) studied Gag-specific CTL responses in subtype B infected Caucasoids 
versus subtype C infected African and found that the two-thirds of the dominant responses 
mapped to 3 peptldes In the p17 and p24 region, irrespective of the subtype, ethnicity or age of 
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the group studied. However, they did find that the Caucasoid response was predominantly in p17 
while the predominant response in Africans was in p24. This difference is a result of different 
dominant HLAs in the different populations. Detailed analysis of subtype C-specific CTL 
responses in infected blood donors in Botswana allowed the identification of immunodominant 
regions within Gag, Tat, Rev and Nef (Novitsky et al., 2001). As in the study by Goulder et al. 
(2000), the dominant Gag-specific responses were in the p24 region. The data on Tat- and Rev-
specific responses indicated distinctive differences in the pattern of immunodominance in these 
regions when comparing responses among subtype B infected people with subtype C infected 
people from Botswana (Novitsky et al., 2001). When the CTL responses were investigated for the 
entire genome, the analysis showed that the magnitudes and frequencies of the responses were 
spread unevenly (Novitsky et al., 2002a). The strongest responses were found in the p24, Vpr, 
Tat and Nef regions with less robust responses distributed in other regions of p24, Tat and Nef as 
well as in Pol, Vif and Env. 
Defining responses associated with control of viral replication is important for designing 
immunogens which should be included in candidate vaccines. An association between plasma 
viral load and HIV-specific CTL responses has been demonstrated for subtype C infections 
(Novitsky et al., 2003). For p24, better CTL responses were detected in individuals with lower 
viral loads but the opposite was true for Nef-specific responses. These results were confirmed in 
a study to determine the relationship between the breadth and magnitude of T-cell responses and 
viral loads in subtype C-infected individuals in southern Africa (Masemola et al., 2004a). In this 
study, Nef was targeted in almost a third of the responses across the genome, while the next 
most frequently targeted was p24, which comprised of 17% of the responses. Although there was 
no correlation between the breadth of the responses and the viral load, there was a weak positive 
correlation between the total magnitude of the responses and the viral load. When investigating 
the hierarchy of the responses, they found that preferential targeting of Gag correlated with viral 
control. Thus targeting of Gag during early stages of infection with subtype C virus Is associated 
with viral control and may be a useful marker of immune efficacy and in vaccine assessment. 
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When screening 38 individuals from KwaZulu-Natal, South Africa with recent subtype C 
infections, 74% of them recognized at least 1 Gag peptide pool and 10 epitopic regions were 
identified across p17, p24 and p2p7p1p6 (Masemola et a/., 2004b). These regions were found to 
be highly conserved and fine epitope mapping revealed that 5 of the identified optimal Gag 
epitopes were novel. 
Novitsky et a/. (2003) reported that lower viral loads were associated with the HLA B44 supertype 
and, in the study by Masemola et a/. (2004b), the defined optimal epitopes were restricted by 
more than one HLA allele. The epitopes did overlap with regions that contain previously 
described epitopes from subtype B infections and the authors suggest that these results add 
weight to the hypothesis that HLA diversity can shape epitope identity but may not be a constraint 
for universal recognition of Gag in highly conserved domains (Masemola et a/., 2004b). 
The neutralizing activity of sera from HIV-1 infected individuals seems to be independent of 
genetic subtype implying that, in general, there is no relationship between subtype and 
neutralization serotype (Kostrikis et a/., 1996 and Weber et a/., 1996). The neutralization 
properties of subtype C viruses from South Africa and Malawi were shown to be similar to 
subtype B virus isolates in both their resistance to inhibition by soluble CD4 and their sensitivity to 
neutralization by the G1b12 monoclonal antibody (Bures, et a/., 2002). However, 2F5, another 
monoclonal antibody that neutralizes subtype B viruses, was only effective against two of sixteen 
subtype C isolates in this study. In addition, all sixteen subtype C isolates were shown to be 
resistant to neutralization by the 2G12 monoclonal antibody. 
Although the neutralizing antibody response was slow to mature following primary infection with 
subtype C viruses in South Africa, the eventual response not only neutralized autologous virus 
but showed extensive cross-neutralization of heterologous subtype C viruses from South Africa. 
This implies a geographic clustering of neutralization serotypes in South Africa meaning that 
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there are a number of shared neutralization determinants at a regional level in South Africa 
(Bures, at al., 2002). 
While most of the serum samples had subtype-specifiC neutralization activity, two of them 
neutralized a broad range of both subtype Band C isolates; indicating that subtypes Band C 
could be made up of multiple neutralization serotypes with varying levels of subtype-specificity. 
The observation that SA subtype C isolates have clusters of shared neutralization determinants 
could mean that vaccine-induced neutralizing antibodies will have a lower level of epitope 
diversity to overcome at a regional level (Bures, et al., 2002). 
1.A.6. CORRELATES OF PROTECTION 
HIV establishes a persistent and chronic infection. HIV infection is not cleared by the host 
immune system nor does natural immunity to reinfection by HIV develop. It has been suggested, 
however, that since superinfection seems to be rare, natural immunity due to an initial HIV 
infection might inhibit the establishment of a superinfection by another HIV (Gottlieb et al., 2004). 
Natural control of infection and control by vaccination are due, in general, to adaptive immune 
responses in the form of neutralizing antibodies and virus-specific T cells (CD4+ and CD8+). 
While neutralizing antibodies protect from infection, cell-mediated immunity protects from disease 
or controls the Infection. 
1.A.6.1. CYTOTOXIC T lYMPHOCYTES (eTls) 
The focus has shifted in recent years to producing anti-HIV CTL or CD8+ T cell inducing 
vaccines, due in part to the difficulties facing researchers in the development of AIDS vaccines 
that elicit a strong neutralizing antibody response. The first phase III trial which tests T-cell 
inducing vaccine prime (canary pox vaccine vector) and gp120 monomer boost is currently 
underway in Thailand and results from these trials may determine whether this line of reasoning 
is sound (see section 1.7), bearing in mind that responses to canary pox vaccines are not very 
immunogenic (Cao et al., 2003). 
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The natural HIV CTL response and control of the virus 
HIV-specific CTLs are able to lyse target cells via apoptosis (Yang at a/., 1996), secrete cytokines 
such as IFN-yand TNF-a that induce an antiviral effect in infected cells or secrete chemokines 
such as CCl3 and CCl4 that block coreceptor molecules and prevent HIV entry into cells 
(Rubbert at a/., 1997; Wagner at a/., 1998; Garzino-Demo at a/., 1998 and Appay at a/., 2000). 
Although high levels of HIV-specific CTls are associated with control of viral load following acute 
infection (Koup et a/., 1994 and Borrow at a/., 1994), they fail to control the virus effectively during 
the entire course of an untreated infection. A significant inverse correlation was observed 
between HIV Gag- and Pol-specific CTl frequency and plasma RNA viral load in individuals at 
different stages of disease (Ogg at a/., 1998). However, more recent analysis of total HIV-specific 
T-cell responses indicated that there is actually a positive correlation between the plasma viral 
load and the total HIV-specific CTl frequency (Betts at al., 2001). A comprehensive epitope 
analysis of T-cell responses directed against the entire expressed HIV-1 genome also showed 
that neither the breadth nor the magnitude of the total HIV-1-specific CTl responses correlated 
with plasma viral load (Addo et a/., 2003). HIV-specific CD8+ T cell proliferation and enhanced 
effector function in asymptomatic infected people is coupled to pertorin expression (Migueles et 
a/., 2002). However, most antiviral CD8+ T cells do not express high levels of pertonn during 
chronic viral infection and are not directly cytotoxic (Zhang at a/., 2003). These results imply that 
not all HIV-specific CTls that are detected in vitro have in vivo functionality and may point to an 
explanation for the fact that certain viral epitopes remain unchanged in infected individuals 
despite the ex vivo detection of perSistent responses to that epitope (Altman and Feinberg, 2004). 
There are a number of possible reasons why the HIV-specific CTls seen during acute infection 
are unable to maintain control of replication at later stages of infection. One of the reasons is the 
plasticity of the HIV genome - the virus readily generates CTl escape mutants carrying changes 
in immunodominant epitopes and their flanking regions (Phillips et a/., 1991; Borrow at a/., 1997; 
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Goulder et a/., 1997; Evans at a/., 1999; Allen at a/., 2000; Barouch et a/., 2002 and Draenert at 
a/. 2004). Primary cells infected with HIV-1 are not lysed efficiently by CTls in the presence of the 
Nef protein, since its expression results in the downregulation of HlA class I expression (COllins 
at a/., 1998). HIV-1 Rev protein activity may be associated with a decreased susceptibility of HIV-
infected cells to CTl-mediated killing (Bobbit et a/., 2003). Although, the majority of circulating 
HIV-specific CD8(+) T cells were able to the secrete of antiviral cytoklnes in response to antigen. 
they are impaired In cytolytic activity (Appay at a/., 2000). Also maturation of HIV-specific memory 
CD8+ T cells during HIV Infection is defective (Champagne at a/., 2001). Further compounding 
the problem and of extreme importance is the fact that CD4+ T cells are preferentially infected 
and killed by HIV which means there is insufficient T cell help to maintain CD8+ T cell function 
(McCune, 2001, Ribeiro at a/., 2002 and Douek at a/., 2002). 
A vacclne·lnduced CTL response could control the virus 
There is evidence that supports the contention that a CTl-response is an important correlate of 
protection against HIV and that it will be important for an effective vaccine to generate such 
responses. These are reviewed below: 
long-term non-progressors (lTNPs) 
Virus-specific CTls that are present in l TNPs maintain a high proliferative capacity which is 
linked to enhanced effector function (Migueles at a/., 2002). This is in contrast to the situation in 
normal progressors. Although early studies by Harrer at a/. (1996a and b) suggested that a 
vigorous in vivo HIV-1-specific CTl response was responsible for the control of viral replication in 
stable non progressive HIV-1 infection, Addo at a/. (2004), found that when responses in 80 
l TNPs were compared to 24 untreated HIV-1 progressors, no statistically Significant differences 
were observed in breadth and magnitude of HIV-1-specific CTl responses. Additionally, some of 
the l TNPs with lowest viral loads also exhibited the lowest levels of CTls. What these results 
imply is that the virus-specific CTl responses were related to the level of antigen rather than 
functioning to suppress virus replication. 
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However, the importance CTL is implied in studies which should an association between HLA and 
disease progression. Delayed progression to AIDS is also linked to a greater HLA class I gene 
diversity and furthermore certain HLA alleles have been associated with slow or rapid progression 
(Tang et a/., 1999; Carrington at a/., 1999 and Costello at a/., 1999). A significantly greater 
number of CTL responses were HLA-B-restricted, compared to HLA-A in 375 HIV-1 infected 
individuals from southern African (Kiepiela et a/., 2004). The rate of disease progression in the 
cohort was strongly associated with HLA-B but not HLA-A allele expression and more selection 
pressure was exerted on HIV-1 by HLA-B alleles than HLA-A alleles. The group concluded that 
the main focus of HIV-specific activity was thus at the HLA-B locus and that HLA-B gene 
frequencies in the population were most likely to be influenced by HIV disease. This is consistent 
with the observation that B alleles evolve more rapidly than A alleles. 
Highly exposed seronegative individuals 
Studies on cohorts of highly HIV-exposed but seronegative individuals lend support to the 
relevance of the CTL-vaccine effort. Low-level HIV-specific CTL responses are detected in these 
individuals: in a group health-care workers (HCW) exposed to HIV contaminated blood, lack of 
subsequent infection appeared to result in the activation of cellular immunity without activation of 
antibody production (Clerici at a/., 1994); in another group of exposed, seronegative HCW, Env-
specific CTL responses were detected (Pinto at a/., 1995); CTL responses to HIV epitopes were 
also detected in exposed seronegative women from Nairobi and Gambia (Rowland-Jones et a/. 
1995 and 1998 and Kaul et a/., 2000 and 2001a). It is suggested that these CTL responses are 
conferring relative resistance to infection in these people. In one of these cohorts - a group of 
highly exposed, seemingly HIV-resistant female sex workers from Nairobi - late seroconversion 
occurred after longer term follow-up (Kaul at a/., 2001 b). This late seroconversion may be 
associated with the waning of HIV-specific CTL responses due to reduced antigenic exposure as 
a result of a break from sex work (Kaul at a/., 2001b). In two other cohorts of exposed but 
persistently seronegative men, virus-specific CTL responses were not detected and the protective 
action of these responses remains unconfirmed (Schmechel et a/., 2001 and Yang et a/., 2002). 
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CTLs and viral load 
The viral load set point is a strong predictor of the rate of progression to AIDS after HIV-1 
seroconversion, with the higher the set point the more rapid the progression (Mellors et al., 1995). 
The viral load is also the chief predictor of the risk of heterosexual transmission of HIV-1 (Quinn 
at al., 2000 and Gray et al., 2001). Studies in HIV-infected humans and SIV-infected macaques 
have demonstrated that HIV-specific CTL activity is associated with initial control of primary virus 
replication (Koup et a/., 1994; Borrow at al., 1994; Reimann et al., 1994 and Kuroda at al., 1999). 
The selection of CTL-escape mutants in HIV and SIV infection also occurs at the time of maximal 
CTL responses which is during primary viraemia (Phillips at al., 1991; Borrow at al., 1997; Price 
at al., 1997; Evans at al., 1999 and Allen at al., 2000). 
Compelling support for the role of CTLs in the control of HIV replication comes from experiments 
in SIV-infected macaques that have been depleted of CD8+ T cells. during either acute or chronic 
infection. These animals were unable to control infection and a dramatic increase in the level of 
viraemia was observed (Matano et a/., 1998; Schmitz at al., 1999 and Jin at al .• 1999). Vaccine-
induced responses in the macaque model have been shown to be partially protective against a 
SHIV-89.6P challenge (Amara et al .• 2001 and Shiver et al., 2002). The reduction in viral load in 
these animals was inversely correlated to the virus-specific CTL response and the magnitude of 
reduction in viremia in the animals was predicted by the magnitude of the vaccine-elicited CTL 
response prior to SIV challenge (Seth et al .• 2000 and Ourmanov at al .• 2000). Importantly. it was 
reported that 22 out of 23 of the vaccinated animals (Amara at al., 2001) wera able to 
successfully control their viremia until their time of euthanasia at 200 weeks postchallenge 
(Sadagopal et al., 2005). The animals had low to undetectable viral loads, normal CD4 counts 
and stable T-cell responses. In addition, high titers of binding and neutralizing antibody persisted 
throughout the postchallenge period and long-term control was effective in macaques of diverse 
HLA types (Sadagopal et al .• 2005). 
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What to expect from an HIV-1 CTL-Induclng vaccine 
It is necessary to determine the difference between natural and vaccine-elicited responses in 
order to facilitate the development of an effective AIDS vaccine. In humans, the virus 
preferentially infects and kills HIV-specific CD4+ T cells resulting in a lack of appropriate T-cell 
help, which in tum cripples the virus-specific CTl response (McCune et al., 2001, Ribeiro et al., 
2002 and Douek et al., 2002). Vaccination with a Cll-based vaccine is expected to yield a pool 
of fully functional HIV-specific CD4+ T helper cells prior to infection that would result in the 
maintenance of CD8+ T cell proliferation and function in the post-infection state. The immune 
system would thus receive a head start in its efforts to control viral replication since the recall 
response would be quicker compared to a naive response. 
It will also be important for a vaccine to elicit a sizable pool of long-lasting memory CD4+ and 
CD8+ T cells. The murine lCMV infection model has demonstrated that CD8+ T memory cells 
are more protective against a second lCMV challenge than CD8+ T effector cells and, 
importantly, that a break from antigen exposure is necessary to achieve complete differentiation 
of virus-specific memory T-cells (Wherry et al., 2004). However, an HIV vaccine would induce 
HIV-specific CD4+ T cell production and the exposure to HIV antigen would be transient in 
vaccinees, so if there is a higher probability that virus-specific memory T cells would develop. A 
pool of vaccine-induced HIV-specific memory CD8+ T cells of sufficient size and consisting of 
fully-differentiated cells available at the time of natural infection should limit viral replication and 
damage -- this would lead to increased levels of virus-specific CD8+ T cells with enhanced 
antiviral capacity being available at the chronic infection stage (Garber et al., 2004a). 
1.A.6.2. NEUTRALIZING ANTIBODIES 
The HIV envelope is a difficult target for antibody neutralization and the efforts to develop 
immunogens that elicit high titre neutralizing antibodies have not borne fruit thus far. Although 
there are conserved structures on the viral envelope glycoproteins, the virus has evolved to 
evade the neutralizing antibody response (Wyatt and Sodroski, 1998). The gp160 glycoprotein 
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precursor is proteolytically cleaved to produce the envelope glycoproteins, gp120 (surface) and 
gp41 (transmembrane) (Earl, at al., 1991). The envelope is composed of homotrimer consisting of 
gp120-gp41 heterodimers (Earl, et al., 1991). The surface glycoprotein consists of five 
hypervariable loops interspersed with five conserved regions and its surface is heavily 
glycosylated (Freed and Martin, 2001). The conserved Env core, containing critical neutralization 
epitopes such as the binding site for the CD4 and CCR5 receptors, are shielded by these surface 
exposed hypervariable loops and the glycosylation of gp120 (Wyatt et al., 1998). Kwong at al. 
(2002) demonstrated that conformational changes are necessary to expose the CCR5 binding 
site on gp120 and that this conformational masking is a further mechanism preventing antibody 
binding to that region of gp120. 
Natural antibody responses to HIV 
During the course of an HIV infection, neutralizing antibodies directed against the envelope are 
made (Wei et al., 2003 and Richman et al., 2003). However, there is immediate selection for viral 
escape mutants and neutralization-resistant viruses eventually predominate, therefore the effects 
of these antibodies are transient (Wei at al., 2003 and Richman at al., 2003). Human monoclonal 
antibodies have been isolated from the sera of a number of HIV-infected individuals and these 
antibodies are capable of neutralizing a variety of primary isolates and laboratory-adapted strains 
(Posner et al., 1991; Ho at al., 1991a and 1991b; Thali at al., 1992 and Trkola et al., 1996). These 
monoclonal antibodies recognize conserved epitopes of gp120 and gp41 using various structural 
features. The monoclonal antibody b12 has a protruding, finger-like domain that penetrates the 
recessed CD4-binding site of gp120 (Saphire et al., 2001). Another monoclonal antibody, 2G12, 
neutralizes a broad range of HIV-1 isolates by binding an unusually dense cluster of carbohydrate 
moieties on gp120 using a unique interdigitation of Fab domains (Calarese et al., 2003). Other 
monoclonal antibodies that are broadly neutralizing target relatively conserved domains in gp41. 
Examples include 4E10 and 2F5 which inhibit the virus-cell fusion process (Zwick at al., 2001 and 
Muster et al., 1993). 
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Protection from infection by passive transfusion of neutralizing antibodies 
Convincing evidence of the protective effect of neutralizing antibodies has been provided by a 
non-human primate prophylactic treatment model whereby recombinant forms of monoclonal 
antibodies were passively delivered prior to challenge. Purified immunoglobulin from 
chimpanzees infected with several different HIV-1 isolates was used for passive immunization of 
macaques (Shibata et al., 1999). The immunized animals were able to completely block infection 
after a challenge with pathogenic SHIV. Similarly, passive intravenous transfer of the monoclonal 
antibody b12 was shown to protect macaques from a vaginal challenge with a CCR5-using SHIV 
(Parren et al., 2001). Topical vaginal administration of the b12 antibody was also shown to prolect 
macaques from SHIV infection through the vagina in a dose-dependent manner (Veazey et al., 
2003). 
Potentially high manufacturing costs for the amount of antibody and the number of doses required 
to achieve protection, and longevity of this protection will likely limit the practicality of these 
approaches in humans (Garber et al., 2004a). Current vaccine efforts have been undertaken to 
design immunogens that can elicit similarly broadly neutralizing antibodies in vivo (Burton et al., 
2004). Designing immunogens which mimic the mature trimeric form located on the virions, as 
well as modified versions which mimic the 'open conformation' or 'triggered' env structure which 
exposes hidden neutralizing epitopes, has proven problematic. A number of approaches are 
under investigation including stripping glycosylations sites or deleting variable loops that shield 
useful epitopes (Johnson et al., 2001 and Srivastava et al., 2003), presenting on surface of 
pseudovirions or proteoliposomes (Yang et al., 2001; Grundner et al., 2002), cross-linking to 
generate stable intermediates of the entry process (Fouts et al., 2002) and linking to CD4 
mimotopes (Dorgham et al., 2005). To date, none of these strategies have managed to elicit 
broadly neutralizing antibodies. 
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1.A.7. CURRENT PROSPECTS FORAN AIDS VACCINE 
1.A.7.1. POSSIBLE OUTCOMES OF VACCINATION AGAINST HIV 
Vaccination against HIV could result in a number of potential outcomes. Since the virus integrates 
into the host cell genome, complete elimination of the virus or sterilizing immunity may not be 
possible. For first generation vaccines, a more realistic target for a successful vaccine may be 
long-term control of the virus. This would be either in the form of a transient infection or a 
controlled infection. With a transient infection, low levels of HIV would be detected following 
exposure but virus replication would be suppressed after an initial peak. In a controlled infection 
scenario, the viral set point would drop to a low or undetectable level after the acute phase and 
remain there. Vaccination with these outcomes would hopefully reduce the viral load in infected 
individuals to a level that results in a slower disease progression and also reduces the rate of viral 
transmission. 
Massad at a/. (2001) developed a mathematical model for the impact of partially protective HIV 
vaccines on the incidence of infection. This model predicted that even the poorest vaccine 
candidates should have an impact on the reduction of virus transmission even when high risk 
behaviour increased. Davenport at a/. (2004) developed an age-structured epidemiological model 
of the effects of a disease-modifying vaccine. Their results suggest that the key predictor of 
vaccine efficacy is the extent of viral load reduction in vaccinated individuals - a one log reduction 
in viral load would significantly reduce HIV-associated mortality. 
1.A.7.2. ONGOING CLINICAL TRIALS OF HIV VACCINES 
The developing world carries the weight of the AIDS pandemic burden and antiretroviral therapy 
does not provide a long term solution to controlling the epidemic. There is thus an urgent need to 
develop an effective and inexpensive prophylactic vaccine against HIV-1. Recently, the results of 
the first two phase III trials of a gp120 subunit vaccine (AIDSVAX) were reported (Cao at a/., 
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2003). These studies showed the lack of protective efficacy of the envelope vaccine, but this was 
not unexpected since AIDSVAX does not induce neutralizing antibodies. There are, however, 
more than 30 ongoing clinical trials of HIV-1 preventive vaccines (Table 1.2; http://www.iavi.orgl). 
These trials are phase I for the most part and are thus designed to test safety and to generate 
preliminary immunogenicity data for the different candidates. 
The trials which are underway are a clear indication of the current breadth of innovation in vector 
design and vaccine approaches. Much progress has been made in eliciting HIV-specific CD4+ 
and CD8+ responses using these candidate vaccines in animal models (Amara et al., 2001; 
Shiver at al., 2002; Barouch at al., 2000 and 2001, Matano at al., 2001; Chen at al., 2001; Rose 
at al., 2001 and Davis et al., 2002) and human trials are necessary to test the validity of the CTL-
based vaccines against HIV infection. 
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Table 1.2. Ongoing Trials of Preventive HIV Vaccines [Last updated: 7 February. 2005; http://www.layl.org] 
Trial Sponsor Start Sites 
Vacdne Antigen Clade Comment 
No. Manufacturer Date (No.) 
Phase III (Large-slze trials in high-risk populations; test vacdne efficacy) 
WRAIR, ALVAC env(E), 16,000 healthy 
N/A AFRIMS. MoH; 
October Thailand vCP1521 gag/pol (B) B,EB, normalHIV 
Aventis. VaxGen 2003 
(several) AIDSVAXBlE env(B, E) E negative adult 
volunteers 
Phase II (Mid-size bials In low- • high-risk populations; test vaccine safety, Immunogenldty) 
US (12), To test whether 
Canada (1), cellular immune 
HVTN 
Peru (2), response 
5021 HVTN, Merck; December 
Dominican MRKAd5 HIV-1 generated by 
Merck Merck 2004 
Republic (1), gaglpoVnef gag, pot, nef B Merck's vaccine is 
Haiti (1), potent enough to 
023 Puerto Rico impact infection 
(1), Australia with HIV In 1,500 
(1) at-risk volunteers 
5 
lipopeptldes CompareCD8 
ANRS ANRS; Aventls September France (6) LlP0-5 
containing B response of 3 
VAC 18 2004 CTL epitopes doses of LIPO-5 
(from Gag, versus placebo 
Pol, Net) 
gag + 25 
IAVI010 IAVI; KAVI 
February UK; Kenya DNA.HIVA 
CTL epitopes 
AA HIV-DNA +/-MVA 2003 MVA.HIVA gag + 25 
CTLepltopes boost 
Phase I D (Mid-sized trials In low-risk populations; test vaccine safety, Immunogenlclty) 
To evaluate safety 
and 
HVTN LlPO-5 immunogenlcity of 
0421 HVTN,ANRS; June 2004 US (13) ALVAC-HIV 
See above BB LlPO-5 alone, 







nef, rev, tat, GTU-MuItIHIV 
GTU- FIT Biotech 
February Finland 
GTU-MultiHIV 
gag, pot, env, B clade B DNA after 
MultiHIV 2004 B clade intradermal and CTL epitopes intramuscular 
injection. 
Phase IB, safety, 
HVTN HVTN; Vlcal 
December US (10) 
VRC-HIVDNA- gag, pot, nef BA,B,C immunogenicity of 
052 2003 oo9-0O-VP env multiclade DNA 
Vaccine 
gag, RT, rev, 
NlA UNSW;AVC June 2003 Australia 
pHIS-HIV-B tat, vpu, env 
BB 
DNA Vaccine + 
rFPV-HIV-B gag, RT, rev, fowlpox boost 
tat, vpu env 
Phase I (Small trials In low-risk populations; test vaccine safety, Immunogenlclty) 
Safety, 
IAVI IAVI;IDT 
January US (2) ADMVA env/gag-pol, C 
immunogenicity of 







NIAID, VRC 2004 US (12) HIVADV014-
polyprotein BA,B,C VP, when given as 




HVTN NIAID, AlphaVax 
October US (5) AVX101 (VEE) gag C 
immunogenicity of 
059 2004 an alphavirus 
repllcon 
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Table 1.2. Ongoing Trials of Preventive HIVVacclnes, continued 
Safety, 
VRC August VRC- gag, pol, nef BA, B, Immunogenlcity of 007 (04- NIAIDNRC US (1) HIVDNA016- a 6-plasmld 
1-0254) 2004 OO-VP env C multlclade HIV-1 
DNA vaccine 
Trial Sponsor Start Sites Vaccine Antigen Clade Comment No. Manufacturer Date (No.) 
TBC-M358 
Safety, (MVA)TBC- env, gag tat, 
HVTN NIAID; Therion M335 (MVA) /ltV, nef, RT 
immunogenlcity of 
055 July 2004 US (6) TBC-F357 env, gag tat, BBBB MVA-HIVand 
(FPV) TBC- /ltV, nef, RT rFPV-HIV alone or 
F349"(FPV) In combination. 
4 Safety and IIpopeptldes Immunogenicity of 
ANRS ANRS; Biovedor L1PO-4T containing IIpopeptides LI PO-July 2004 France (6) CTl epltopes B VAC 16 SA (lPHIV-1) (from Gag, 4T, by two 
Pol-RT, Pol, administration 
Nef) routes. 
Safety, tolerability, 
VRC VRC- gaglpol Immune response of a multiclade HIV 006(04- NIAID; GenVec May 2004 US HIVADV014- polyprotein BA,B,C adenoviral vector 1-0172) OO-VP env vaccine In 
uninfeded adults. 
18 health 
Anthrax- volunteers. Aim: 
AVANT; NIAID; derived inducing strong NJA WRAIR May 2004 US lFn-p24 polypeptide B and persistent lFn gagp24 HIV-1 gag specific 
protein CD8 TCeIl 
responses. 
Safety of and 
HVTN 
CTl epltopes Immune response 
056 
NIAID, Wyeth April 2004 US (7) HIVCTlMEP from envor B toa newHIV 
gag vaccine: HIV CTl 
MEP 
DNA prime: 1 gag 
gag + 5 env gene (C) + 5 env 
DNA 5 A,B,C,E genes (A, 2 B, C, NJA UMMS;ABl April 2004 US Proteins recombinant A,B,C,E E). Boost: 5 gp120 
gp120 (same Isolates as DNA). Adjuvant: 
QS21. 
HVTN Thailand, Replication 
0501 NIAID; Merck January Brazil, Haiti, MRKAd5 HIV-1 gag B defective Ad-5 
Merck 2004 Puerto Rico vector 018 
Phase I (Small trials In low-risk populations; test vaccine safety, Immunogenlclty) (continued) 
IAVl IAVI; Targeted December 
Belgium (2); gag, Recombinant AAV Germany (2); tgAAC09AAV C A001 Genetics 2003 India (1f protease, rt vector; single shot 
IAVl IAVI; ADARC; December US (2) ADVAXDNA gag, env, pol, C Multl-gene C001 Vical 2003 nef, tat approach 
Safety, 
Gag and Env gag, env Immunogenlcity of 
HVTN HVTN; Chlron December US (8) DNAlPlG DNAlPlG; BB DNAlPlG and env 049 2003 Oligomeric Oligomeric DNAlPlG prime, 
gp140IMF59 gp140 oligomeric 
gp1401MF59 boost 
Safety, 
HVTN December VRC-HIVDNA- gag, pol, nef immunogenicity of 
044 
HVl"N; Vical 2003 US (3) 009-00-VP env BA,B,C of multiclade DNA Vaccine with Il-
21lg DNA adjuvant 
South Africa 
IAVl 011 IAVl, SAAVlIDT 
November (2), UK (1), MVA-HIVA gag + 25 A Dose response 2003 Switzerland CTlepltopes 
(1) 
EnvPro StJude's September US EnvPro protein gp140 0 Purified env 
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Table 1.2. Ongoing Trials of Preventive HIV Vaccines, continued 
2003 protein 
Trial Sponsor Start Sites 
VaCCIne Antigen Clade Comment No. Manufacturer Date (No.) 
Safety, 
immunogenlcity of 
ISSP- September HIV-1 Tat the recombinant 




Merck: Aventis MRKAd5HIV- env. MRKAd5 HIV-1 NJA Pasteur 2003 US (17) 1; ALVAC gag, pol B prime,ALVAC vCP205 vCP205 boost 
HVTN US (4); Safely and 
040 NIAID; SAAVI July 2003 South Africa AVX101 VEE gag C immunogenicity of (2) VEE vector 
gp120(MN Safety and ANRS ANRS: Aventis June 2003 France (2) gp160MNJLAI- strain), gp41 B Immunogenicity, VAC14 2 (LAI strain) using several 
routes 
21 CTL 
HVTN NIAID; US (2); EP HIV-1090 epitopes Safety and 
048 Epimmune April 2003 Botswana DNA from gag, All immunogenicity pol, env, net, 
mv, vor 
VRC ; I November US VRC- gsg, poI,ne' A,B,C Safety and 
004 (03- Vical 2002 HIVDNAOO9- (clade B): immunogenicity of 
1-0022) oo-VP env(elades a multiclade 
A,B, C) varone 
Response to 
vacdne 
B011; ALVAC-HIV subcutaneously 
RV 138 WRAIR; Aventis July 2002 US vCP205 env, gsg, pol B (via dendtritlc cells), 
Intradermally, or 
Intramuscularly 
NJA Merck 2002 US gag DNA gag B Dose response 
01-1- NIAIDNRC; January US VRC4302 DNA gag,poI B Dose and immune 0079 Vical 2001 response 
N/A Merck 2001 US 
~ 
gag gag BB Evaluation of DNA 
vs. Ad5 prime + 
Ad5boost 
KEY: 
ABL: Advanced BloSelence Laboratories, Inc.; ADARC: Aaron Diamond AIDS Research Center; AFRIMS: Armed Forces 
Research Institute of Medical Sciences, Bangkok, Thailand, is a joint U.S.-Royal Thai Army Command; AlphaVax: AlphaVax 
Human Vaccines Inc.; ANRS: Agence Nationale de Recherche sur Ie SIDA; AVANT: AVANT Immunotherapeutics, Inc.: AVC: 
Australan Vacdne Consortium: Aventls: Aventls Pasteur; CAN: Canada; Chiron: Chiron Corporation: CTL: cytotoxic T-
lymphocyte; Eplmmune: Eplmmune Inc.: Excel!: Excell Biotech; GSK: GlaxoSmllhKline; HVTN: HIVVaccine Trials Network; IAVJ: 
Intemational AIDS Vacdne Initiative; lOT: Impfstoffwerk Dessau Tomau GmbH; ISS: Istltuto Supertore dl Sanlti; KAVI: Kenyan 
AIDS Vacdne Initiative: MoH: Ministry of Health (ThaBand); MRC: UK Medical Research Counctl; NIAID: U.S. Nallonallnstitute 
Allergy and infectiOUS Diseases: NL: Netheriands: PACTG: Pediatric AIDS Clinical Trials Group; PR: Puerto Rico; SAAVI: South 
African AIDS Vacdne Initiative; St Jude's: St Jude's Childrens Hospital; Therian: Therion Biologics Corporation; TT: Tetanus 
Toxoid; UMMS: University of Massachusetts Medical School; UNSW: University of New South Wates; US: United States; UVRI: 
Uganda Virus Research Institute; VEE: Venezuelan equine encephalitis; Vical: Vicallnc.; VRC: Varone Research Center; 
WRAlR: Walter Reed Army Institute of Research 
1.A.7.3. HIV VACCINE STRATEGIES 
The kinds of vaccine strategies being employed include live virus vectors, live bacterial vectors, 
DNA vaccines, pseudovirions, subunit vaccines and peptide vaccines (Table 1.3), The South 
African AIDS Vaccine Initiative (SAAVI) has funded a group working at the University of Cape 
Town to develop candidate vaccines using a number of these approaches. These include 
recombinant bacterial [bacillus Calmette Guerin (BCG) and Salmonel/a] and viral [modified 
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vaccinia Ankara (MVA)] vaccines, DNA vaccines (van Harmelen et al., 2003) and protein subunit 
vaccines (Jaffray et al., 2004). The major vaccine strategies are reviewed briefly below. 
Table 1.3. HIV vaccine strategies (adapted from BoJak et .'.,2002 and www.nlald.nlh.govlvacclne/concepts.htm ) 
VACCINE 
STRATEGY 
DESCRIPTION ADVANTAGES DISADVANTAGES STATUS 
Live viral vectors Recombinant viruses Can control amount and Complicated to prepare; In phase II 
expressing HIV genes (eg. kind of viral protein current vaccines elicit trials 
MVA, Canarypox) produces only modest immune 
responses 
Replicon Viruses that are replication Increased expression of the Complicated to prepare In phase I trials 
vaccines incompetent expressing HIV viral protein 
genes (eg. VEE and MV) 
Live bacterial Recombinant bacteria Simple and Inexpensive to Can only accommodate Close to phase 
vectors expressing HIV genes (eg. produce a linited amount of I trials 
BCG and Salmonel/a) genetic material; stability 
concerns 
DNA vaccines Plasmid DNA expressing HIV Simple and Inexpensive to Worries about integration In phase I trials 
genes produce of HIV genes into human 
cells; elicit only modest 
immune responses 
Pseudovirions Non-replicating VLPs Present HIV proteins in a Difficult to produce In phase I trials 
relatively natural 
conformation 
Subunit vaccines Recombinant viral proteins Safe and simple to produce Vaccine-elicited In phase II and 
such as gp120, p24 antibodies have failed to phase II trials 
recognize primary HIV 
isolates 
Peptide vaccines Chemically synthesized Simple and inexpensive to Can only accommodate In phase I trials 
protein fragments and/or produce; safe a limited amount of 
epitopes genetic material 
Combined Combinations of the above Should stimUlate both Current combinations In phase II 
vaccines strategies in prime-boost humoral and cellular elicit modest immune trials 
modalities (eg. DNA prime- Immune responses responses; antibodies 
rBCG boost) are not neutralizing 
WA, modified Vaccinia Ankara; VEE, Venezuelan equine encephalitis; MV, Adeno-assodaled virus; VLP, vlrus~ike partides 
Live viral vectors 
A number of viral vectors in the form of replication-defective or live-attenuated viruses have been 
developed for use in vaccine research and are currently in phase I, II and III clinical trial (Table 
1.2 and 1.3). 
Poxviruses have been studied the most and have proceeded furthest in human trials (Table 1.2). 
An early study by Hu et al. (1992) demonstrated that macaques immunized with recombinant 
vaCCinia virus expressing SIV gp160 and boosted with soluble protein was able to protect the 
animals from challenge with homologous virus. Later studies showed that the protective response 
was of limited breadth since macaques vaccinated with vaccinia virus expressing SIV Gag, Pol 
and Env and boosted with SIV particles were not protected from challenge with a low dose of 
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heterologous SIVmac; (Daniel at a/., 1994). Complete protection could only be achieved when the 
challenge virus was matched to the vaccine (Polacino at a/., 1999). Macaques immunized with 
recombinant MVA expressing Gag-Pol and Env were Infected upon SIV challenge; however, 
there was a significant reduction in viraemia and an increase in survival compared to control 
animals (Seth at a/., 2000 and Ourmanov at a/., 2000). Importantly, the reduction in viral load was 
inversely correlated to the Gag-specific CTL response and the magnitude of the CTL response 
was a predictor of the magnitude of viral load reduction. 
A number of poxvirus vectors have entered human trials with the most data available on the 
canarypox vaccines. Both humoral and cell-mediated immune responses have been elicited in 
human volunteers inoculated with canarypox vaccines expressing Gag-Pol and Env (Belshe at 
a/., 2001, Gorse at a/., 2001, Gupta at a/., 2002 and Cao at a/., 2003). In these studies, CTL 
responses and neutralizing antibody responses to T-cell laboratory-adapted isolates (Belshe at 
a/., 2001) and primary isolates (Cao at a/., 2003) were induced in most of the volunteers and the 
magnitude of these responses was increased by the administration of recombinant gp120 (Belshe 
at a/ .• 2001, Gorse at a/., 2001 and Gupta at a/., 2002). Despite low responses these approaches 
has moved into phase III clinical trials (Table 1.2). 
The results of phase I testing of an MVA vaccine alone or as a boost following a DNA prime was 
found to be safe and was able to stimulate HIV-speclfic T-cell responses in most of the vaccinees 
(Mwau at a/., 2004). MVA alone induced stronger and more frequent responses than DNA alone 
and the prime-boost regimen was found to induce similar levels to MVA alone. 
One of the most promising vaccine approaches used attenuated Adenovirus vector. An 
adenovirus-SIV envelope vaccine followed by a recombinant gp120 boost has been tested in 
macaques (Buge at a/., 1997 and 1999). SIV-speclfic humoral and cellular responses were 
detected and although Infection resulted after challenge, vaccinated animals had a lower viral 
load at setpoint. In chimpanzees, the adenovirus-HIVenvelope vaccine with a recombinant gp120 
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boost elicited neutralizing antibodies which were effective against clinical and laboratory strains of 
HIV (Lubeck at al., 1997). The chimpanzees also developed HIV-specific CTL responses. 
Casimiro at al (2003) tested the immunogenicity of replication-incompetent Adenovirus type S 
(AdS) and DNA-based HIV-1 codon-optimized Gag vaccines in baboons. The AdS vaccine was 
able to elicit strong CTL responses, while the DNA vaccine Induced weak responses that were 
moderately enhanced by chemical adjuvants. However, the DNA vaccine was an effective prime 
for both AdS and MVA vaccine boosts. 
Repllcon vaccines 
These vaccines make use of replication incompetent viruses which can copy their genome. The 
HIV genes are inserted into the genome for expression and the viruses are used to deliver the 
HIV genes to the cells. 
Venezuelan equine encephalitis virus (VEE) replicon particles carrying SIV Gag and Env induced 
humoral and cellular immune responses in vaccinated macaques (Davis at al., 2000). After 
challenge with a pathogenic uncloned stock of SIV, all four of the vaccinated animals were 
protected against disease for 16 months. Vaccinated animals also had a mean peak viral load 
that was 2 orders of magnitude lower than unvaccinated controls and the viral load after the acute 
infection phase was 7S0-fold lower. This strength of the protective response and the reduction in 
viral load correlated with the magnitude of SIV-specific antibody and CTL responses. 
Other replicon viral vectors include sindbis virus (Vadjy et al., 2001), semliki forest virus (Hanke at 
al., 2003) and adeno-assoclated virus (AA V; Xin at al., 2001) 
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Live bacterial vectors 
BCG, Salmonella and Listeria have been developed for use as HIV vaccine vectors. 
Immunogenicity testing of live bacterial vectors vaccines is not as far along as viral vector testing, 
but results in various preclinical animal models have been encouraging. 
The recombinant BCG approach is the subject of this thesis and is discussed in further detail in 
Chapter 1: Part B. 
Salmonella spp. have been attenuated for use as potential vectors to stimulate immune 
responses in the gastrointestinal mucosa (Schodel and Curtiss, 1995). Berggren et al. (1995) 
were able to show proliferative responses in mice immunized with S. typhimurium expressing HIV 
gp120. Lymphoproliferative responses have also been shown in macaques vaccinated with S. 
typhimurium expressing the SIV capsid p27 (Steger et al., 1999). Macaques inoculated with S. 
typhimurium expressing HIV-2 gag were not protected from a challenge infection with HIV-2 
(Franchini et al., 1995). S. typhi and S. typhimurium expressing fragments of SIV Gag fused to 
the type III-secreted protein SopE were shown to effectively prime a CTL response in vaccinated 
macaques (Evans et al., 2003). Although only lOW-level responses were detected after 
Salmonella inoculations, boosting with MVA Gag yielded strong Gag-specific responses. 
However, there animals did not show an improved control of virus replication following an SIV 
challenge. 
Listeria monocytogenes has been attenuated for use as a vaccine vector (Frankel et al., 1995 
and Lieberman and Frankel, 2002). L. monocytogenes expressing HIV gag was shown to induce 
strong and long-lasting CTL responses in immunized mice (Lieberman and Frankel, 2002). These 
CTL responses were able to protect mice from infection in a vaccinia virus challenge model. 
Peters et al. (2003) were also able to show that mucosally administered L. monocytogenes 
expressing HIV gag eliCited HIV-specific CD8+ T cells in the spleens of vaccinated mice and that 
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this response could be maintained by boosting. Safety and immunogenicity studies in macaques 
are ongoing (Lieberman and Frankel, 2002). 
DNA vaccines 
Extensive testing of HIV DNA vaccines performed in small animals and non-human primates 
(Robinson, 1997). DNA vaccines have been shown to elicit neutralizing antibodies to laboratory-
adapted viruses and CTL responses against both HIV and SIV antigens (Boyer et al., 1997; 
Letvin et al., 1997; Robinson et al., 1997; Barouch et al., 2001; Akahata et al., 2003 and Bazhan 
et al., 2004). In some cases these responses have been protective (Boyer et al. 1997) or have 
resulted in a significant decrease in viral load at set point and prevention of disease (Boyer et al., 
1997; Letvin et al., 1997; Barouch et al., 2000; Kumar et al., 2002 and Akahata et al., 2003). 
DNA vaccines alone are poorly immunogenic and a number of approaches have been used to 
optimize of antigen expression by DNA vaccine and improve immune responses to the antigens: 
optimizing codon usage (Andre et al., 1998; zur Megede et al., 2003; van Harmelen et al., 2003 
and Ramakrishna et al., 2004); including immunomodulatory cytokine genes in the vaccine 
(Barouch and Letvin, 2000; Billaut-Mulot et al., 2000; Boyer et al., 2000 and Kim et al., 2001) and 
formulation of the DNA vaccine with adjuvants or novel delivery systems (Ara et al., 2001; Denis-
Mize et al., 2003 and Otten et al., 2004). Prime-boost strategies using the DNA vaccine as the 
prime or the boost has also been investigated as a way to enhance the responses (see 
Combined vaccines below). 
Clinical trials of a number of DNA vaccines on their own or as part of a prime-boost regimen are 
underway (Table 1 .2). The results of a therapeutic DNA vaccine phase I trial using a plasmid 
expressing HIV-1 Env and Rev indicated that the vaccine was safe in the HIV-infected individuals. 
There were modest increases in anti-gp120 antibodies and gp160-specific CTL and 
Iymphoproliferative activity (MacGregor et al., 1998). When this DNA vaccine was administered to 
HIV seronegative volunteers, antigen-specific CD4+ T helper responses, Iymphoproliferative 
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responses and antigen-specific production of both IFN-yand l3-chemokine were detected (Boyer 
et al., 2000 and MacGregor at al., 2002). Another more recent trial evaluated a DNA vaccine and 
an MVA expressing HIV-1A p24/p17 fused to a string of CTL epitopes either separately or in a 
DNA prime-MVA boost combination. All three regimens were found to be safe and induced HIV-
specific responses in the majority of the vaccinated people (Mwau at al., 2004). 
Pseudovirions 
Non-infectious virus-like particles (VLPs) which are morphologically similar to immature HIV 
virions have been produced in a number of recombinant systems via expression of Pr55Gai1 
(Gheysen at aI., 1989; Overton at al., 1989; Shioda & Shibuta, 1990; Vernon at al., 1991; Royer 
at aI., 1991, 1992; Jowett at al., 1992; Margener at al., 1992 and Nermut at al., 1994, 2003). 
Other epitopes and complete proteins are often incorporated into the Gag VLPs. Type I VLPs 
have small epitopes fused or integrated within the particle, while Type II VLPs incorporate the 
foreign protains on the outer surface (Deml at al., 2005). VLPs have been shown to stimulate 
both humoral and cellular immune responses in vaccinated animals (Table 1.4.). 
A number of clinical trials In human volunteers have been conducted using HIV-1 p17/p24:Ty 
VLPs (p24-VLP) which is expressed in yeast (Adams at al., 1987). In HIV-seronegative 
volunteers, the vaccine was shown to be safe and to induce production of anti-p24 antibodies and 
proliferative T-cell responses (Martin at al., 1993 and Weber at al., 1995). Although the vaccine 
was shown to be safe in HIV-seropositive individuals as well, there was no induction of antibodies 
against p24 (Veenstra at al., 1996; Peters at al., 1997 and Kelleher at al., 1998). However, at 
higher doses, marginal Gag-specific immune responses were elicited in limited numbers of HIV-1-
seropositive individuals, with some showing transient elevation of HIV-1 viral load (Klein at al., 
1997). When p24-VLP was administered in combination with zidovudine to HIV-positive 
individuals, the antibody levels did not change Significantly and no proliferative responses were 
induced, although the CTL activity was augmented (Kelleher et al., 1998 and Benson at a/. , 
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1999). In a long-term follow-up of HIV seropositive subjects vaccinated with p24-VLP, it was 
found that the vaccine did not slow progression to AIDS (Linden burg at al., 2002). 
Combined vaccines 
Although a single vaccine against HIV would be preferable, a number of studies have shown that 
the prime-boost regime induces stronger and broader immune responses. Several studies have 
shown that a heterlogous prime-boost strategy can yield protection from challenge in non-human 
primate models. A DNA prime-fowl pox virus boost was shown to contain viral challenges in 
macaques (Robinson at al., 1999). A multigene DNA prime-vaccinia virus boost or vaccinia virus 
prime-multi gene DNA boost regimens protected vaccinated macaques from CD4+ T cell loss and 
decreased the viral load at setpoint after SHIV89.6P challenge (Doria-Rose at al., 2003). Bertley 
at al., 2004 demonstrated anti-SHIV humoral and cellular responses in macaques using a DNA 
prime-MVA boost strategy that reduced CD4+ T cell loss and progression to AIDS after challenge 
with SHIV89.6P. A mucosal challenge with SHIV89.6P was controlled in macaques that received 
a DNA prime (Gag-PoLEnv) followed by an equivalent MVA boost (Amara at al., 2001). In 
baboons, Casimiro at al. (2004) demonstrated that a replication-defective adenovirus prime-
poxvirus boost regimen elicited responses that were Significantly greater than either vaccine 
alone or by poxvirus prime-adenovirus boost. Laung at al. (2004) used a DNA prime-protein boost 
strategy to achieve antigen-specific antibody and Iymphoproliferative responses in vaccinated 
baboons. 
Several human clinical trials based on the prime-boost approach are ongoing (Table 1.2). 
Examples include an Australia phase 1111 trial testing a DNA prime-fowlpox boost regimen and a 
US phase I trial of a adenovirus prime and boost strategy. 
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Table 1.4. Induction of humoral and cellular immune responses by recombinant VLP Immunogens (taken from Oeml et a/., 2005) 
Immunogen Animal model Antibodies Neutralisation ClL Protection Reference 
Carrier Foreign POllpe~tlde Carrier Foreign ~Iype~tlde 
Naked Gag-VlP Rhesus macaques n.d. n.d. Strong n.d. Paliard et al., 2000 
Type IVLPs 
HIV-2 GagN3, Rabbits Detectable Detectable Weak n.d. n.d. n.d. Luo et al., 1992 
Gag/CD4BR, 
GagN3+CD4BR 
HIV-1 GagN3 BALBIc mice, rats Strong Weak Weak n.d. Strong n.d. Griffiths et al., 1993 
HIV-1 GagN3 BALBIc mice Strong Weak to medium Weak n.d. Strong n.d. Wagner et al., 1996 
Type IIVLPs 
VLP/gp160 New Zealand White n.d. Strong Medium n.d. n.d. n.d. Haffar et al., 1991 
Rabbits 
VLP/chimeric HIV- SJLIL mice Strong Strong Medium n.d. n.d. n.d. Rovinski et al., 1992 
1lA11MN gp 160 
VLP/EHV-1 gp14 BALBIc mice n.d. Good n.d. n.d. n.d. Complete Osterrieder et al., 
protection 1995 
VLP/gp120TM BALBIc mice Strong Medium Weak, depending n.d. n.d. n.d. Demtet al., 1997a 
variants on gp120 variant and b 
VLP/gp160 +0821 Rhesus macaques Detectable (WB) Detectable (WB) Weak Weak; transient n.d. n.d. Montefiori et al., 
200t 
VLP(GagPoiNefY BALBIc mice Strong Strong Weak Strong Strong n.d. Buonaguro et al., 
g~120TM 2002 
Unless otherwise noted, all polypeptides were derived from HIV-1 isolates. Abbreviations: VLP: virus-like particle; n.d.: not defined; Gag: group-specific antigen; HIV: human immunodeficiency virus; gp: 
glyeoprotein; V3: third variable loop of HIV-1 gp120; gp120: extemal HIV-1 glycoprotein; CD4BR: CD4-blnding region of HIV-1 gp120; gp160: uncleaved HIV-1 envelope protein precursor; EHV-1: equine 
herpesvirus type-1; TM; transmembrane danain; OS1: natural saponin adjuvant derived from the tree Quillaja saponaria Molina; Pol: polymerase; Net: negative-regulatory factor. 
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PART B: RECOMBINANT BCG VACCINES 
1.B.1. BACKGROUND 
Bacille Cal mette-Guerin (BCG), the vaccine against Mycobacterium tuberculosis, is the most 
widely administered vaccine worldwide. Calmette and Guerin developed the original strain of 
BCG from a virulent M.bovis strain isolated by Nocard (Oettinger et al., 1999). From 1908 to 
1919, the "Iait Nocard" strain was passaged 230 times over glycerinated bile potato medium until 
they declared that organism was safe in guinea pigs, cows, horses, hamsters, mice and rabbits 
and provided protective immunity to virulent M.tuberculosis challenge (Guerin and Rosenthal, 
1957). In 1921, after this preliminary animal testing, Weill-Halle administered the vaccine orally to 
infants (Calmette, 1931). 
Over the ensuing years, based on the reported protection of 90% shown in the vaccinated 
children, BCG was distributed all around the world. Different laboratories passaged and 
maintained their cultures and seed lots differently and there are now BCG variants that have 
emerged during production (Behr and Small, 1999). The substrains that are used most 
extensively today include Connaught, Danish, Glaxo, Moreau, Pasteur and Tokyo (Oettinger et 
al., 1999). Behr and Small (1999) worked out an evolutionary framework of the substrains based 
on the variability of 156110 and mpt64 typing (fig.1.7.). 
BCG has numerous advantages associated with its use: it can be given to neonates; a single 
vaccination can lead to long-lasting immunity; it has a proven safety record; it is heat stable and it 
is inexpensive to produce (Bloom and Fine, 1994). However, the reported protective efficacy of 
BCG varies widely in different regions. Colditz et al. (1995) performed a meta-analysis of 
published literature on the efficacy of the vaccine and concluded that BCG vaccination reduced 
the risk of tuberculosis in infants and neonates by over 50% on average. BCG vaccination also 
protected against pulmonary TB and disseminated TB (78% protective effect), tuberculous 
meningitis (64% protective effect) and reduced the risk of death by 71 % (Colditz et al., 1995). 
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Flg.1.7. Evolutionary framewoft( of BCG strains based on variability of IS6110 mpt64 typing showing the BCG 
variants that have emerged during production. (Behr and Small, 1999) 
1.B.2. RECOMBINANT BCG TECHNOLOGY 
BCG is a challenging organism to manipulate genetically. It has a slow growth rate with a long in 
vitro doubling time of 20-24 hours - it takes 2-4 weeks to form colonies on solid media. The lipid-
rich cell wall means that BCG will not form Single colonies on solid medium and it forms clumps in 
liquid culture unless a detergent is added to the growth medium (0' Donnell, 1997). DNA 
transformation of BCG is inefficient. Other properties such the high GC content of the genome 
and Mycobacterial promoters and origins of replication have necessitated the development of 
genetic manipulation tools that are Mycobacterium-specific. 
Jacobs et al. (1987) constructed the first shuttle vectors that allowed the introduction of foreign 
DNA by infection into M.smegmatis and BCG. These recombinant shuttle phasmids were 
chimaeras that contained mycobacteriophage DNA and an E.coli cosmid; they were thus able to 
replicate as plasm ids in E.coli and as phages in Mycobacteria. A plasmid transformation system 
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was developed by randomly inserting an E.coli plasmid expressing a kanamycin resistance gene 
into the M.fortuitum pAL5000 plasmid (Snapper et al., 1988). This shuttle vector expressed 
kanamycin resistance and was capable of replication in E.coli, M.smegmatis and BCG. Husson et 
al. (1990) described a method of gene replacement in M.smegmatis that made use of 
homologous recombination. Ranes et al. (1990) constructed an E.coli-Mycobacterium shuttle 
vector that expressed kanamycin resistance In both M.smegmatis and BCG, while Matsuo et al. 
(1990) used the extracellular a-antigen of M.kansasii to establish a foreign antigen secretion 
system in Mycobacteria. With this system, BCG was shown to secrete a B-cell epitope of HIV-1 
p17 along with the a-antigen. Lee et al. (1991) made use of mycobacteriophage L5 to construct 
plasmid vectors that transformed M.smegmatis, M.tubercu/osis and BCG by site-specific 
integration of the plasmid into the genome. These initial forays into shuttle vector construction 
lead to further studies where recombinant BCGs (rBCG) were manufactured that expressed 
foreign antigens that induced immune responses. Recombinant BCGs have been produced which 
express bacterial, parasitic and viral antigens, as well as rBCG expressing cytokines (see section 
3.1.5). 
1.B.3. IMMUNE RESPONSE TO FOREIGN ANTIGENS 
EXPRESSED IN rBCG 
Tables 1.5. to 1.6. summarize the results of experiments investigating the immune response to 
foreign antigens expressed in rBCG in various animal models. Below is a brief review of the 
results. 
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Table 1.5. Immune responses In vaccinated animals to rBCG expressing viral antigens under the control of different promoters with or without localization sequences 
Antigen source Antigen Vector features Animal Immune response Reference 
Promoter Gene or localization 
sequence fused to 
I!:omoter 
HIV-1 p17 B-cell epitope M. kansasii a- M. kansasii a-antigen mice antibodies in 3f7 mice; persisted for >14 Wada et al., 1996 
antigen signal months 
V3 loop epitope M. kansasii a- M. kansasii a-antigen mice CTLs produced Kameoka at aI., 1994 
antigen signal 
PND of V3100p M. kansasii a- M. kansas;i a-antigen Guinea pigs DTH response, CTLs, antibodies; Honda at al., 1995 
antigen Signal neutralization of lab and primary strains of 
HIV by serum antibodies; passive protection 
in immune deficient mice 
mice high titres of long-lasting antibodies; IgG Hiroi at al., 2001 
detected in serum was able to neutralize 
primary strains in vitro 
epitopes from M. kansasii a- M. kansasi; a-antigen Guinea pigs serum IgG from animals inoculated Ylith the Chujoh at al., 2002 
PND of V3100p antigen signal 12aa epitope-rBCG neutralized the WHO 
(subtype E) reference strain and primary strains of 
subtype E and Thai B(B') 
19aa codon- M. kansasii a- M. kansasii a-antigen Guinea pigs DTH responses. IgG and IgA serum Kawahara at al., 2002 
optimized V3 loop antigen signal antibodies, enhanced neutralization of HIV~, 
sequence from and high levels of IFN-y and IL-2 production 
Japanese Ylith combination of id and ir routes 
consensus 
Gp120 BCG hsp70 none mice MHC-l-restricted CTLs Stover at al., 1991 
Gp41 and Gp120 BCG hsp60 none mice anti-Gp41 antibodies and Gp120-specific Fuerst at aI., 1992 
CTLs 
Nef Streptomyces none mice proliferation Winter at al., 1991 
albus 
groES/groEL 1 
Gag and Env hsp70 none mice IgG antibodies; IFN-y and IL-2 production; A1dovini and Young. 
CTLs produced 1991 
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Table 1.5. Immune responses In vaccinated animals to rBCG expressing viral antigens under the control of different promoters with or without localization sequences, 
continued 
Antigen source Antigen Vector features Animal Immune responsetr Reference 
Promoter Gene or localization 
sequence fused to 
promoter 
SIV Gag hsp70 first few codons of macaques CTLs produced Yasutomi et al., 1993 
lacZ 
Nef M.paratuberculosis ORF2 mice proliferation and CTLS produced Winter et al. 1995 
PAN (subcutaneous immunization) 
Lagranderie et al., 
proliferation and IFN-y and TNF-a production 1997 
after oral immunization 
N-terrninal portion pBlaF* none mice and guinea CTLs produced in mice Lim et al., 1997 
of Gp110 pigs 
IgG antibodies in mice and guinea pigs that 
could neutralize field isolates of SlVmac251 
Nefand Gag PAN none mice cocktail of all three rBCG elicited IgA and IgG Lagranderie et al., 
antibodies; CTLs produced 1998 
Env pBlaP 
macaques same cocktail elicited CTLs and IFN-y MlIderl6 et al., 2003 
production; challenge with SIVmac251 
elicited cellular and antibody responses but 
did not prevent infection 
Nef-Gag fusion pBlaP none mice IFN-y production after Gag protein boost; MlIder16 et al. 2002 
antibodies 
Gag, Pol, Env, hsp70 none macaques cocktail of all four rBCG elicited IgA and IgG Leung et al.; 2000 
Nef antibodies; CTLs produced; proliferation 
Measles virus N protein hsp60 influenza virus NS C3H1He mice proliferation; antibodies; low levels Fennelly et al., 1995 
protein neutralizing antibodies; after challenge: 
reduction in virus titre, decrease in 
hsp60 BCG 19kDa signal encephalitis incidence and decrease in 
mortality 
Streptomyces Streptomyces 
coelicolor A3 coelicolor A3 agarase 
agarase protein protein signal 
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Table 1.5. Immune responses in vaccinated animals to rBCG expressing viral antigens under the control of different promoters with or without localization sequences, 
continued 
Antigen soun::e Antigen 




Hepatitis C virus NSSa 
Rabies virus N protein B- and 
T-cell epitopes 
Porcine GPSandM 





Promoter Gene or localization 
sequence fused to 
promoter 
hsp60 Influenza virus NS 
protein 
hsp70 none 
M.kansssii a- M.kansasii a-antigen 
antigen signal 




BeG 19kDa signal 
Animal Immune response Reference 
Infant macaques proliferation but no antibodies; after Zhu at a/., 1997 
challenge: did not prevent systemic infection 
but did reduce lung inflammation, virus titres 
were reduced and viral shedding was shorter 
BALBlcand DTH, proliferation and antibodies; E7-specific Jabbar at aI., 2000 
C57BU6mice CTLs; responses were less potent than 
conventional vaccine 
mice CTLs produced; reduction in virus titres Uno-Furuta at a/., 
following challenge 2003 
mice higher antibody titres than conventional Da Cruz at a/., 2002 
rabies vaccine 
BALBlcmice antibodies; IFN-y production Bastos at a/., 2002 
and 2004 
pigs antibodies but no IFN-y production; following 
challenge vaccinated pigs showed lower 
temperature, viraemiaand viral load 
1.B.3.1. VIRAL ANTIGENS 
A number of different viral antigens have been expressed in rBCG and have induced both cellular 
and humoral immune responses in vaccinated animals (Table 1.5.). 
HIV-1 antigens 
Matsuo et al. (1990) were the first group to express a viral antigen in rBCG. They expressed a B-
cell epitope of HIV-1 p17 fused to the a-antigen from M.kansasii and demonstrated high titres of 
long-lasting antibodies to the epitope in 3 of 7 mice inoculated with the rBCG (Wada at al., 1996). 
This a-antigen secretion system was used to express various HIV-1 Env antigens in rBCG: 
An immunodominant epitope from the V3 loop of HIV-1 gp120; splenocytes from 
mice inoculated subcutaneously with this rBCG generated a CTL response against 
V3-peptide pulsed P815 cells (Kameoka et al., 1994) 
The principal neutralization domain (PND) of the HIV-1 V3; responses included a 
specific DTH response, specific lysis of V3-pulsed P815 cells and anti-PND 
antibodies in guinea pigs (Honda et al., 1995); strong neutralization of HIVMN and 
primary isolates by serum antibodies and protection against HIV-1 infection after 
passive transfer of serum antibodies into SCID/hu or SCID/PBL mice (Honda at al., 
1995); high titres of long-lasting antibodies after nasal inoculation in mice and high 
levels of prolonged serum-lgG which were able to neutralize clinical isolates of HIV-1 
in vitro in Th1- and Th2-deficient mice (Hiroi et al., 2001) 
V3 PND rBCG using epitopes (15, 12 and 11 amino acids) from a subtype E HIV-1; 
serum IgG from guinea pigs inoculated with the 12aa rBCG neutralized the WHO 
reference strain as well as field isolates of subtype E virus and Thai B(B") strains 
(Chujoh at al., 2001) 
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Codon-optimized DNA fragment encoding the 19 aa tip of the V3 sequence from the 
Japanese consensus HIV-1; significant DTH responses to V3 in guinea pigs 
inoculated with a combination of the intrarectal and intradermal routes; significantly 
higher titres of HIV-1 specific serum IgG and IgA and enhanced neutralization of 
HIVt.AN compared with those immunized by the intrarectal route only; induction of high 
levels of IFN..., and IL-2 in PBMC. splenocytes and intraepithelial lymphocytes was 
detected at least 110 weeks post-inoculation (Kawahara et al., 2002) 
rBCG expressing HIV-1 subtype B gp120 from the hsp70 or hsp60 promoters elicited MHC-I 
restricted CTLs in immunized mice (Stover et al .• 1991 and Fuerst et al. 1992. respectively). while 
gp41 expressed from the hsp60 promoter elicited anti-gp41 antibodies (Fuerst et al .• 1992). rBCG 
expressing subtype B Gag and Env (hsp70 promoter) elicited low but detectable levels of IgG 
antibodies against p24. p17 and gp160 in mice (Aldovini and Young. 1991). rBCG-Gag also 
induced substantial IFN-y and IL-2 production and Gag-specific CTLs. Subtype B net 
(Streptomyces albus groESlgroEL1 promoter; episomal) induced in vitro proliferation of lymph 
node cells from subcutaneously immunized mice (Winter et ai, 1991). 
SlY antigens 
Yasutomi et al. (1993) attempted to enhance expression from the hsp60 and hsp70 promoters by 
fusing the SIVmac251 gag gene to the first few codons of lacZ. The hsp70-reguiated rBCG-Gag 
was given intradermally to macaques. No anti-Gag antibodies or Gag-specific CTL were 
detected. However. after a boost at 19 weeks, they were able to show MHC-I restricted lysis of 
vaccinia-SIVgag-infected target cells. The SIVmac251 nef gene fused to ORF2 in rBCG (PAN 
promoter from M.paratuberculos/s) induced Significant proliferation in lymph node cells from mice 
inoculated subcutaneously (Winter et al .• 1995) and specific proliferation and production of IFN-y 
and TNF-a in mice inoculated orally (Lagranderie et al .• 1997). The N-terminal portion of SIVmac 
gp110 in rBCG (pBlaF* promoter) induced CTL responses in mice and systemic IgG directed 
against gp110 in mice and guinea pigs by parenteral routes of inoculation (Lim et al., 1997). 
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These antibodies were able to neutralize primary field isolates of SIVmac251. Oral immunization 
of guinea pigs also produced significant levels of anti-gp11 0 antibodies in faeces. 
Mice were inoculated with a cocktail of rBCG consisting of SIV nef and gag expressed (PAN 
promoter) and SIV env (pBlaF* promoter) via the oral, aerogenic, nasal and rectal routes 
(Lagranderie et al., 1998). All routes induced IgA antibodies against SIV Env and Gag in 
bronchial lavages and faeces, as well as specific IgG in serum. Strong, specific cytotoxic 
responses against Nef, Env and Gag were induced in splenocytes by all mucosal routes of 
inoculation. Mederle et al. (2003) administered this cocktail to cynomolgus macaques and after a 
single intradermal inoculation they found CTL responses to the 3 antigens in Circulating blood 
cells as well as IFN-y secretion. Rectal or oral boosting elicited anti-SIV IgA in the rectum and 
increased IFN-y secretion by the Circulating blood cells. After rectal challenge with pathogenic 
SIVmac251, anti-SIV cellular and antibody responses were higher in rBCG-inoculated monkeys 
than in controls, however, the viral load in plasma was comparable for all animals. This indicates 
that anti-SIV CD4+ T-cell memory was induced even though infection was not prevented. rBCG 
expressing the entire SIV gag, pol and nef genes and a truncated env gene in separate shuttle 
vectors (hsp70 promoter) were given to rhesus macaques in a single intravenous inoculation of 
all four rBCG (Leung at a/., 2000). SIV-specific IgA and IgG antibodies, CTL responses and 
helper T cell proliferation were induced. 
A nef-gag (SIVmac251) fusion in rBCG expressed under the control of the pBlaF* promoter in 
both integrative and episomal vectors was developed by Mederle at al. (2002). They found that a 
high level and persistent expression of the gag gene was required for the generation of memory T 
cells in mice inoculated with this rBCG. However, after a Gag protein boost, similar levels of IFN-y 
production were detected from mice inoculated with either the episomal or the integrative vectors. 
This suggested that only an initial high level of gag expression in the rBCG was critical for the 
induction of cellular immune responses. This is further confirmed by the fact that they could not 
detect cellular responses to Nef, which was expressed at a lower level. Despite a low level of Gag 
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expression in one of the integrative vectors, however, high levels of anti-Gag antibodies were 
detected. rhis implies that the same is not true for the humoral response in this system. 
Measles virus antigens 
Fennelly et a/. (1995) attempted to develop an immunization strategy that would permit priming 
for T cell memory for measles virus (MV) in infants using rBCG expressing the full-length 
nucleocapsid (N) protein. They constructed three rBCGs with the MV N protein fused to: the 
influenza virus non-structural (NS) protein under the control of the hsp60 promoter; the 
Mycobacterial 19kOa signal sequence also under hsp60 promoter control; the Streptomyces 
coelicolor A3 agarase protein (Oag) under the control of its own promoter. T cells from C3H/He 
mice immunized with the three rBCGs were able to proliferate when stimulated with recombinant 
N antigen and with MV. Anti-MV antibodies were also generated in Immunized mice. while low 
levels of neutralizing antibodies were detected after intracranial infection with the CAMlR40 strain 
of MV. They also reported a considerable reduction in virus titre recovered from brain 
homogenates. a decrease in encephalitis incidence and severity and a decrease in mortality in 
rBCG-immunized mice compared with controls. 
The same group tested rBCG expressing MV N protein in rhesus macaques (Zhu et a/ .• 1997). 
Infant monkeys were immunized with the rBCG and then challenged with MV. Although. N 
protein-specific Iymphoproliferation was detected. no anti-N protein antibodies were. rhe rBCG 
vaccination did not prevent systemiC MV infection but did reduce the lung inflammation after 
challenge. In addition. virus titres were Significantly reduced in the lymph nodes and viral 
shedding was shorter in some of the monkeys. 
Human papillomavirus antigens 
The immunogenicity of rBCG vaccines expressing the L 1 protein of hUman papillomavirus (HPV) 
6b and the E7 protein of HPV-16 (hsp70 promoter) was evaluated in BALB/c and C57BU6 mice 
(Jabbar et a/ .• 2000). Both rBCG-L 1 and rBCG-E7 elicited specific immune responses - OTH. 
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proliferation and antibody responses were demonstrated for both and rBCG-E7 induced specific 
lysis of E7-expressing tumour cells. However. the observed responses were at a lower level than 
those elicited by the convential recombinant protein/adjuvant approach and the authors felt that 
the rBCGs would only be useful to prime or retain memory responses to antigens. 
Hepatitis C virus antigens 
An rBCG vaccine expressing a CTL epitope of the hepatitis C virus (HCV) nonstructural protein 
Sa (NS5a) fused to the M.kansasii a-antigen was tested in mice (Uno-Furuta et al .• 2003). NS5a-
specific cytotoxic T lymphocytes that were MHC-I restricted were produced and when these mice 
were challenged with recombinant vaccinia virus expressingNS5a. they showed a significant 
reduction in virus titre compared with control mice. 
Rabies virus antigens 
Rabies virus nucleoprotein B-ceU and T-cell epitopes were cloned into the M./eprae 18kOa 
antigen gene and the fusion protein was expressed under the control of either the hsp60 
promoter or the 18kDa promoter in rBCG (Oa Cruz et al .• 2001). Both rBCG were able to induce a 
higher antibody titre in vaccinated mice than the conventional rabies vaccine - the higher 
response was eliCited by the rBCG expressing the epitopes from the 18kOa promoter. 
Porcine reproductive and respiratory syndrome virus antigens 
Bastos et al. (2002 and 2004) used rBCG to express a truncated form of GP5 and M protein of 
porcine reproductive and respiratory syndrome virus (PRRSV) under the control of the hsp60 
promoter. Four different rBCG were constructed with both proteins being expressed either in the 
cytosol or as fusion proteins with the 19kDa protein on the cell membrane. BALB/c mice 
immunized with these rBCG were able to produce anti-GP and anti-M antibodies 30 days post-
inoculation. At 60 and 90 days post-inoculation. PRRSV-specific IFN-y was detected in the 
splenocytes of these mice. When these rBCG vaccines were given to pigs. they were also able to 
produce anti-GP and anti-M antibodies. but were not able to generate PRRSV-specific IFN-y 
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production. However, following challenge with a pathogenic PRRSV strain, rBCG-immunized pigs 
showed a lower temperature, viraemia and virus load in bronchial lymph nodes than control 
animals. This was suggestive of partial protection against PRRSV infection. 
1.B.3.2. BACTERIAL ANTIGENS 
Various bacterial antigens expressed in rBCG have also been shown to induce cellular and 
humoral immune responses in vaccinated animals (Table 1.6.). 
E.coli antigens 
Stover at al. (1991) were the first to report expression of a bacterial antigen in rBCG. They 
expressed E.coli ~-galactosidase (p-gal) from the BCG hsp60 promoter in both an integrative and 
an episomal vector. BALB/c mice inoculated intravenously with rBCG:/acZ produced high levels 
of antibodies to ~-gal. even after inoculation with as few as 200 cfu. Strikingly, the antibody 
response to ~-gal was not only higher than the response to BCG antigens but also persisted for 
longer. IFN-y production and cytotoxic activity was also demonstrated in mice receiving this 
rBCG. 
The lacZ gene fused to part of ORF2 from IS900 and expressed from the M.paratuberculosis PAN 
promoter elicited proliferative responses, IFN-y production and antibody responses that were ~­
gal speCific in mice Inoculated subcutaneously with this rBCG (Murray et al., 1992). In guinea pigs 
inoculated by the oral, respiratory and intradermal routes (Lagranderie at al., 1993), antibody 
responses to J3-gal were induced. The rBCG:/acZ induced a mucosal IgA antibody response when 
administered orally and a DTH response to J3-gal was also shown. Strong J3-gal-specific T-cell 
proliferative responses were seen in the spleen and lymph node cells and the induction of TNF 
was seen in the sera of the guinea pigs. 
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Table 1.6. Immune responses In vaccinated animals to rBCG expressing bacterial antigens under the control of different promoters with or without localization sequences 
Antigen source Antigen Vector features Animal Immune response Reference 
Promoter Gene or localization 
sequence fused to 
promoter 
fE.coli Jl-gal hsp60 none BALBlcmice long-lasting antibodies; IFN-y production, Stover at al., 1991 
cytotoxic activity 
PAN none BALBlcmice antibodies; proliferation, IFN-y production Murray at al., 1992 
PAN none Guinea pigs antibodies, DTH, proliferation Lagranderie at al., 1993 
a-antigen a-antigen signal BALB/c mice Thi1·like response with IFN-y and IL·2 Kumar at aI., 1999 
production 
MalE BALBlcmice antibody and proliferative responses highest Himmelrich at al., 2000 
for secreted form 
Tetanus toxin ToxC hsp60 none NIH Swiss mice antibodies; protection from challenge Stover at al., 1991 and 
Fuerst at 81., 1992 
Pertussis toxin S1·TIC hsp60 mice antibodies to tetanus toxin; neutralized toxins Abomoelak at al., 1999 
and tetanus toxin in challenge; IL-2 production 
Ag85A Ag85A signal none 
Pertussis toxin S1PT pBlaP Jl-Iactamase BALB/cmice low-level antibodies Nascimento at 81., 2000 
Swiss mice IFN-y production; protection from challenge 
Diptheria toxin CRM197 pBlaP BALB/cmice antibody response; no neutralization Mlyaji at 81., 2001 
in combination with rBCG-FC neutralization Miyaji at aI., 2001 and 
was shown Mazzantin! at al., 2004 
Tetanus toxin FC pBlaP BALBlcmice antibodies Mazzantini at aI., 2004 
in combination with rBCG-CRM197 also elicited 
antibodies and induced protection 
antisera from animals neutralized tetanus and 
Guinea pigs diptheria toxin 
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Table 1.6. Immune responses In vaccinated animals to rBCG expressing bacterial antigens under the control of different promoters with or without localization sequences, 
continued 
Antigen source Antigen Vector features Animal Immune response Reference 
Promoter Gene or localization 
sequence fused to 
f!romoter 
E.coIi heat labile LT-Bh hsp60 none BALBlcmice IgG and IgA antibodies with all three Hayward 8t al., 1999 
enterotoxin 
19kDa antigen 19kDa antigen signal mucosal and serum IgA antibodies with all 
three but greater for secreted and membrane-
a-antigen Signal associated 
hsp60 
Cholera toxin CTB hsp60 a-antigen Signal mice anti-BCG IgA responses that correlated with Biet 8t aI., 2003 
TGF-Il production 
Borrelia OspA hsp60 none BALBlc; C3H/HeJ protective antibody responses (highest for the Langermann 8t a/., 1994a 
burgdorferi and Swiss membrane-associated form) 
membrane Webster 
(outbred) mice IgA response better than ip IgA response; 
secreted disseminated throughout the mucosal immune 
system 
Edelman at al., 1999 
hsp60 membrane Humans initially PPD-skin test and OspA antibody 
negative; converted to PPD-skin test positive 
but didn't develop anti-OspA antibodies 
streptococcus PspA hsp60 none BALBIcand antibodies with comparable titres; protective Langermann at a/ .. 1994b 
pneumoniae C3H1HeJ mice responses for membrane-associated and 
membrane secreted fonns; antisera showed passive 
protection in immunodeficient mice 
secreted 
Ustaria paO hsp60 none BALBlcmice membrane-associated and secreted fonns Grode at al., 2002 
monocytogenes protected from challenge 
19kDa antigen Signal 
Ag85B Signal 
M.tuberculosis 30kDa major 30kDa major none Guinea pigs better protection from challenge than wild-type Horwitz at al., 2000 
secretory protein secretory BCG 
protein 
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Immune response Reference 
Hsp60 fusion yielded higher antibody Bao et al., 2003 
responses and IFN-y production; both strains 
conferred protection against challenge but not 
better than wild-type BCG 
Th2 response from rBCG-19kDa (lL-10 Rao et al., 2003 
production) 
Th 1 response from rBCG-38kDa (IFN-y 
production) 
mixed Th11Th2 response from ESAT-6 (-IL-10 
and IFN-y levels) 
multiplication of M.leprae in mouse footpads 
was inhibited to larger extent than with wild-
typeBCG 
BCG-specific immune responses that were 
predominantly Th1 in nature 
Ohara et al. 2000 and 
2001 
Dhar et al., 2003 
proliferation and IFN-y production; inhibition of Martin et al., 2001 
M.avium growth after challenge but not better 
than wild-type 
DNA vaccine induced similar proliferation and 
IFN-y production, which was enhanced by a 
boost; reduced M.avium growth 
DNA prime-BCG boost better than BCG alone 
but not better than DNA alone 
Splenocytes taken from mice vaccinated with an rBCG that secreted E.coli l3-gal secreted under 
the control of the BCG a-antigen promoter and signal sequence produced larger amounts of 13-
gal-specific IFN-y and IL-2 and lower amounts of IL-5 compared with controls (Kumar at al., 
1999). They also had significantly lower l3-gal-specific serum IgE, indicating that rBCG secreting 
antigens could be used to induce a Th1-like response. 
Himmelrich et al. (2000) expressed E.coli MalE as cytosolic, membrane-associated or secreted 
protein in rBCG and found that both humoral and proliferative responses were highest in mice 
receiving rBCG that secreted MalE. 
Bacterial toxins 
Stover at al. (1991) expressed fragment C (ToxC) of Clostridium tatani tetanus toxin from the 
BCG hsp60 promoter. Although the expression of ToxC was only 1/250th that of l3-gal expressed 
in the same system, NIH Swiss mice receiving rBCG:toxC intradermally were able to mount an 
antibody response which increased for at least 12 weeks. Antibody responses to rBCG:toxC 
expressed from an integrative vector were able to completely protect or partially protect NIH 
Swiss mice (inoculated either intradermally or intraperitoneally) from challenge with 100 lethal 
doses of tetanus toxin (Fuerst at a/. 1992). 
Two rBCGs expressing a hybrid protein containing the S1 subunit of pertuSSiS toxin fused to 
fragment C of tetanus toxin were constructed (Abomoelak at al., 1999). This S1-TIC protein was 
expressed under the control of either the BCG hsp60 promoter or the 85A antigen promoter and 
signal peptide. Although expression was obtained from both rBCGs, secretion was not obtained 
with the 85A antigen signal peptide and only the hsp60 rBCG was able to induce antibodies 
specific to the tetanus toxin in inoculated mice. These antibodies were able to neutralize toxin 
activity in a challenge model. In addition, this BCG induced S1 and TIC-specific IL-2 production 
in the vaccinated mice. 
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In the first step towards an alternative to the diptheria-pertussis-tetanus toxoid (OPT) vaccine, the 
detoxified S1 subunit of pertussis toxin (S1PT) was expressed under the control of the 
M.fortuitum ~-Iactamase promoter, pBlaF* in fusion with either the entire ~-Iactamase signal 
sequence or the entire ~-Iactamase protein (Nascimento et al., 2000). rBCG-S1 PT induced low-
level antibody production in immunized BALB/c mice, whereas Swiss mice showed elevated IFN-
y levels in their splenocytes after stimulation with pertussis toxin. These mice also had a high 
level of protection against intracerebral challenge with live Bordetel/a pertussis. 
Next, the potential of CRM197, a mutated nontoxic derivative of diphtheria toxin, was analyzed as 
an antigen for expression in rBCG (Miyaji et al., 2001). The mutated toxin was also expressed 
under the control of the M.fortuitum pBlaF* promoter. BALB/c mice immunized with this rBCG 
mounted an anti-diphtheria toxoid antibody response, but the antisera from these mice were 
unable to neutralize diphtheria toxin activity. However, when the rBCG was administered in 
combination with an rBCG expressing the tetanus toxin fragment C (FC), the antibodies produced 
did show neutralizing activity; this suggested that the rBCG-FC had an adjuvant effect on the 
response induced by rBCG-CRM197. The rBCG-CRM197 has an adjuvant effect on the response 
induced by rBCG-FC (pBlaF*promoter) as well (Mazzantini et al., 2004). The rBCG-FC alone and 
in combination with rBCG- CRM197 induced anti-tetanus toxin antibodies in immunized mice; the 
combination reduced the time required for the immune response to mature and increased the 
levels of anti-tetanus antibodies. The combination of the two rBCGs also protected 75% of mice 
from challenge with 100 minimum lethal doses of tetanus toxin. Additionally, antisera from guinea 
pigs immunized with both rBCGs were able to neutralize both tetanus and diphtheria toxin. 
Hayward et al. (1999) constructed three different rBCGs that expressed the B sububit of E.coli 
heat labile enterotoxin (L T-Bh) in either cytosolic (hsp60 promoter), membrane-associated 
(19kOa antigen promoter and signal sequence) or secreted (hsp60 promoter and a-antigen signal 
sequence) form. IgG and IgA antibodies to LT-Bh were induced in BALB/c mice inoculated 
intraperitoneally with these three rBCG. Oral inoculation induced both mucosal and serum IgA 
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antibodies to L T -Bh but antibody responses were greater for secreted or membrane-associated 
LT-Bh than the cytoplamically expressed LT-Bh. 
An rBCG strain producing (hsp60 promoter) and secreting (a-antigen secretion signal) the 
cholera toxin B subunit (CTB) induced anti-BCG IgA responses in the bronchoalveolar lavage 
fluids of intranasally immunized mice that were stronger than the responses to wild-type BCG 
(Biet at a/., 2003). This IgA response correlated well with increased TGF-~ production in the mice. 
The results indicated that the CTB-producing rBCG could be used as a powerful adjuvant for 
mucosal vaccines. 
Sorrella burgdorferl OspA 
The outer surface protein A (OspA) of Borrelia burgdotfari was expressed under the control of the 
hsp60 promoter as a cytosolic protein, as a secreted fusion protein or as a membrane-associated 
lipoprotein (Stover at a/., 1993). The membrane-associated form resulted in protective antibody 
responses that were 100-1000-fold higher than the responses elicited by the other forms in three 
different mouse strains (BALB/c, C3H/HeJ and outbred Swiss Webster) after two intraperitoneal 
inoculations of 106 cfu. When investigating the intranasal route of delivery, they found that the IgG 
response was similar to that in mice inoculated ip. The IgA response, however. was potent and 
highly sustained (Langermann at a/., 1994a). This secretory IgA response was disseminated 
throughout the mucosal immune system and was also shown to have the features of a systemic 
Immune response by the appearance and persistence of lymphoid aggregates. 
Based on these results, the rBCG expressing OspA in membrane-associated form was used in 
the first phase I clinical trial involving a rBCG vaccine (Edelman at a/., 1999). The vaccine was 
administered intradermally to 24 healthy adults in four progressively higher doses (from 2x104cfu 
to 2x1 07 cfu) over a period of 28 weeks. Initially the volunteers were both PPD-skin test negative 
and OspA antibody negative. Eventually. 13 of the 24 converted to PPD-skin test positive but 
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none of them developed antibodies against OspA. The rBCG had a safety profile that was 
deemed comparable to that of the parental BCG. 
Streptococcus pneumoniae PspA 
The parental vectors described by Stover et a/. (1993) were used to express the NHz-termlnal 
portion of Pneumococcal surface protein A (PspA) of Streptococcus pneumoniae in BCG 
(Langermann et al., 1994b). All the rBCG:PspA strains induced PspA-specific antibodies with 
comparable titres in BALB/c and C3H/HeJ mice. Animals immunized with the rBCG that 
expressed PspA in secreted or membrane-associated form were able to mount protective 
responses to a lethal dose of virulent pneumococci. The antisera from these animals were shown 
to passively protect immunodeficient mice from challenge with three different highly virulent strain 
of S.pneumoniae. 
listeria monocytogenes p60 
BALB/c mice inoculated with rBCG strains expressing (hsp60 promoter) the L.monocytogenes 
p60 Ag in secreted (Ag85B secretion signal) and membrane-associated (19kDa secretion signal) 
form yielded equivalent anti-listerial protection, while the cytosolic form yielded no protection 
(Grode et a/., 2002). 
Mycobacterial antigens 
In an effort to increase the efficacy of BCG as an anti-tuberculosis vaccine, Horwitz et a/. (2000) 
developed an rBCG vaccine expressing the M.tuberculosis 30-kDa major secretory protein. The 
protein was expressed from its own promoter in two BCG host strains (Connaught and Tice). 
They tested the efficacy in a highly susceptible guinea pig model and found that after challenge 
with a highly virulent strain of M.tuberculosis the guinea pigs that received the rBCG had 0.5 logs 
fewer bacilli In their lungs and 1 log fewer in their spleens than those that received conventional 
BCG. The animals receiving the rBCG also had fewer and smaller lesions in their lings, spleen 
and liver than those receiving parental BCG vaccines. 
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A similar strategy was employed to express the esat-6 gene of M.tuberculosis in rBCG under the 
control of the hsp60 promoter either as a fusion protein linked to Hsp60 or as a secreted protein 
(a-antigen; Bao et al., 2003). The rBCG expressing the fusion protein yielded significantly higher 
specific antibody responses and higher levels of antigen-specific IFN-y production in immunized 
BALB/c mice, while the rBCG expressing the secreted ESAT-6 induced immunity similar to that of 
wild-type BCG. Although both strains of rBCG conferred protection against virulent M.tuberculosis 
challenge, this protection was not Significantly better than that conferred by wild-type BCG 
vaccination. 
The M.tuberculosis 19kOa antigen, 38kOa antigen and ESAT-6 antigen genes were cloned under 
the control of the strong M.tuberculosis ribosomal RNA promoter, Trrn, for expression in rBCG 
(Rao et al., 2003). The immune response in BALB/c mice immunized with these rBCG strains 
was modulated significantly in comparison with the response in mice receiving wild-type BCG. 
The responses to the antigens, however, were markedly different: the rBCG expressing the 
19kOa antigen exhibited a Th2-type response characterized by a high level of IL-10 production 
after BCG sonicate stimulation; the rBCG expressing the 38kOa antigen produced high levels of 
IFN-y in response to stimUlation and was thus polarized towards a Th1-type response; the ESAT-
6 expressing rBCG exhibited a mixed Th1ITh2 response with levels of antigen-specific IFN-y and 
IL-10 production more or less comparable. 
The multiplication of M.leprae in the footpads of BALB/c and C57BU6 mice immunized with rBCG 
that overproduced two of the Mycobacterial antigen 85 complex of major secretory proteins -
Ag85A and Ag85B - and the related protein, MPB51 along with their native signal sequences 
under the control of their own promoters was inhibited to a greater extent than the inhibition 
induced by parental BCG (Ohara et al., 2000 and 2001). 
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Martin et a/. (2001) compared the immune response induced by rBCG over-expressing the 
M.avium 35kDa protein to that induced by a DNA vaccine expressing the same antigen. rBCG-35, 
expressing the protein from the pBlaF* promoter, induced strong antigen-specific IFN-y-secretlng 
and proliferative responses in the T-cell of immunized C57BU6 mice. DNA-35 induced similar 
levels of proliferation and IFN-y secretion after a single immunization and this was enhanced by a 
further immunization. While rBCG-35 immunization did inhibit virulent M.avium growth after 
challenge, the level was similar to that induced by wild-type BCG; DNA-35 immunization 
significantly reduced M.avium growth. DNA prime-rBCG boost strategies yielded better protection 
than rBCG alone but not better than DNA alone. 
BALB/c mice immunized with rBCG expressing Ag85B under the control of either the M.leprae 
hsp65 promoter, the T31 or the S16 promoters (from a Mycobacterial promoter library) mounted 
BCG-specific immune responses that were analyzed to determine whether they were Th1 or Th2 
in nature (Dhar et a/., 2003). Investigating the antigen-specific IFN-y versus IL-10 and the IgG2a 
versus IgG1 responses indicated that, although the responses ranged from a mixed Th11Th2 to 
Th1, they were predominantlyTh1 in nature. 
1.B.3.3. PARASITE ANTIGENS 
rBCG technology has been used for the expression of various parasite antigens from different 
promoters. Animals immunized with these rBCG have been shown to mount cellular and humoral 
Immune responses to these antigens (Table 1.7.). 
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Table 1.7. Immune responses In vaccinated animals to rBCG expressing parasite antigens under the control of different promoters with or without localization sequences 
AntIgen source Antigen Vector features Animal Immune response Reference 
Promoter Gene or localization 
sequence fused to 
~romoter 
Plasmodium CSP 64kDa antigen none mice no humoral or proliferative responses Haeseleer et al., 
falcipsrum 1993 
hsp70 BALBlcmlce antibodies; IFN-yand IL-2 production; enhanced Zhang et al., 2001 a 
by boost and 2002 
MSA2 hsp70 none BALBlcmlce significant and sustained antibodies; proliferative Zheng et al., 2001 b 
responses; IFN-y and IL-2 produdion 
P.yoelii CSP B cell epitope a-antigen a-antigen signal mice long-lasting antibodies in 117 mice Matsumoto et al., 
1996b 
MSP1 a-antigen a-antigen signal C3H1Hemice IFN-y production related to clearance of parasite; Matsumoto et al., 
antisera was shown to proted against challenge 1998 
Leishmania major gp63 hsp60 none BALBlc and CBAlJ significant protection against Lmexicana Connell et aI .• 1993 
mice challenge but only CBAlJ mice proteded against 
Lmajor 
pBlaP M. fortuitum IHac protein BALBlcmice significant protection against Lmajor challenge Abdelhak et al .• 
1995 
Lchsgasi LCR1 hsp60 none BALBlcmice better protection against challenge with rBCG Streit et al .• 2000 
than with LCR1 protein alone; IFN-y production 
Schistosoma Sm28GST hsp60 none BALBlcmice significant antibodies enhanced by booster; ~retat. 1996 
mansoni neutralization of Sm28GST enzyme activity; 
IgG1. IgG2a. IgG2b and IgA isotypes produced 
Sm14 pBlaP M.fortuitum p-lac protein BALBlcmice IFN-y production; 48% decrease in worm burden Varaklo et al .• 2004 
after cercarial challenge 
S. haematobium Sh28GST hsp60 none BALBicmice strong antibodies; IgG1. IgG2a. IgG2b and IgA ~r et al .• 1998 
Isotypes produced 
Toxoplasma goodii GRA1 Ag85A Ag85A signal OF1 outbred mice no humoral or cellular response Supply et al., 1999 
sheep 
proliferation and IFN-y production; partial 
I!rotectlon from challe!:!Se 
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Malarial antigens 
The first attempt to induce an immune response to malarial antigens using rBCG technology was 
unsuccessful. Haeseleer et al. (1993) were able to express the first 412 amino acids of the 
Plasmodium falciparum circum sporozoite protein (CSP) under the control of the BCG 64kDa 
antigen promoter in an integrative shuttle vector system but were unable to induce humoral or 
proliferative responses in immunized mice. In a more recent study, the CSP gene from 
P.falciparum strain FCC-1/HN was expressed under the control of the M.tuberculosis hsp70 
promoter in rBCG (Zheng at al., 2001 a). BALBlc mice immunized with this rBCG developed a 
significant anti-CSP antibody response that was enhanced after a booster inoculation (Zheng et 
al., 2002). Specific proliferative responses, IFN-y and IL-2 production were also demonstrated 
after stimulation with malarial antigens and these all increased after the boost (Zheng et al., 
2002). In addition, the same system was used to express the merozoite surface antigen 2 (MSA2) 
from P.falciparum in rBCG (Zheng et al., 2001b). The administration of rBCG-MSA2 to BALB/c 
mice induced significant and sustained anti-MSA2 antibodies. Specific proliferative responses, 
IFN-y and IL-2 production were also induced after malarial antigen stimulation. 
A B-cell epitope of the CSP from the rodent malarial parasite, P.yoelii, expressed under the 
control of the M.kansasii a-antigen promoter and signal sequence yielded a long-lasting antibody 
response in 1 mouse out of 7 inoculated with the vaccine (Matsumoto et al., 1996b). Using the 
same system group the COOH-terminal fragment of MSP1 from P.yoelii was also expressed in 
rBCG (Matsumoto et al., 1998). When comparing the protective efficacy of rBCG-MSP1 with 
recombinant MSP1 in RIBI adjuvant or incomplete Freund's adjuvant in immunized C3H1He mice, 
the rBCG yielded the highest degree of protection and mouse splenocytes were able to produce 
MSP-speciflc IFN-y that was important in the clearance of the parasites in a challenge 
experiment. Antibody responses specific to MSP1 were not involved in clearance, however, after 
challenge, antisera carrying IgG2a antibodies were shown to be protective. The endurance of this 
protective response was observed for as long as nine months after the final immunization 
(Matsumoto et al., 1999). 
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Leishmania antigens 
The Leishmania major surface proteinase gp63 gene was cloned and expressed in rBCG under 
the control of the hsp60 promoter (Connell et al., 1993). BALB/c and CBAlJ mice were immunized 
with the rBCG and then challenged with promastigotes of L.major and L.maxicana. Both mouse 
strains demonstrated significant protection against L.mex/cana but only the CBAlJ mice were 
protected against L.major - a delay in L.major growth was observed in immunized BALB/c mice. 
Challenge with L.mexlcana amastigotes also resulted in a strong protective immune response. 
The L.major gp63 gene expressed in rBCG as a fusion with the N-terminal region of the 
M.fortuitum p-Iac protein (pS/aF* promoter) was able to induce Significant protection in immunized 
BALB/c mice that were challenged with L.major (Abdelhak at al., 1995). 
Another Lasihmanla antigen, LCR1 from L.chagasi, was expressed in rBCG under the control of 
the hsp60 promoter (Streit at al., 2000). A better protective response was elicited in BALB/c mice 
inoculated subcutaneously with rBCG-LCR1 than in mice that received the LCR1 protein alone. 
These mice also produced significantly more LCR1-specific IFN-y. 
Schistosoma antigens 
Kremer et al. (1996) developed an rBCG expressing (hsp60 promoter) the 28kDa glutathione S-
transferase of Schistosoma mansoni (Sm28GST). BALB/c mice give a single inoculation with the 
rBCG via the intravenous, intraperitoneal, subcutaneous or intranasal route were able to mount 
Significant anti-Sm28GST antibody responses. These responses were enhanced by a booster 
dose and remained at a high level for as long as a year post-immunization. Isotyping of the 
antibodies showed that antigen-specific IgG1, IgG2a, IgG2b and IgA antibodies were elicited. 
Strong neutralization of the Sm28GST enzyme activity by the antibodies was also demonstrated. 
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An rBCG expressing the glutathione S-transferase of S.haematobium (Sh28GST) In the same 
system was also constructed (Kremer et a/., 1998). Intraperitoneal and intranasal immunization of 
BALB/c mice resulted in strong anti-Sh28GST antibody responses that were enhanced by a 
booster immunization. The mice inoculated intranasally produced IgG1, IgG2a, IgG2b and IgA 
antibodies. An interesting finding was that, although Sm28GST shares over 90% identity with 
Sh28GST, a much stronger humoral response was elicited by rBCG-Sh28GST after intranasal 
inoculation (this was not the case for intraperitoneal inoculation). 
Recently. Varaldo et a/. (2004) developed an rBCG expressing the Sm14 antigen of S.mansoni 
as a fusion with the M.fortuitum p-Iac protein under the control of the pBlaF* promoter. 
Immunization of BALB/c mice with rBCG-Sm14 did not elicit an antigen-specific antibody 
response, but IFN-y was produced in the splenocytes of the mice when stimulated with rSm14. 
Immunized mice were challenged with live S.mansoni cercaria amd showed a 48% decrease in 
worm burden; a reduction comparable with three doses of rSm14. 
Toxoplasma antigens 
OF1 outbred mice immunized with rBCG expressing the GRA1 antigen of T.gondii in rBCG 
(M.tuberculosis Ag85A promoter and fused to its signal sequence) did not mount GRA1-specific 
humoral or cellular immune response (Supply et al .• 1999). When sheep were immunized 
subcutaneously and then boosted intravenously with the rBCG, GRA 1-specific proliferation and 
IFN-y production was Induced; no antibody responses were observed. These sheep were 
challenged with T.gondli oocysts and displayed an abbreviated temperature response compared 
with controls; this result suggested partial protection. 
1.B.3.3. IMMUNOMODULATORS 
A number of cytokines have also been expressed in BCG in attempts to enhance its anti-cancer 
and anti-tuberculosis properties. These include IL-2 (O'Donnell et al., 1994; Murray et a/., 1996; 
Yamada et al .• 2000), IL-4, IL-6 (Murray et al., 1996) and IL-18 (Biet et al., 2002). Other 
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immunomodulators that have been investigated are IFN-y (Murray at a/ .• 1996; Kong et a/ .• 1997). 
IFN~cx. (Luo et a/ .• 2001) ~nd GM~CSF (Murray et a/ .• 1996). 
AIM OF THIS WORK 
There is an urgent need to develop an effective and inexpensive prophylactic vaccine against 
HIV-1. Until recently. most vaccine development efforts have focused on subtype B strains of 
HIV-1. however. subtype C viruses predominate in the southern African region and worldwide. 
The overall aim of this project was to identifly subtype C isolates for inclusion into candidate HIV 
vaccines and to evaluate BCG as an HIV vaccine vector. 
As HIV diversity may impact on vaccine efficacy, the initial aim of this thesis was to 
select an HIV-1 subtype C gag gene that is relevant to the southern African region for 
inclusion in vaccine candidates (Chapter 2). 
A number of integrative or episomal E.colilMycobacterium shuttle vectors for Gag 
expression from different combinations of promoters and cellular localization signals 
were constructed (Chapter 3); 
To determine which shuttle vectors were suitable candidates for further study, the 
stability and Gag expression levels of the shuttle vectors were compared in 
recombinant M. smegmatis (Chapter 3); 
In addition, assessment of Gag expression in rBCG cell culture and in rBCG-infected 
macrophages was also performed in preparation for immunogenlcity studies (Chapter 
3); 
Immunogenicity testing of the rBCG:Gag vaccine candidates in the mouse model 
using two approaches - a DNA prime~rBCG boost and 5 inoculations of rBCG - was 
also performed (Chapter 4). 
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CHAPTER 2 
SELECTION OF A HIV-1 SUBTYPE C GAG GENE FOR 
USE IN VACCINE DEVELOPMENT 
2.1. INTRODUCTION 
The design of early candidates HIV vaccines was restricted to genes from laboratory adapted 
strains of HIV-1 subtype B as these were the available reagents (Hu et al., 1987; Graham at 
al., 1992; Belshe at al., 1993 and Raedelli at al., 1994). Howaver, by tha aarly 1990s, as the 
diversity of the pandemic became evident, it was apparent that non-B subtypes predominated 
in the regions most affected by the epidemic and there was increased interest in developing 
vaccines based on these subtypes. It may also be of benefit to design vaccines using 
sequences from recently Infected individuals as these may contain unique signature patterns 
compared to viruses from chronic infection (Derdyn et al., 2004). The aim of this study was to 
identify a gag gene, of a recently transmitted virus, representative of the viruses circulating in 
South African 
Strains from the same HiV subtype can differ by up to 20% in Env and this can reach as high 
as 35% between strains from different subtypes (Gaschen et al., 2002). As this variation may 
impact on epitope recognitlon~ and thus vaccine effectlveness~ it may be advantageous to 
match vaccines to the local epidemics. The influenza virus vaccine strains. for example, 
needs to be changed when the amino acid differences between the circulating strain and the 
vaccine are - 2% (Korber at al., 2001). HIV diversity exceeds that of any other known virus 
(Rambaut at al., 2004) with the viral diversity within an infected individual comparable to the 
global diversity of Influenza virus In a given year (Korber at al .• 2001). Thus, the design and 
choice of Immunogens to Include in a candidate HIV-1 vaccine may be crucial to minimize the 
impact that the enormous diversity of this virus may have on vaccine efficacy. 
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Ideally a vaccine will need to elicit both neutralizing antibodies, as well as cellular immune 
responses which will protect from infection. This study is focused on vaccines that will elicit 
cellular immune responses. Cross-reactive CTL responses have been demonstrated in 
various studies (McKinney at al., 2004; Barugahare at al .. 2005 and Currier at al., 2005). 
CTLs from individuals infected with HIV-1 are able to mount significant cross-reactive 
responses to other subtypes (Coplan at al., 2005) and CTLs from un infected, vaccinated 
individuals are also able to respond to HIV isolates from different subtypes (Ferrari at al., 
1997). However, the CTL responses to peptides matched to the Infecting strain tend to be 
stronger, more durable and have more breadth (McKinney at al., 2004; Currier at al., 2005 
and Coplan at al., 2005). It is thus unlikely that a vaccine that is genetically distant from the 
infecting virus, for example a subtype B vaccine for a subtype C epidemic, will provide a 
better immune response than a vaccine genetically matched to the circulating subtypes 
(Novitsky at al., 2002a). 
The ideal vaccine is one genetically matched to the potential infecting strains. However, as it 
is not possible to achieve complete homology between the vaccine and circulating viruses, 
strategies to minimize the genetic distance between them have been developed. 
One of these strategies makes use of actual viral sequences where regional strains are 
selected opportunistically from viruses within the geographic area where the vaccine is 
intended for use (Goudsmlt, 2000). In reviewing available results and sequences for subtype 
C, Gaschen at al. (2002) found that, while there were clear phylogenetic outliers, there was 
no single choice of a sequence most representative of the diversity in a given region. 
However, they suggested that it may be advantageous to select a sequence with a short 
branch length relative to the common ancestor which most closely resembles the sequence of 
the epidemic-founding strain. This central sequence would be most similar to the majority of 
contemporary sequences in the tree (Foley at a/., 2000 and Gaschen at a/., 2002). 
Other strategies make use of artificial sequences constructed based on analysis of 
phylogenetic relatedness between sequences (Korber et al.. 2001; Gaschen at a/., 2002; 
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Learn and Mullins, 2000; Mullins at al .• 2002; Novitsky st al., 2002a; Nickle at al., 2003 and 
Gao st al., 2003). There are several approaches that have been proposed which derive 
sequences which are most similar to the contemporary circulating viruses. These Include: 
A consensus sequence which is derived from the most common arrino acid In 
each position in an alignment (Korber at al., 2001 and Novitsky at al .• 2002a) 
An ancestral sequence reconstructed from an evolutionary model (Leam and 
Mullins, 2000; Mullins at al., 2002) 
A centre of tree (COT) sequence which is at the point on the phylogany where 
the average evolutionary distance from the COT to each tip is minimized (Nickle 
st al., 2003) 
A consensus sequence is more similar to the circulating vlrusas than they are to each other 
(Korber st al., 2001). Lukashov and Goudsmlt (1997) found that an HIV-1 subtype consensus 
was fairly stable over time since the sequences within a subtype are constrained to a space 
which is a fixed distanca from that consensus. One use for the consensus approach would 
be In regions like the Democratic Republic of the Congo where there are multiple subtypes 
and CRFs circulating that the regional diversity is sirrilar to the global diversity (Mokili st al., 
1999 and Vidal st al .• 2000). Here, an M-group consensus derived from a set of subtype 
consensus sequences might be useful (Gaschen st al .• 2002). 
The construction of these artificial sequences is dependent on the sequences included in the 
analysis and the consensus sequence, in particular, will change as the available sequences 
accumulate. The ancestral sequences are also more similar to contemporary viruses than 
they are to each other (Learn and Mullins, 2000; Mullins st al., 2002). Nickle st al. (2003) 
state that although consensus and ancestral vaccines rrinlmize the distance between vaccine 
antigens and circulating viruses when they are derived from symmetrical phylogenies. they 
may not be as accurate when the phylogenies are asymmetrical (multiple subtypes or CRFs). 
They suggest that an ancestral sequence has more chance of generating a protein that will 
fold and function correctly and that it is unlikely to require much change when new sequences 
are added to the analysis. However, they developed another method for vaccine antigen 
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design which is similar to ancestral sequences but is less sensitive to phylogenetic outliers. 
This Centre of Tree (COT) is derived from a phylogenetic tree at the point where the 
evolutionary distances between the COT and other sequences in the analysis are minimized. 
The COT is designed to be more similar to rapidly evolving viral subtypes than an ancestral 
sequence and still maintain similarity to the slower evolving lineages. It may thus be more 
useful when trees are asymmetrical (Nickle at sl., 2003). 
Being artificial sequences, the expression, antigenicity and biological activity of the consensus 
and ancestral sequences need to be characterized before use in a vaccine (Gaschen at sl., 
2002 and Novitsky at sl., 2002a). However, although structure may be Important for the 
generation of antibody responses where discontinuous epitopes recognition occurs, this is 
less critical for CTl responses where recognition of linear peptides may even be improved 
with the use of consensus sequences (Gaschen at sl., 2002). The consensus and ancestral 
sequences have been shown to conserve both CTl epitopes and predicted 
Immunoproteasome cleavage sites, implying that CTl responses would not be affected by 
their use (Gaschen at sl., 2002). This analysis also predicts that using a subtype B·based 
vaccine against a subtype C epidemic would be less effective than a subtype C·based 
vaccine and a subtype C consensus would be the most effective (Gaschen at sl., 2002). 
In a summary of the use of the COT, ancestral and consensus methods, Gao at sl. (2003) 
state that the three derived sequences will only be slightly different from each other since they 
are subject to different biases but that the biological properties of such artificial sequences 
cannot be predicted. Experiments need to be conducted to test their preservation of key 
antigenic domains, their immunogenicity and the extent to which they induce cross-reactive 
protection. 
Other strategies that attempt to deal with the problem of diversity in vaccine design include 
the design of modified envelope proteins which enhance the exposure of hidden epltopes 
known to induce broadly neutrallsing antibodies (Bamett at sl., 2001 and Saphire at sl., 
2001), the use of polyvalent peptides or epitopes that span a region that induces strain-
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specific neutralising antibodies and T -cells (Llao at al., 2002 and Zhan at al., 2004) and 
vaccine cocktails expressing the same gene from a number of different subtypes (Ljungberg 
at al., 2002). 
2.1.1. RATIONALE 
This objective of this study was to identify a gag sequence~ from a recently transmitted virus, 
that was closest to a South African consensus sequence derived from circulating viruses, for 
inclusion into CTL inducing vaccines. Viruses belonging to the same subtype are more 
closely related to each other than to viruses belonging to other subtypes and consequently 
viruses of the same subtype have more shared epitopes. Also, CTL responses of infected 
inviduals to epitopes of viruses from the same subtype are better than the responses to 
epitopes of viruses from different subtypes (McKinney at al., 2004 and Currier et al., 2005). It 
has been shown that there are differences in selection pressure on subtype Band C envelope 
genes, Implying that there is lineage-specific immunogenlclty (Gaschen at al., 2002). 
Together, these data argue for the use of subtype-specific vaccines that would maximize the 
number of potentially cross-reactive epitopes between the vaccine and those in viruses 
circulating in the target population. In this study a sequencing survey of currently circulating 
viruses In South Africa was performed, a gag subtype C consensus sequence was derived, 
and a sequence most closely related to this consensus selected for inclusion into vaccines. 
The HIV-1 gag gene was selected as a model immunogen to include in vaccine candidates 
as: the gag gene has been shown to be rich in CTL epltopes (HIV Molecular Immunology 
Database; http://hiv-web.lanl.gov/contentlimmunoloay/ctl search); regions of the gag gene 
sequence are highly conserved across different subtypes (Korber at al., 2001); some studies 
have shown that anti-Gag responses are associated with control of viral replication (Ogg at 
al., 1999 and Masemola at al., 2004a). As detailed in section 1.5.2, a high frequency of Gag-
specific CTL-responses have been demonstrated in a number of different cohorts infected 
with HIV-1 subtype C (Goulder at al., 2000; Novitsky et al., 2001, 2002a and Masemola et al., 
2004a and b). 
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The vaccine strain was selected based on the virus which was most closely matched to the 
amino acid sequence of the consensus, from an individual with acute infection and which 
grew in tissue culture. This approach attempts to minimise the distance between the vaccine 
and Circulating strains while still utilizing genes from wild type virus and thus not requiring 
resynthesis of the gene for use in the vaccine candidate. The sequence survey was 
performed using representative, recently transmitted subtype C isolates from patients either 
within 1 year of infection (acute infection) or with CD4 counts >500 cellslcm3• Selection of 
genes from individuals with acute HIV-1 infection has the advantage that they have properties 
close to the transmitted virus. The selected strain would be used in the development of Gag 
vaccines targeted for South Africa. 
2.2. METHODS 
2.2.1. SAMPLES 
To ensure geographical representation, samples were collected from HIV-1 infected 
individuals from three provinces: KwaZulu Natal, Gauteng and the Westem Cape. Ethical 
approval was obtained for sample collection from University of Cape Town Research Ethics 
Committee [UCT Research Ethics Committee number: 137/95]. Samples were classified into 
two groups based on the timing of their infection. 
Individuals near seroconverslon 
This group was composed of samples collected from 14 female sex workers (Du prefix) from 
five truck stops between Johannesburg and Durban. The demographics of the individuals and 
the viral characteristics are shown in Table 2.1. The women were participating In a phase III 
HIV-1 prevention microbicide trial (van Damme et a/., 2002) and were being screened 
monthly for HIV-1 infection. Samples were provided from individuals within 1 year of infection 
although two of the women had seroconverted 14-16 months before sample collection (Du174 
and 179). Samples were provided by G. Ramjee (Medical Research Council, South Africa) 
and S. Abdool-Karlm (University of KwaZulu-Natal, South Africa). 
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TABLE 2.1. Clinical data. viral phenotype and coreceptor usage from recently Infected Individuals from the 
Du cohort (adapted from Williamson et a/ •• 2003). 
Sample EstImated months CD4+cell Viral load (HIV.1 Viral Coreceptor 
number after .... oconverslon· count (cells/j.lI) RNA coplHlml) phenotypeb usage· 
Ou115 6.8 437 7597 
Du123 3.5 841 193331 NSI R5 
Du151 2.1 367 >500000 NSI R5 
Ou156 <1 404 22122 NSI R5 
Ou172 3.2 793 1916 NSI R5 
Ou174 14.1 634 9454 NSI R5 
Du179 16.1 394 1359 SI R5X4 
Du204 6.5 633 8734 NSI R5 
Ou258 6.3 433 9114 
Du281 4.7 594 24689 NSI R5 
Ou386 8.3 670 13933 NSI R5 
OU422 2.0 409 17118 NSI R5 
Ou457 3.5 665 6658 
Ou467 3.2 671 19268 
'All women were screened monthly for HIV·1 infection. except for OU172. whose last negative ELISA and first 
positive EUSA were 4 months apart. Estimated months after seroconversion was taken from the midpoint between 
the last negative and the first positive ELISA 
b Negative PCR or culture; NSI = nonsyncytium Inducing; SI = syncytium Inducing 
<Negative PCR or culture; Viral Isolates could not be made from the PBMCs of 4 of the cohort samples 
Prevalent asymptomatic Individuals 
This group was composed of 2 Individuals from outpatient clinics in Cape Town (CTSC 
prefix). 7 women attending an antenatal clinic in Johannesburg (GG prefix; samples provided 
by G.Gray; Chris Hani Baragwanath Hospital. South Africa) and 9 men attending a sexually 
transmitted disease clinic at the West Driefonteln mine in Carltonville (RB prefix; samples 
provided by R. Ballard; Carltonville). These individuals were clinically well and had CD4+ cell 
counts greater than 500cellsl~1 (information provided by National Institute for Communicable 
Diseases; C. Gray). 
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2.2.2. RT ·peR 
RNA Isolation 
Viral RNA was isolated from 1401-11 patient plasma using QIAamp Viral RNA Kit (Qlagen. 
Germany); the RNA was eluted with S0J,11 RNase-free water. 
Primers 
Primers were designed to amplify 939bp of gag, incorporating p17 and most of p24. 
Table 2.2 lists the primers used in the RT-PCR. 


























The viral RNA was heated at 9SoC for 2 min and then placed on ice for 2 min. Thereafter, 3J.11 
of the RNA was used to synthesize cDNA In a reverse transcription mastermlx containing 2J.11 
of 10x HIFI buffer with MgCI2; 0.4J,11 of 2SmM dNTPs; 1.SJ,11 of the J..gag-r primer at 10pmollJ,1l; 
0.2SJ,11 of 40U/J,11 RNASln and OAJ,11 of AMV RT in a final reaction volume of 201-11. The reaction 
mix was incubated at 42°C for 30 min. After deactivating the AMV RT for S min at 9SoC, the 
reaction was placed on ice for a further S min. The cDNA produced by this reaction was used 
In the outer PCR mix. 
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The 20",1 of cDNA produced in the RT reaction was added to the 30",1 outer PCR mix that 
consisted of 3",1 of 10x HiFi Buffer with MgCI2; 1.5",1 of the I-gag-f primer at 10pmoV",I; 0.75",1 
of Expand High Fidelity Taq (3.5U1",1; Roche, Basel, SWitzerland). The thermocycle for the 
outer reaction consisted of a cycle of 95°C for 2 min followed by 10 cycles of [95°C for 45 sec; 
55°C for 45 sec; 68°C for 1 min], then 10 cycles of [95°C for 45 sec; 55°C for 45 sec; 68°C for 
2 min], 10 cycles of [95°C for 45 sec; 55°C for 45 sec; 68°C for 3 min] and 10 cycles of [95°C 
for 45 sec; 55°C for 45 sec; 68°C for 4 min]. The PCR was completed with a final elongation 
cycle of 7 min at 72°C. 
The Inner PCR mix was made up of 5",1 of 10x HIFi Buffer with MgCI2; 0.4",1 of 25mM dNTPs; 
1.5",1 of each primer (UPIDN) at 10pmoV",I; 0.75",1 of Expand High Fidelity Taq (3.5U/",I; 
Roche, Basel, Switzerland) and 3",1 of the outer PCR product in a 50",1 reaction volume. The 
thermocycle for the inner reaction was the same as that for the outer reaction. 
2.2.3. SEQUENCING AND SEQUENCE ANALYSIS 
The Inner PCR amplification products (514bp and 589bp) were purified using the OIAqulck 
PCR purification kit (Olagen, Germany). The purified products were quantitated on agarose 
gels by comparing band Intensities to bands of known concentration and 20-30ng of each 
product were used in sequencing reactions. The Inner PCR primers (Table 2.1) were used in 
sequencing reactions performed on both strands, carried out on an ABI-Prlsm 377 DNA 
sequencer (Applied Biosystems, Foster City, CA; Mr K. van Heerden, University of 
Stellenbosch). 
Phylogenetic analysis 
The DNA sequences were assembled and translated using Genepro version 6.1 (Riverside 
SCientific, MN, USA) to identify ORFs. The gag DNA sequences were compared 
phylogenetically with a subtype C consensus sequence (http://hiv-web.lanl.gov), Indian 
subtype C sequences (http://hiv-web.lanl.gov), Malawian subtype C sequences (R. 
Swanstrom; UNC Centre for AIDS Research, University of North Carolina, USA; personal 
communication) and reference gag sequences for the non-subtype C subtypes (http://hiv-
web.lanl.gov). The gag DNA sequences were also compared phylogenetlcally with Southern 
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African sequences from Johannesburg, Durban, Zambia. Zimbabwe and Malawi (the 
HIVNET028 study; H. Breden, unpublished); subtype C sequences from the Los Alamos HIV 
sequence database (http://hiv-webJanl.gov) and the del1ved ancestral sequence for subtype 
C (http://hiv-web.lanl.gov). 
Sequence alignment was performed using ClustalX (Thompson at a/.. 1997) or BioEdit 
Sequence Alignment Editor (version 7.0; Isis Pharmaceuticals Inc: Hall, 1999) with final 
manual adjustment. A neighbour-joining phylogenetic tree was generated with the Kimura 
two-parameter distance correction (Kimura, 1980) with 100 bootstrap replicates using 
TreeconW software (van de Peer and de Wachter. 1994). DNA and amino acid distance 
matrices were calculated with ClustalX (Thompson at a/., 1997) or Mega2 (version 2.1, 
Molecular Evolutionary Genetic Analysis, Kumar at al., 2001). An entropy plot was also 
performed using BioEdit Sequence Alignment Editor (version 7.0, Isis Pharmaceuticals Inc; 
Hall, 1999). 
A South African consensus sequence was generated using DNAMAN (version 4.0, Lynnon 
Biosofl, Vandreuil-Dorion. Canada) and defined the most common amino acid at each 
poSition. The consensus sequence (ZA_CON) was Included in the analysis. 
2.3. RE8UL T8 
2.3.1. PHYLOGENETIC RELATIONSHIPS BETWEEN THE GAG 
SEQUENCES 
A total of 32 partial gag sequences (939bp) were generated; 14 from recently infected 
individuals from the Durban cohort (Du), 2 from outpatient clinics in Cape Town (CTSC): 7 
from women attending antenatal clinics (GG) and 9 from men attending an STD clinic (RB). 
All the sequences were classified as subtype C (Fig 2.1). There was limited internal structure 
in the tree with South African sequences grouping within four subclusters supported by 
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significant bootstrap values (~70). The sequences in the first subcluster RB14 and 18, were 
closely related and most likely share a common origin, reflecting either direct transmission or 
infection from common partner. The linkage between these sequences was maintained In 
other genes (pol, anv) confirming that it was not a contamination (Williamson at al., 2003). 
The second subcluster consisted of sequences from different geographical origin, Du174, 
GG5 and RB13; the third subcluster was made up of sequences from the Du cohort, Du151 
and 422, while the fourth subcluster comprised of two Malawian sequences and the South 
African GG10 and RB22 sequences. The Ethiopian and Brazilian reference sequences 
grouped as a subtype C outlier to the southern African and Indian subtype C. 
The average nucleotide distance between the gag gene sequences of the South African 
subtype C viruses was 5.9%. The greatest nucleotide distance between sequences was 9.5% 
(between CTSC1 and Du204) and the closest distance was 1% (between RB14 and 18). 
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Fig 2.1. Nelghbour-lolnlng phylogenetic tree generated to subtype the South Africa HIV-1 Gag sequences (939bp) 
100 bootstrap replicates were perfonned; Dlstenee bar = 10%; Red box indicates Du422, the Isolate selected for the vaccine (see below) 
Key: BE, Belgium; BR, Brazil; BW. Botswana; CF, Centml African Republic; DC, Democratic Republic of the Congo; ET, Ethiopia; FI, Finland; 
FR, Fmnce; IN, India; KE, Kenya; MW, Malawi; SE, Sweden; UG, Uganda; US, United States; ZA, South Africa; CPZ, chimpanzee; ZA_CON, 
South African Consensus; CONS_AlBIC, Subtype consensus 
2.3.2. SELECTION OF A GAG GENE FOR A CANDIDATE VACCINE 
In OIdel 10 rOent"y .. lepresent(JI .... e gil<} gene for ,rdUSOQn In too VitCC",e. a South AI"""n 
SUDtypc C consensus SCQ<I<>IlCC was denved Dy oelrnlng 1M mosI co mmon amino acid at 
cacfl poSlt lOO lor 100 South Alrocan 5eC!""nces(n:32) The mean drvcfSlty t>etweoo the $o/J;h 
Alfiean anuno aod SOO\lell<:e8 was. 6 6% w~h a distance range 01 , 4% 10 125% The South 
Alncan seq<JetlC('$ were belweeo 91 4 ..-.:I 98 3% idenllc.;oi 10 lhe SoUlh Alncan conSCOIWS. 
With" mean idcntrtyoJ 936% IFig 2.2) The Du422 s.eQ<ICf'ICe was Ci<>SCSt to the collSCnsos 
(98 3% anuno acid idenbly) This sequence was !l"ooratcd from an It'<lMdual """" had been 
InfOOed for 2 months all:! lhe VIrUS was shown to be viable In bssue cult ... e (performed b)' 
LI""" Moms Nahonal Insl ,lute d CommuJlIcartlle Dseases. Sot.O:n Alnca Witf;amoon eI 01 
2003) The mean dIStance or ;r/f tOO South AI"can seq.>ences from Du422 was 47%. Wllh 
Qu2Bl. RB27 and GGI bel"9 most closely related at 2 5% distaJlCl' at'<l Du174 ..-.:I Qu2().:1 
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2.3.3. EFFECT OF INCLUDING ADDITIONAL SEQUENCES ON 
SELECTION OF Du422 AS THE GAG VACCINE STRAIN 
The selection of the Du422 strain was based on the analysis of samples collected in 1999. 
Since then, sequences have become available within the laboratory generated from South 
Africa, Zambia, Zimbabwe and Malawi (the HIVNET028 study; H. Bredell, unpublished) as 
well as more recently published sequences from the Los Alamos HIV sequence database 
(http://hiv-web,lanl.gov). The relatedness of the vaccine strain to southem African sequences, 
as well as to the derived ancestral subtype C sequence lhttp://hiv-web,lanl.gov), and to the 
latest global subtype C consensus lhttp://hiv-web.lanl.gov)wasdetermined.This was done to 
determine the current relationship of the vaccine strain to South African and southern African 
sequences and, in addition, to determine whether any advantage would have been gained 
from the use of a subtype C consensus or ancestral sequence instead of Du422. 
Du422 remained the closest amino acid sequence to the updated South African consensus 
(98.2% amino acid identity). The updated South African consensus sequence based on 80 
sequences was 99.8% similar to the consensus sequence derived from sequences collected 
in 1999. In addition, Du422 remained the most closely related South African sequence to both 
the ancestral and the global subtype C consensus (95.9% and 97.3% amino acid identity). 
In this larger database, the mean amino acid distance of all southem African sequences (n = 
202) was 5.5% (0.6% to 13%), which Is similar to the mean amino acid distance between the 
80 South African sequences of 5.9% (range 0.8% to 11.5%), and slightly lower than the mean 
amino acid distance between the 32 South African sequences in the original 1999 database 
of 6.6% (range 1.2% to 12.5%) (Fig. 2.3.). 
The mean amino acid distance of Du422 to southern African sequences was 4.2% compared 
to 3.9% distant from South Africa sequences (fig 2.3.). These distances compare well with the 
earlier analysis (see above) where the distance of the 32 South African sequences from the 
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Du422 sequence was 4.7%. When the distance of the mean of all the southern African 
sequences was measured from the updated South African consensus, the global subtype C 
consensus and ancestral subtype C sequences, it was found to be 3.3%, 3.3% and 4.1%, 
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A phylogenetic comparison between Du422 and this larger dataset did not change the Initial 
relationships identified on the smaller subset although there is evidence of a South African 
cluster evoMng (fig 2.4). Du422 falls within a cluster of South African sequences with sllghUy 
shorter branch length than the more recent sequences. Similat1y, limited geographic 
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2.3.4. IMMUNOLOGICAL RELEVANCE OF Du422 
CTL eprtopes in Gag, wllkh afa q"go\OO "r 1Outr>em Alncan .,dividuals inlectad wlln wo!)'pe 
C. we", !l85CIibed oy Ma$~ al ~ l2004b) USing an IFN--r EUSPOf Ilt$s.ey, !hey 
I<IenMl1Id 100, pepl<le 5Uel(7lM 00I"I18,"'"11 Cll epilopes In pl7 ana low In p24 Thas.e 
peplod$"l ~ racognlSfld II d'ner.nc lrequllllOH In Iha 1ndlYir;luals.studi!ld \1\g 2.51 The 1'17 
pe¢Ides .... e racognlsed I t Irequenges ..nglng from 1 Mro to 34 6% wNle the 1'24 ~, 
__ .-..c:ognosed al ,,"aquencills ,,"om 7 Mro 10 ttl 2'110 flu Itud"y ublzlld peptide, Oased on 
_ lub1ype C seQUence whldllI tI8~ l"IOi ilOlogouS to Du422 We wllfe inrllffl$Ul<l in 
OIi\..".,irIg if 0..422 conr.fned ........ unoIogically rHCt, ... pepticMs idenlified in !hi •• 'ud y 8nd 
10 det""",",, Iha VIIrlability 01 sequ-enc:es with .. theM ",,'opes 
lllil Vllfllbiltty 01 reSIdues w;O"n Iha sublype C 1/'1/ \I_S from tile Soolh Alrialn cohorts wao 
'",,"lWId by generating an ernropy pia! on the aligned amino 1<;1<1 -.quence.\FiO 2.5.). The 
p17 region WIS highly vlll"lable wWe tile pl. region contair\ed more conserved rMidues 01 
!he ~~I peptodll5 fllCovnlHid. rwo w ... I<Ienuc.l fO 011'122; lour had a tingle amino ..., 
cl\a1lQfl ao><l two contained 2 amino ..., cn.nges (FIg 26). 01'16 reg_ or p24 _ was 
~ • .,ogno_ als> kad low QRMlic v.nabllily (Fig 2.5) .... \hhI pepllOli Is highly 
OOI"I~ II may ~ ",,_nl to inc:tude In • ~sed wt>type C V8>CClntI allhovgh • I, not 
known M "'opon'" \0 ... ~ ION ~~t.., _ contr.,. 01 ...... 'aplico""n o.sp~ 
hogI> .... ,~y In 1'17. the peptide '!fetch TGTEELRSlYNlVATLYCVH.I\GIEV was 
racognlNd III .... 1"IIgIo_ ~ (35~). It 5I>ou1d btl nol.., that the E~ISPOT ,1\11'>",. wiS 
based on 15 ........ whlch encompass the 9·.,.,... HLA epilopoo. Not 8~ amino add <:hange. wUI 
affect racognl~on and Ihe HLA .n<:!>or bmding $lte and T--cell raCQgn,tlon 111M .... most 
Imoortanl 
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P!2tide 1 9RGGKLDKWEKIRLRPGGKKHYMLKHL34 
Du422 16KH IVWASRELERFAL 30 
**-************ 
Pe2tide 2 16KHLVWASRELERFAL3O 
Du422 7oTGTEELKSLYNTVATLy86 
******-********** 
Pe2tide 3 7oTGTEELRSLYNTVATLy86 
Du422 121KAA. D. GKVSQNYPIV134 
***-*-********** 
Pe2tide 4 119KAAADKGKVSQNYPIV134 
Du422 157WVKVIEEKAFSPEVIPMFl14 
****************** 
P!2tide 5 157WVKVIEEKAFSPEVI PMFl74 
Du422 170PMFTALSEGATPQDLNTMLNTVGGH196 
************************* 
Pe2tide 6 170PMFTALSEGATPQDLNTMLNTVGGH196 
Du422 259pVGDIY. KRWIILGLNKIVRMYSPVSI 284 
******-******************** 
P!2tide 7 259PVGDIYWKRWIILGLNKIVRMYSPVSr285 
Du422 289GPKEPFRDYVDRFFKTLRAEQATQEV314 
************************-* 
Pe2tide 8 289GPKEPFRDYVDRFFKTLRAEQATQDV314 
FIg.2.8. Comparison of Du422 amino acid sequence with Immunologically reactive peptide stretches 
Identified by (M.emola et .,. (2004b) using IFN..,. EUSPOT 
Peptldes are numbered to match fig 2.4. 
• Indicates homologous bases; • indicates base differences;. indicates Insertion or deletion 
Residue numbers are indicated in superscript 
2.4. DISCUSSION 
Gag was selected as a model immunogen in first generation vaccines as it is rich in CTL 
epitopes and responses to Gag have been associated with control of viral replication. In 
addition, it is a frequently recognised protein with up to 74% of infected individuals responding 
to this protein (Masemola et al., 2004a). In this study. we aimed to minimise the potential 
impact of diversity on vaccine protection by selecting a sequence that was most closely 
matched the consensus sequence generated from circulating strains in South Africa. The 
sequence was chosen from a group of strains that were recently transmitted since such 
strains would have properties close to that of transmitted virus. Oerdeyn et al. (2004) have 
recently shown that the envelope glycoproteins of transmitted viruses have characteristics 
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that influence transmission and that these characteristics are lost during chronic Infection due 
to immune escape. The transmitted viruses were more sensitive to neutralization and thus the 
selection of recently transmitted variants used in this study may have more relevance for anv 
gene-based vaccines. 
Based on genetic analyses, Du422 was selected since it was the most closely related 
sequence to the derived South African consensus sequence for the gag gene. This sequence 
was cloned directly from plasma and was not a derived, artificial gene sequence thus avoiding 
the need for resynthesis. Although an artificial consensus sequence approach could have 
been used, further analysis indicated that not much would have been gained from using such 
a strategy. In addition to being 98.2% related to the South African consensus sequence, 
Du422 was found to be 95.9% similar to the derived ancestral sequence and 97.3% similar to 
the derived global consensus sequence for subtype C. The results of this study indicate that 
Du422 remains well-suited as a regional Gag vaccine strain for southern Africa since a larger 
database of sequences and an updated consensus sequence did not alter the close 
relationship it has to the consensus. 
Du422 amino acid sequence contains eight epitopes recognized by southern African 
Individuals infected with subtype C HIV-1 (Masemola at a/., 2004b), of which two were 
identical and six had one or more changes. This provides further support for the relevance of 
Du422. Some of these peptides occur in regions of the gag gene that have a limited ability to 
change, possibly due to functional constraints, and thus may be Important for inclusion in a 
vaccine to produce cross-subtype responses. Since these peptides are recognised by the 
target population for the vaccine, Du422 gag has been incorporated into a number other HIV-
1 vaccine candidates. These include vaccines being developed within the South African AIDS 
Vaccine Initiative (SAAVI) group working at the University of Cape Town DNA vaccine such 
as recombinant Salmonella vaccines, DNA vaccines (van Harmelen at al., 2003) and protein 
subunH vaccines (Jaffray at al., 2004). In addition, the gag gene from Du422 has been 
included in vaccines which are currently in clinical trial including: Venezuelan equine 
encephalitis virus replicon particle (VRP) vaccine (http://www.hvtn.orgltrialsD and an adena-
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associated virus (AA V) vaccine (http://www-iavirep.orgltrialsbdl ). The VRP0u422 vaccine 
candidate was the first vaccine to enter phase I dinlcal trials In South Africa and the AAV 
candidate is currently being tested in Gennany and is due to enter phase I trials in South 
Africa in 2005. 
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CHAPTER 3 
THE CONSTRUCTION OF E.COLIIMYCOBACTERIAL 
SHUTTLE VECTORS EXPRESSING HIV-1 SUBTYPE C 
GAG: STABILITY AND EXPRESSION STUDIES 
3.1. INTRODUCTION 
In this chapter the construction of recombinant M.smegmatis and M.bovis BCG expressing HIV-1 
subtype C Gag is described. The gag gene from isolate Du422 (see chapter 2) was amplified and 
cloned in 8 different Ecoli/Mycobactarial shuttle vectors. These gag-shuttle vectors were 
introduced into M.smagmatis where the genetic stability of the plasmids and expression of gag 
were studied. The shuttle vectors were then introduced into M.bovis BCG in preparation for 
immunogenicity studies (Chapter 4). The expression of gag in rBCG was also investigated in 
bacteria and infected macrophage cultures. 
3.1.1. PROMOTERS AND FOREIGN PROTEIN EXPRESSION IN rBCG 
A number of different promoters have been used to drive expression of the foreign antigen in the 
rBCG system; ego the BCG hsp60 (Stover at a/. 1991), the M. fortuitum pBlaF* (Nascimento et a/., 
2000), the Streptomyces albus groESlEL (WInter et a/., 1991) and the M.kansasii a-antigen 
(Matsuo et a/., 1990) promoters. The promoters pertinent to this study and the effects they may 
have on the production of foreign antigens are reviewed briefly below. 
The hsp60 promoter 
The highly conserved hsp60 protein is a major antigen of mycobacteria (Young et a/., 1988). It is 
expressed constitutively under all growth conditions but Is expressed in higher amounts in 
response to stress (Buchmeier and Heffron, 1990). Two transcription start sites that were 
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responsive to stress with heat and acid have been identified (Stover st a/., 1991). The hsp60 
promoter is active in Ecoli and, compared to the M.lepras 18kDa and 28kDa protein promoters, it 
gave the highest level of expression of ~-galactosldase in M.smsgmatis and BCG (Dellagostin st 
a/., 1995). AI-Zarouni and Dale (2002) also showed activity for the hsp60 promoter In Ecoli, 
however, they found a surprisingly low level of expression of the dtxB gene from hsp60 In BCG 
Pasteur. Further investigation revealed that this observed level was due to 95% of the plasmid 
containing deletions that affected or abolished expression. Batoni st a/. (1998) demonstrated low 
levels of hsp60 promoter activity in exponentially growing M.avium but activity increased in late 
exponential phase and was maximal during late stationary phase. This suggested that the hsp60 
promoter is responsive to starvation stimuli. Significant induction in exponentially growing cells 
was demonstrated by shifting the incubation temperature from 37°C to 45°C but no induction was 
seen when hydrogen peroxide was added to the cultures (Batoni st a/., 1998). 
The 18kDa promoter 
The M.lspras 18kDa protein induces both cellular and humoral responses in tuberculoid leprosy 
patients (Dellagostin st a/., 1993). It is related to the alpha crystallin family of eukaryotic heat 
shock proteins (Nerland st a/., 1988). Initial sequencing of the gene encoding the 18kDa protein 
did not identify the promoter sequence (Booth st a/., 1988) but examination of two fragments 
upstream of the start codon identified a transcriptional start site as well as the -10 and -35 
sequences (Dellagostin st a/., 1995). In addition there is an undefined element upstream of the 
transcription start site that appears to be Involved in regulation of expression. During in vitro 
growth in Ecoli the 18kDa promoter was relatively strong; however, the expression in 
M.smegmatis and BCG was very low compared to expression from the hsp60 and 28kDa 
promoters (Dellagostin st a/., 1995). The 18kDa promoter appeared to be specifically activated in 
vivo when expression was tested in macrophages (a ten-fold higher expression than the hsp60 
promoter). AI·Zarouni and Dale (2002) found the highest activity from the 18kDa promoter in 
Eco/i but the expression in BCG Pasteur was relatively low. 
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The mtrA promoter 
Via et a/. (1996) isolated a two-component regulatory system, mtrA-mtrB, from M.tuberculosis. 
These systems are associated with environmental signal recognition and induction of adaptive 
responses. The first gene in the system, mtrA, is a response regulator. The transcription and 
translation initiation sites for the mtrA promoter were identified (Zahrt and Deretic, 2000) and it 
has been demonstrated that expression of the gene is induced in macrophages (Via et aI, 1996). 
The response regulator is essential for M.tuberculosis viability; however, it is not known whether it 
is also essential for the growth of BCG (Zahrt and Derelic, 2000). In M.tuberculosis the mtrA gene 
was expressed constitutively and expression was thus unchanged upon macrophage entry but, in 
BCG, it was expressed only upon infection of macrophages (Zahrt and Deretic, 2000). 
The katG promoter 
The M.tuberculosis katG gene encodes the catalase-peroxidase enzyme that contributes to 
survival in the macrophage by protecting the bacterium against excess hydrogen peroxidase 
(Heym et a/., 1997). Mulder et a/. (1999) identified a 559bp region that incorporated the 
M.tuberculosis katG promoter. They mapped two transcription start sites upstream of the katG 
GTG initiation codon and identified putative -10 and -35 sites for each transcription start site. 
Deletion studies in the promoter fragment revealed a region that was essential for promoter 
activity in Ecoli and required for optimal activity in M.smegmatis. This upstream activator region 
was able to increase expression from the M.paratuberculosis PAN promoter in both Ecoli and 
M.smegmatis. The katG promoter was induced by ascorbic acid but repressed by oxygen 
limitation and elevated temperatures. Expression peaked during late exponential growth but 
declined during stationary phase. The promoter had similar activities in BCG and M.smegmatis. 
Targeting of the foreign antigen 
Efforts to enhance the immunogenicity of the target antigens lead to the use of signal peptides 
derived from lipoproteins to direct export or membrane-associated surface expression of the 
antigens (Stover et a/., 1993). Numerous antigens were expressed in the cytOSol in rBCG but the 
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expression levels were highly variable from one antigen to the next and weak humoral responses 
were elicited to certain antigens even when they were highly expressed (Stover at a/., 1993). The 
signal peptide strategy had the advantages of the potential for improved antigen presentation by 
surface expression and enhanced immunogenicity - lipid acylation increases immunogenicity of 
synthetic peptides and lipoproteins from bacterial pathogens are highly immunogenic. rBCG 
vaccines expressing outer surface protein A (OspA) from Borre/ia burgdorfari as a membrane-
associated lipoprotein (using the M.tubarcu/osis 19kDa gene secretion signal) resulted in 
protective antibody responses that were 100-1000-fold higher than responses from rBCG 
expressing OspA in the cytosol or as a secreted fusion with the mycobaterial alpha antigen 
(Stover et a/., 1993). Others have followed a similar strategy with similar results (eg. Langermann 
et a/., 1994b; Bastos et a/. 2002; Grode et a/., 2002; Bao at a/., 2003). For more detail and further 
examples, see various reports described in section 1.B.5. 
The level of production of foreign protein 
The level of production of foreign antigens in the rBCG system varies widely from one study to 
the next. Reports range from 15% of the total BCG protein (Fuerst et a/., 1991; Stover at a/., 
1991) to 0.1% (Aldovini and Young, 1991). Bacterial antigens, particularly Mycobacteria/ 
antigens, tend to yield the highest expression levels irrespective of the promoter/signal sequence 
combination. However, different promoter/signal sequence combinations have been shown to 
express the same foreign antigen to different levels. A brief review of reported expression levels 
follows. 
Fuerst et a/. (1991) expressed ~-gal to 15% of the total BCG protein when the /acZ gene 
expression was hsp60-driven on an episomal vector. However, HIV-1 gp120 in the same system 
could only reach levels that were 200-fold lower than the ~-gal expression (Fuerst at a/., 1992). 
When Streptococcus pnaumoniae PspA protein was expressed under the control of hsp60 in 
cytosolic, membrane-associated and secreted form, the cytosolic form accounted -15% of the 
total BCG protein (Langermann at a/., 1994a). This was 2- to 5-fold higher than the membrane-
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associated or secreted expression. Comparing expression levels of hybrid pertussis toxin-tetanus 
toxin in rBCG showed that expression under the control of the hsp60 promoter was approximately 
10-fold more than expression from the Ag85A promoter (5ng of total protein vs 0.4ng of total 
protein; Abomoelak at al., 1999). The production of another bacterial protein, E.coli MalE, was 
optimal in secreting rBCG strains (Himmelrich at al., 2000). The total amount of MalE was 3.3-8.6 
times higher when secreted. However, the percentage of MalE in the total BCG protein in each 
fraction ranged from as low as 0.003% to 2.149%. 
The parasite antigen CSP1 from Plasmodium fa/Ciparum was expressed in rBCG to a level of 1 % 
of the total BCG protein, under the control of the 64kDa antigen promoter of BCG (Haeseleer at 
a/., 1993). 
Lower production levels of viral antigens are reported generally. Full-length HIV-1 Gag protein 
was produced to only 0.1% of total BCG protein from the hsp70 promoter (Aldovini and Young. 
1991). while HIV-1 Nef was expressed to 1% of the total protein under the control of the S.albus 
groES/groEL 1 promoter (Winter at a/ .• 1991). When SIV nafand gag genes were expressed from 
the pBlaF* promoter as an operon. the percentage of Gag in the total protein was 1.11 % in an 
episomal vector compared to 0.14% in an integrative vector (Mederle at a/., 2002). However. 
another integrative vector was able to express Gag to 1.04% of the total protein. despite there 
being only a single copy of the gag gene present in that recombinant. 
3.1.2. STABILITY OF rBCG 
In vitro stability of rBCG 
In order to maintain a sufficient level of antigen expression and ensure a strong immune 
response. it is important to have a genetically stable rBCG. In addition. for future production in 
sufficient batches for general vaccination, the rBCG needs to be stable during the manufacturing 
and storage process. 
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Various groups have reported results from in vitro stability experiments. In one of the first 
experiments to assess in vitro stability, it was found that rBCG carrying vectors with only 
kanamycin resistance markers and no heterolgous genes were genetically unstable (Matsumoto 
et al., 1996). Only one vector in their series (pS0246) was stable up to 50 generations. 
Comparing E.coli lacZ expression in M.smagmatis transfonned with episomal and integrative 
vectors demonstrated that the integrative vectors were more stable by about 120-fold (Kumar at 
al., 1998). The loss of stability in episomal vectors was also observed in rBCG expressing a 
SIVmac251 Gag-Nef fusion from the pBlaF* promoter, while stable maintenance of integrative 
vectors carrying the same gene fusion was demonstrated (Mederle et al., 2002). However, an 
rBCG expressing a Mycobacterial protein - the 30kDa major secretory protein from 
M.tubarculosis - was found to be highly stable even though the gene was carried on an episomal 
shuttle vector (Horwitz at al., 2000). 
The genetic stability of vectors expressing j3-gal from different promoters in different 
Mycobacterial host strains has also been investigated (Medeiros et al., 2002). The shuttle vector 
expressing j3-gal from the hsp60 promoter was highly unstable in M.smegmatis but was more 
stable in M. vaccae. The pAN promoter shuttle vector was more stable than hsp60 vector in both 
host strains. When testing the plasm ids expressing the dtxB gene in different strains of BCG, 0/30 
clones carried intact plasmid in BCG Moreau, while 7/30 were intact in BCG Tokyo and BCG 
Pasteur (A1-Zarouni and Dale, 2002). 
Structural modification of the shuttle vector has been identified as the cause of the loss of 
expression. Episomal vectors with deletions that encompassed the promoter (hsp60) with either 
part of the heterologous gene or the entire gene have been described (Kumar at a/., 1998). AI-
Zarouni and Dale (2002) reported that 95% of the plasm ids recovered from rBCG contained 
deletions. An insertion in an integrative vector (Kumar et a/., 2002) as well as transposition of an 
insertion sequence (Chawla and Das Gupta, 1999) has been shown. Loss of the shuttle vector 
has also been demonstrated (Mederle at al., 2002). In one case, no gross structural modifications 
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were identified despite loss of heterologous gene expression (Medeiros at a/., 2002) and in 
another case, sequencing of the shuttle vector revealed the deletion of one nucleotide at the 
codon preceding the stop codon, resulting in a frame6 shift and expression of a larger protein 
(Bastos at a1. 2002). 
In vivo stability of rBCG 
A number of groups have also investigated the in vivo stability of the shuttle vectors usually by 
plating homogenates of organs from inoculated animals on media with or without selection Table 
3.1.). Retention of kanamycin resistance is compared and, in some cases, expression of the 
heterologous gene is determined. Stability levels vary quite considerably from one study to the 
next. In some studies, the constructs continue to stably express the heterologous gene after 
Immunization ego 100% expression of p~al after 2-4 weeks (Stover at a/., 1991); 100% 
expression of gp63 after 10 weeks (Connell at a1., 1991). In most studies, however, there Is soma 
loss of expression - 26% p-gal expression after 2 months (Murray at a1., 1992) - or complete loss 
of expression - 0% Env expression in one of two macaques (Mederle, 2003). 
3.1.3. GENERAL CONCLUSIONS 
rBCG candidate vaccines for a variety of pathogens have been developed and many induce 
immune responses in animal models (section 1.B.5). These rBCG vaccines are often unstable 
(section 3.1.2) and it has been shown that, in general, integrative vectors are more stable than 
episomal ones. However, integrative constructs have a lower level of expression. The level of 
expression of the foreign antigan in rBCG is also influenced by the nature of the antigen, the 
promoter used to drive expression and the use of a localization signal to direct transport of the 
antigen (section 3.1.1). Bacterial antigens have been expressed to the highest levels but different 
promoternocallzation signal combinations have been shown to improve the expression of 
antigens. The three promoters that have been used most often to yield good expression of and 
immune responses to a wide variety of antigens are hsp60, PAN and pBlaF*. In addition, 
comparativa studies have shown that antigens that are fused to a localization signal tend to 
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express at a higher level and are more stable than their cytosolic counterparts. A number of rBCG 
vaccines have shown partial protection against infection In animal models (section 1.B.5). The 
fact that only partial protection has been observed could mean that both a neutralizing antibody 
response and a CTL response are required to achieve full protection. An rBCG vaccine in 
Table 3.1. In vIvO stability of rBCG expressing various heterologous proteins 
Antigen Antigen Vector features Animal In vivo stabl7ity Reference 
source Promoter localization 
oruene 
fusion 
E.CO/i p-gal hsp60 cytosol BALB/c recovery from spleens; 2-4 weeks P.9St- Slover et al., 1991 
mice Immunization: all colonies were KmR 
and expressed P-gal 
PAN cytosol BALB/c recovery from spleens; 2 months post- Murray at 81 .• 1992 
mice Immunization: 45% of colonies retained 
KmR but only 26% expressed 13-ga1 
PAN cytosol Guinea recovery from spleens; 4 weeks post- Lagranderie et aI., 
pigs immunization: 50% of colonies 1993 
expressed p-gal 
recovery from draining lymph nodes; 
16 weeks post-lmmunization: 50% of 
colonies expressed p-gal 
Borrelia OspA hsp60 membrane- mice recovery from spleens; 9 weeks post. Edelman et aI .. 1998 
burgdoderi associated immunization: all KmR colonies were 
expressing 0spA 
Pertussis S1PT pBlaP p-lactamase BAL8Ic recovery from spleens; 1 or 2 months Nascimento et 81., 
toxin mice post-immunization: 88% of colonies 2000 
wereKmR 
leishmania gp63 hsp60 cytosol mice recovery from spleens; 10 weeks post- Connell at aI .• 1993 
immunization: 515 colonies expressing 
gp63 
Measles virus N protein hsp60 cytosol mice recovery from spleens; 8 weeks post· Fennelly et 81.,1995 
inoculation: 100% expressing N protein 
macaques recovery from draining lymph nodes; 6 Zhu at a/., 1997 
months post-lmmunization: !ilXPression 
of N protein in >90% of KmR colonies 
Human L 1 hsp70 cytosol mice recovery from spleens; 3 colonies were Jabbar at III., 2000 
papillomavirus protein still expressing HPV-L 1 
SIV Nef-Gag pBlaF* cytosol mice recovery from spleens; after 28 days: Ml!lderle et aI .• 2002 
fusion episomal vector lost from 40% of 
colonies; after 100 days: episomal 
vector lost from 75% of colonies but 
integrative vectors lost from only 2·15% 
of colonies; after 70 days: 25% of 
coionlas retained Nef and Gag 
expression for the episomal vector 
pBIaF* cytosol 2 while all colonies retained expression Ml!lderle et 81., 2003 
Net, Gag and PAN macaques for the Integrative vectors 
and Env 
recovery from exudatlng lesions; 70% 
and 40% KmR colonies; Gag 
expression In 58% and 90%; Nef 
expression in 24% and 10%; Env 
expression In 18% and 0%. 
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combination with another vaccine candidate in a prime-boost strategy could provide a more broad 
response that offers a higher level of protection from infection. 
An rBCG vaccine requires a high level expression of the foreign antigen combined with maximum 
genetic stability: an episomal vector with a strong promoter and an antigen that is localized to the 
extracellular milieu or the cell surface. 
3.2. METHODS 
3.2.1. BACTERIAL STRAINS AND GROWTH CONDITIONS 
All cloning and DNA manipulation steps were performed in E.coli DHSa (Hanahan, 1983) grown 
in 2X YT broth or on 2X YT agar supplemented with kanamycin (30IJ,g/ml). Mycobacterium 
smagmatis mc21SS (Snapper at a/., 1990) and M.bovis BCG (Tokyo and Pasteur) were used as 
mycobacterial host strains. Liquid cultures of Mycobacteria were grown in 100ml Sauton's 
medium containing tyloxapol detergent to prevent clumping (Appendix A) in 11 glass bottles on a 4 
rpm roller at 37°C, while plating was on Middlebrooks 7H10 medium containing O-ADC (Appendix 
A), both supplemented with kanamycin (1S/lglml) when appropriate. 
3.2.2. RT ·PCR AND CLONING OF FULL·LENGTH Du422 gag GENE 
The Du422 gag gene was amplified from serum by RT-PCR and then cloned In the pGEM-T Easy 
vector. 
Reverse transcription 
Reverse transcription was performed on RNA obtained from serum sample Du422 as described 
in section 2.2.2. using the GIBCO-BRL kit (Invitrogen, MD, USA). The primer used for the reverse 
transcription was o-gag-r (S'-ACC TCC AAT TCC TCC TAT C-3'; HXB2 numbering: 2390-2408; 
S. Loubser, Division of Medical Virology, University of Cape Town, unpublished). 
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PCR 
Nested PCR to amplify the Du422 gag gene was performed using the primers listed in Table 3.2. 
The outer reaction components consisted of a SOIlI amplification mix with 1 x buffer (Southern 
Cross Biotechnology, South Africa) containing 1.5mM MgCI2 (Southern Cross Biotechnology. 
South Africa), 2.5mM of each dNTP (Roche. Basel. Switzerland), 1.5U Supertherm Taq DNA 
polymerase (Southern Cross Biotechnology. South Africa) and 25pmol of each primer. The 
cDNA (41l1) used for the template was obtained from the RT reaction described above. The 
thermocycle profile consisted of an initial denaturation at 94°C for 5 min, followed by 35 cycles of 
94°C for 30 sec. 55°C for 30 sec and 72°C for 1 min. The reaction was ended with a final 
elongation step of 5 min at 72°C. 
The Inner reaction was performed using 4 III of the outer PCR product and consisted of a SOIlI 
amplification mix containing 1.5mM MgCI2 (Southern Cross Biotechnology, South Africa), 2.5mM 
of each dNTP (Roche, Basel, Switzerland). 1.5U SuperTherm Taq DNA polymerase (Southern 
Cross Biotechnology, South Africa) and 25pmol of each primer. The thermocycle profile consisted 
of an initial denaturation at 94°C for 5 min, followed by 5 cycles of 94°C for 30 sec, 55°C for 30 
sec and 72°C for 1 min. This was followed by 35 cycles of 94°C for 30 sec and 72°C for 1 min 
with a final elongation step of 72°C for 5 min. 
Table 3.2. PeR prtmers used to amplify the Du422 fIlIlI gene by neated PeR 
Primer name Sequence (5'-3') HXB2 numbering- Source 
outer primer set: 
o-gag-f AAA TCT CTA GCA GTG GCG 623-640 S.Loubser' 
o-gag-r ACC TCC AA T TCC TCC TAT C 2390-2408 S.Loubser 
Inner primer set 1: 
p17apa-F GGG CCC ATG GGT GCG AGA GCG TCA ATAe 790-810 P.Eickhauso 
I~g-cta-R ATC GAT AAT ACT GTA TCA TCT GCT CCT G 2329-2350 S.Loubser 
Inner primer set 2: 
p17eco-F GAA TIC ATG GGT GCG AGA GCG TCA ATA 790-810 P.Eickhaus 
~ag..sal-R GTC GAG AA TACT GTA TCA TCT GCT CCT G 2329-2350 S.Loubser 
WWW:llhiv-web.lanl.gov/; b Division of Medical Virology, University of cape Town, unpublished; • restriction enzyme sites 
underlined 
Cloning of the Du422 gag gene in pGEM-T Easy 
PCR products were purified using the QIAquick PCR purification kit (Qiagen Operon, CA USA) 
following the protocol supplied. DNA concentrations of the purified products were estimated by 
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electrophoresis on a 1 % agarose gel alongside samples of known DNA concentration and 
comparing the fluorescence emitted by the samples. The amplicons were then ligated to pGEM-T 
Easy (Appendix D; Promega, WI, USA), a T-tailed vector, following the manufacturer's 
instructions. Ligation reactions were introduced into competent E.coli DH5a cells by the heat 
shock method (Appendix B). Transformants containing the amplification products were selected 
by plating transformation mixes on 2X YT agar (Appendix A) containing 50~g/ml of ampicillin 
(Ranbaxy; South Africa). 
Putative transformants were cultured in 5ml 2X YT agar (Appendix A) containing 5O~g/ml of 
ampicillin (Ranbaxy; South Africa). Small-scale plasmid DNA extraction was performed on the 
cultures using the High Pure plasmid extraction kit (Roche, Germany) following the 
manufacturer's protocol. The plasm ids were digested with EcoRI (Appendix B) and 
electrophoresed on 1 % agarose at 80V to identify positive transformants. A positive transformant 
for each of the inner primer sets was selected and designated pRT001 (inner primer set 1) and 
pRT002 (inner primer set 2). 
3.2.3. SEQUENCING OF THE CLONED Du422 gag GENE 
The DU422 gag gene Inserts from pRT001 and pRT002 were sequenced on both strands. 
Template for DNA sequencing was prepared using the High pure plasmid extraction kit (Roche, 
Germany). DNA sequencing was performed on plasmid DNA as described in Appendix B. The 
primers used for sequencing are listed below. 
Sequencing primers 
M13 universal forward and reverse primers 
HXB2 numbering in brackets (www:llhiv-web.lanl.gov/) 
*Gag1d: 5'- ACA TGG GTA TTA GCT CTG GGC T -3' (1282-1303) 
*Gag2u: 5'- CAC CTA GAA CTT TGAATG CAT G -3' (1232-1253) 
*Gag2d: 5'- TCT AAT GAA GCC CCT GGT CCT AAT -3' (1797-1820) 
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Gagand: 5'- ITG GAT GAC AGA CAC CIT G -3' (1724-1753) 
* = Williamson at al., 2003 
3.2.4. SHUTTLE VECTOR SUBCLONING 
Properties of E.colllMycobacterium shuttle vectors 
Six different E.colilMycobactarium shuttle vectors were modified in this study to generate 8 
constructs carrying the Du422 gag gene (Table 3.3.). 
Table 3.3. Properties of the E.coIUMycobacterlum shuttle vectors used In this study 
VECTOR PROMOTER LOCALIZATION SIGNAL INTEGRATIVE! EPISOMAL SOURCE 
pMV361 hsp60 none Integrative Medlmmunei 
pMV33A hsp60 Full alpha antigen Integrative M.Dennehy" 
pMV3319 hsp60 19kDa signal sequence Integrative M.Dennehy 
pMV119 mtrA 19kDa signal sequence Integrative J.Macleanc 
pCB112 18kDa Alpha antigen signal Episomal W.R. Jacobs J,.o 
pCB119 mtrA 19kDa signal sequence Episomal W.R. Jacobs J,.o 
• = Medlmmune Inc.; Maryland, USA; b = M. Dennehy, 2003; • = J. Maclean, 2004; d = C. Berkower and W. Jacobs Jr.; 
Howard Hughes Medical Institute. Albert Einstein Coilege of Medicine, New York. USA; unpublished 
The integrative shuttle vectors carry the origin of replication for Ecoli (oriE) and an attP 
attachment site and an integrase gene (Int) from mycobacteriophage L5. The episomal vectors, 
pCB112 and pCB119, carry the origins of replication for EcO/i (oriE) and Mycobacteria (oriM), the 
malarial msp1 gene and a lysA gene expressed from an hsp60 promoter (for use in auxotrophic 
hosts). Both integrative and episomal vectors have a kanamycin resistance marker (aph). 
Amplification and cloning of the katG promoter 
The katG promoter was excised from pJCkat06 (Mulder at al., 1999) using BamHI and Hlndlll 
(Appendix B). The BamH I IHind II I fragment was then used as a template in an amplification 
reaction in order to change the restriction sites at the ends. The following primer pair was used in 
the PCR: katG·f: 5'-TCT AGA GAT GGG GGA TCG -3' and katG-r: 5'- CAT ATG GAT CCT 
TCC AGG -3'. The Xbal and Ndel restriction enzyme sites are underlined. The PCR amplification 
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was performed in 50J.11 containing 1x polymerase buffer (manu), 1.5mM MgCI2, 1.25mM of each 
dNTP, 10pmol of each primer and 1U of Taq DNA polymerase. The thermocycle profile was as 
follows: 94eC for 5 min; 35 cycles of 94e C for 20 sec, 55°C for 20 sec and 72e C for 20 sec; and a 
final elongation step of 72eC for 5 min. 
The Xbal/Ndel PCR product was purified using the QIAqulck PCR purification kit (Qiagen 
Operon, CA USA) following the kit protocol. The purified product was then ligated into the pGEM-
T Easy vector (Appendix D: Promega, WI, USA) following the manufacturer's instructions. After 
introduction Into E.coli DH5a (Appendix B), transformants were screened by PCR using 2J.11 of 
culture in the same amplification mix detailed above. Positive transformants were confirmed by 
sequencing both strands of the insert (Appendix B) using the M13 forward and reverse primers. 
The clone was designated pRT004. 
Subcloning strategies 
large volume (100ml) cultures of the E.coli isolates carrying the 8 shuttle vectors as well as 
pRT001 and pRT002 were grown and large-scale plasmid isolation was performed using the 
Nucleobond AX-100 kit (Machery-Nagel, Germany). Ligation reactions were performed on DNA 
inserts and vectors with compatible ends as described In Appendix B. 
In preparation for cloning into pMV361, pMV33A and pMV3319, the Du422 gag gene from 
pRTOO2 was excised as an EcoR1/Sa/1 fragment. This fragment was cloned Into pUC19 
(Appendix D) prepared with EcoRl/San to yield pRT003. The gag gene was then excised from 
pRT003 as an EcoRl/Hindlll fragment and cloned into pMV361 , pMV33A and pMV3319 prepared 
with the same enzymes; yielding pRT101, pRT102 and pRT103 (Appendix D). Cloning Into 
pMV119 required a different strategy. The gag gene from pRT001 was excised as an Apal/Clal 
fragment. Digestion of pMV119 with Apal/Clal yielded two fragments (3557bp and 1315bp) since 
there is an Apal site outside of the vector multiple cloning site (see Appendix D). The Apal/Clal 
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gag gene fragment was first ligated to the smaller 1315bp Apal/Apal vector fragment. This 
fragment was then ligated to the bigger 3557bp Apal/Clal vector fragment to yield pRT104. 
The Du422 gag gene from pRT001 was excised as an Apal/Clal fragment. The malarial msp1 
gene was excised from pCB112 and pCB119 with an Apal/Clal digest and the gag gene was 
ligated in Its place to yield pRT105 and pRT106, respectively (Appendix D). In order to generate 
pRT107 and pRT108, the 18kDa promoter from pRT105 and the mtrA promoter from pRT106 
were excised with an Xbal/Ndel digest and replaced with the katG promoter (Xbal/Ndel fragment) 
from pRT004 (Appendix D). 
The 8 shuttle vectors containing gag were confirmed by means of restriction mapping. 
Mycobacterial transformation: preparation of competent cells 
Mycobacterial cells were prepared for electroporation based on the method of Parish and Stoker 
(1998). Briefly, liquid mycobacterial cultures were grown until the 00600 reached 0.8·1.0. The 
cells were pelleted at 3000rpm for 15min at room temperature in a benchtop centrifuge. The 
pellets were resuspended in 50ml of 10% glycerol and then centrifuged as before. This process 
was repeated three times. The cells were then resuspended in 14ml of 10% glycerol. 
Mycobacterial transformation: electroporation 
One hundred microlltres of the competent Mycobacterial cells were aliquoted into 0.1 cm gap 
electroporation cuvettes (BioRad, CA, USA). The shuttle vector DNA was added (500ng) and the 
cells were electroporated using a GenePulser II electroporator (BioRad, CA, USA). The 
GenePulser was set at a capacitance of 25flF and a resistance of 1000n and a 1.8kV charge 
was passed through the cuvette. After electroporation, 0.9ml of Sauton's media was added to 
each cuvette and the transformation mix was removed to a microfuge tube that was placed at 
37°C for 2hr (M.smegmatis) or 24hr (M.bovis BCG). The transformation mix was pelleted gently 
at 3000rpm in a microfuge for 2 minutes, 500fll of media was removed and the pellet was 
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resuspended in the remaining media. The recombinants were selected by plating the 
resuspended cells on Middlebrooks 7H10 media containing kanamycin (15f.lglml) at 37°C for 2 
days (M.smegmatis) or 3-4 weeks (M.bovis BCG). 
Identification of recombinant Mycobacteria: integrative shuttle vectors 
Colonies from transformation plates were grown in 5ml of Sautons medium at 37°C until mid-
logarithmic phase (00600 = 0.6-0.8). Recombinants carrying the integrative shuttle vectors were 
identified by Southern hybridization of genomic DNA with an appropriate probe. Genomic DNA 
was isolated from putative recombinants following the method described by Ausubel st al. (1987; 
Appendix B). The genomic DNA was digested with Xbal and Clal restriction enzymes and 
separated on 0.8% agarose at 20V overnight. The DNA from the gel was transferred to Hybond N 
membrane using standard methods (Appendix B) and cross-linked to the membrane with 
ultraviolet light. The probe used in the hybridization was a PCR product encompassing the p24 
portion of the DU422 gag gene. It was amplified using the gag B primer set (fwd: 5' 
CCATATCACCTAGAACTTTGAAT 3'; rev 5' CTCCCTGACATGCTGTCATCAT 3'). The probe 
was labeled using the ECl direct nucleic acid labeling and detection system (Amersham 
Pharmacia Biotech) following the kit protocol. The hybridization was performed using the ECl 
system and following the manufacturer's instructions. 
IdentifIcation of recombinant Mycobacteria: episomal shuttle vectors 
Recombinants carrying episomal shuttle vectors were Identified by restriction mapping of plasmid 
DNA recovered in E.co/i. After small-scale isolation of plasmid DNA was performed by alkaline 
lysis following the method of Sam brook st al. (1989; Appendix B) from recombinant Mycobacteria, 
the plasmid DNA was introduced into E.coli DH5a cells by means of the heat shock method 
(Appendix B). Eco/; transform ants were selected on 2x YT agar containing kanamycin (15J.lg/ml) 
and plasmid DNA was isolated from 10-15 transformants. Maps of the plasm ids generated by 
restriction enzymes were compared to parental plasmid maps in order to identify recombinants. 
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3.2.5. RECOMBINANT M.smegmatis (rMS) STABILITY AND EXPRESSION 
Growth at 37°C and 42°C 
After transformation of M.smegmatis with the shuttle vectors, 250p.1 of the transformation mixes 
were plated in duplicate on Middlebrooks 7H10 media containing kanamycin. One set of plates 
was incubated at 37°C and the other at 42°C for 2 days. Duplicate plates were then screened and 
compared for growth and size of colonies. 
Protein extraction 
Mycobacterial cultures were grown until the 00600 was 0.6-0.7. Total protein was extracted by 
means of 50S-boiling lysis of the bacterial cells. Briefly, SOml of culture was centrifuged in a pre-
cooled rotor at 12000g for 4 minutes at 4°C. Pellets were resuspended in 20ml of ice-cold PBS 
and centrifuged as before. Pellets were then resuspended in 250p.1 of 1x lysis buffer (3% 50S, 
10% glycerol, 0.0625M Tris-CI pH 6.S) and the tubes were placed in a boiling water bath for 30 
minutes. The lysed cells were centrifuged at 27000g for 10 minutes at room temperature. The 
supernatant was further clarified by centrifugation at 15000g in a mlcrofuge and was then 
transferred to a clean tube and stored at -20°C. 
Protein concentrations were determined using the DC protein assay kit (Bio-Rad Laboratories, 
CA, USA) following the manufacturer's instructions. 
Genetic stability and expression of gag 
Genetic stability and expression of gag were studied by subculturing recombinant M.smegmatis 
for 42 generations. Recombinants were grown in liquid culture until the 00600 reached 0.6-0.S 
(mid-logarithmic growth) before inoculating new cultures at a starting 00600 of 0.01 to 0.03. Total 
protein was extracted after each subculture. In addition, for the recombinants carrying episomal 
vectors, plasmid DNA was extracted by standard alkaline lysis (Appendix B) after the first culture 
(subculture 1) and at subcultures 6 and 10. Recombinants carrying integrative vectors had 
genomic DNA extracted from them after the first and last subculture. The process was repeated 
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until 40-42 generations had passed. The number of generations was calculated using the 
formula: (InX-lnY)/ln2; where X = 00 at harvest and Y = 00 at inoculation. 
The plasmid DNA extracted from the M.smegmatis recombinants was introduced into E.coli 
DH5a and plasmid DNA was then extracted from 10-15 individual Ecoli transformants (Appendix 
B). The plasmid samples were subjected to restriction enzyme mapping with Xbal and Pst!. A 
selection of these samples was also mapped with EcoRI. Sspl and Not!. The genomic DNA 
extracted from recombinants was digested with Xbal and Clal and Southern hybridization was 
performed on the DNA after transfer to a nitrocellulose membrane using the gag probe described 
above (section 3.2.4). 
The relative expression level of Gag from each recombinant was determined by measuring the 
level of p24 in the protein samples using an automated capture ELISA. This was performed using 
the HIV type 1 (groups M and 0) p24 Ag test on the Elecsys 2010 immunoassay analyzer 
(Roche. Basel. Switzerland) following the manufacturer's instructions. Five micrograms of total 
protein extracted from the recombinant cultures during the 42 generation-long serial passage was 
subjected to the Ag test. 
Expression during different phases of growth 
Recombinant M.smegmatis carrying the episomal shuttle vectors were grown to early log phase 
(00000 -0.4). mid log phase (00600 -0.7) and late log/stationary phase (00000 >1). Protein was 
extracted from the cultures at each point and the level of p24 was measured as described above. 
3.2.6. CYTOSOLIC VS MEMBRANE-ASSOCIATED GAG EXPRESSION 
rMS and rBCG Tokyo and Pasteur were cultured to mid-log phase and protein from the cytosolic 
and membrane fractions was extracted. Protein concentrations were determined using the DC 
protein assay kit (Bio-Rad Laboratories, CA. USA) following the manufacturer's instructions. 
Expression of p24 was assayed using 5-10l-1g of each protein fraction in the HIV type 1 (groups M 
and 0) p24 Ag test described above. 
100 
Cytosollc protein extraction 
Cultures were grown until mid-log phase and harvested at 3000rpm in a benchtop centrifuge for 
20 min. The pellet was resuspended in PBS and centrifuged as before. This washing step was 
repeated and the pellet was resuspended in 4ml PBS. The suspension was then divided into 2 
screw-cap tubes (Quality Scientific Plastics, CA, USA) containing 0.1 mm zirconia silica beads 
(Biospec Products, OK, USA) to the 100,...1 level. The tubes were placed in a Fastprep FP120 
bead beater (Bio 101 Systems, CA, USA) and subjected to four 30 sec shakes at speed 6. Tubes 
were placed on ice for 3 min between each shake. The Iysates were clarified by centrifugation at 
10000rpm in a microfuge and the cellular debris was retained for extraction of the cell membrane 
protein (see below tI). The supernatant containing the cytosolic protein was removed and the 
remaining debris was removed by further centrifugation. The Iysates were stored at -20°C. 
Cell membrane and Insoluble protein extraction" 
The cellular debris retained from the cytosolic protein extraction was resuspended in PBS 
containing 1 %SDS. The suspension was boiled for 10 minutes to release the insoluble protein 
and the protein in the BCG membrane fraction. After centrifugation to repellet the debris 
(1oooorpm, 10 min), the supernatant containing the membrane protein fraction was collected and 
stored at -20°C. 
3.2.7. rBCG:GAG EXPRESSION IN BALB/C PERITONEAL MACROPHAGES 
Infection 
The peritoneal lavages from 10 BALB/c mice were pooled and the cells were harvested by 
centrifugation at 1500rpm for 5 min. The pellet was resuspended in 2ml R10 medium (RPMI-1640 
medium with Glutamax-1 containing 10% foetal bovine serum, 100units/mL Penicillin-G and 100 
,...g/mL Streptomycin). After counting, the cell numbers were adjusted to 6X105 cellslml in R10 
medium. Two milliliters of cells were then aliquotted into the wells of a 24-well plate (Nalge-Nunc 
International, Denmark). The plates were incubated at 37°C/5%C02 for 4 hours; the non-adherent 
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cells were discarded, the medium was changed and the adherent macrophages were incubated 
overnight. The cells were washed with R10 without penicillin and streptomycin. The rBCG stocks 
at a concentration of 1.8X1 06cfu/ml were added to the macrophages (6 wells per rBCG) such that 
the BCG:macrophage ratio was 10:1. Infection was allowed to continue for 4hours, the plate was 
washed three times with R10 (without penicillin and streptomycin) and incubation was continued 
for 24 hours and 48 hours. 
Lysis 
Each well was drained of its supernatant and washed twice with 1 ml ice-cold PBS/2mM PMSF. 
Two hundred microlitres of RIPA lysis buffer (RIPA buffer containing 0.01 %SDS, 1 x protease 
inhibitor) was added and the plates placed at -20°C overnight. After thawing the Iysates, the cells 
were removed from the well bottoms manually with a syringe plunger. The Iysates were sonicated 
(X3) on ice using a Mlcroson Ultrasonic Cell Disruptor XL (Misonix Inc; Farmingdale, New York, 
USA) set at 2.5 and 0.01W. After sonication, Iysates were clarified by centrifugation at 10000rpm 
at 4°C in an Eppendorf centrifuge. The protein-containlng supernatants were transferred to fresh 
tubes and stored at -BO°C. 
Gag expression 
Fifty microlitres of each lysate, diluted 1:5 in dH20, was subjected to the HIV type 1 (groups M 
and 0) p24 Ag test described above. Protein concentrations were determined using the Pierce 
BCA Microassay kit following the manufacturer's instructions. 
3.3. RESULTS 
3.3.1. CLONING THE FULL-LENGTH gag GENE 
The gag gene from isolate DU422 was amplified by RT-PCR using 2 primer sets with different 
restriction enzyme sites on the ends. The resulting ApaliC/al and EcoRl/Sall amplicons were 
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cloned into pGEM-T Easy to produce pRT001 and pRT002, respectively, and sequenced. The 
DNA sequences are shown in Appendix C. 
The sequences were compared with the parental DU422 gag sequence using DNAMAN 
alignment software. pRT001 had 3 amino acid changes compared to the parental sequence, 
while pRT002 had 1. The nucleotide changes responsible are all In the third base position of the 
respective codons. They are thus reflective of the different viral quasispecies transcribed by the 
reverse transcriptase and amplified by the Taq DNA polymerase. In addition, the changes are all 
previously described HIV-1 subtype C gag sequences. Fig 3.1. shows an alignment of the three 
sequences. 
3.3.2. SHUTTLE VECTOR SUBCLONING 
The gag gene from pRT002 was subcloned into pUC19 to yield pRT003 (see section 3.2.4) and 
after an EcoRl/Hindlll restriction digest, was cloned into the four integrative shuttle vectors 
pMV361, pMV33A, pMV3319 and pMV119 to yield pRT101, pRT102, pRT103 and pRT104, 
respectively. The gag gene from pRT001 was cloned into the episomal vectors pCB112 and 
pCB119 in place of the malarial msp1 gene to yield pRT105 and pRT106. pRT107 and pRT108 
were generated by replacing the 18kDa promoter of pRT105 and the mtrA promoter of pRT106 
with the katG promoter from pRT004, respectively (Table 3.4. and Appendix D). The shuttle 
vectors were mapped with restriction enzymes to confirm that the gag gene had been 
successfully cloned into them before introduction into Mycobacteria smegmatis and BCG (data 
not shown). The DNA sequence of the promoters and signal sequences for the different shuttle 
vectors are shown in Appendix C. Shuttle vectors were introduced into Mycobacterial cells by 
electroporation and recombinants were identified as described in section 3.2.4. rMS were 
































































































Fig. 3.1. Amino acid sequence alignment Of Du422 gag 
gene and the fIIItI gene In pRTOO1 and pRT002. The 
amino acid differences are Indicated 
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Table 3.4. List of vectors generated In this study. The parental vector used to generate them and pertinent 
properties of the vectors are alao listed. 
VECTOR PARENTAL VECTOR PROPER11ES 
pRTOO1 pGEM-TEas? gag with ApailClal ends cloned into pGEM-T Easy 
pRTOO2 pGEM-T Easy" gag with EcoRI/Sa" ends cloned Into pGEM-T Easy 
pRTOO3 pUC19b gag from pRTOO2 cloned into pUC19 at EcoRI/Sa" sites 
pRTOO4 pGEM-T Easy" katG promoter cloned into pUC19 
pRT101 pMV361c gag, hsp60 promoter. no localization Signal, integrative 
pRT102 pMV33A c gag. hsp60 promoter, a-antigen signal. integrative 
pRT103 pMV3319 c gag, hsp60 promoter, 19kDa signal. integrative 
pRT104 pMV119c gag, mtrA promoter, 19kDa signal, integrative 
pRnOS pCB112 c gag, 18kDa promoter, a-antigen signal, episomal 
pRT106 pCB119c gag. mtrA promoter, 19kDa signal. episomal 
pRT107 pRnOS gag, katG promoter, a-antigen signal. episomal e,b Appendix 0; 
pRT108 pRn06 gag, katC3 promoter, 19kDa Signal, episomal cTabie 3.2 
3.3.3. AN INVESTIGATION OF STABILITY AND EXPRESSION OF SHUTTLE 
VECTORS IN RECOMBINANT M.smegmatls 
Genetic stability: Integrative shuttle vectors 
Recombinant M.smegmatis carrying the four integrative shuttle vectors (pRT1 01, pRT102, 
pRT103 and pRT104) were subcultured for about 40 generations. At subcultures 1 and 6 
(corresponding to generations 16 and 33, respectively) genomic DNA was extracted from each 
culture. The genomic DNA was subjected to restriction enzyme digestion with Xbal and Clal and 
Southern hybridization using a gag gene probe. Fig.3.2 is a photograph of the agarose gel and a 
scan of the resulting autorad. The signals obtained for each vector was at the expected molecular 
weight for both subcultures (2kb for pRT1 01; 2.8kb for pRn 02; 1.97kb for pRT103 and 2.4kb for 
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A comparison 01 the Gag expression level in the InlegralivB and episomal shuttlo vectors 
In order 10 del8fmUle how Ihe genetrc stab~'ly of Ihe ,e<:omb,nant M.smegmat,s carryIng the 
shuTtle vectors Impac:s on the explessloo of Gag from Ihese vectors, expressIon from mese 
cu llures WaS mor.lored over a numl)e; 01 ",enerallons Total prOlein WaS exlracted from the 
recombonant M.smegmalis cu:tu res a'ier e\leo-y subculture as descnbed ,n section 3.2 5 and The 
relative level of p24 was measured usong Tne HIV type t (groups M and 0) p24 Ag te sl 
When comparIng the expreSSIon tevels from the genetically stable integrat ive shuMle veclors it 
was clear tnat eXpl"esslOfl from rMS·RT101 was higher than from lI1e oTher recoml>inants. 
However. all fou r recomb<nants expressed at a low level that was malntaoned (fig 3.4) In other 
wordS. the geJ1f!tlc stab~lt y 01 these rMS allowed lor a ma<nlenance of expreSSIon tevel but thai 
leve' was low 
The levels 01 p24 from recombln<>nts carrying the ep·somal vectors snow that there were 3 
d,stinct paTtems of expressl<:lIl. ,MS RTl05 expressed al a high level IIlI1Ia1ly but th iS level 
dropped rap<d ly rMS RTl06 expressad at a more moderale level 8Ild was able 10 ma-ntaln th,s 
level 01 express!(lIllor abouT 30 seneratlOfls before aedlmng The expresSLon pattems for these 
recombinants compared well w'th lIle" SeJ1f!fiC slab-lILly profi le rMS RT10S was hHJltfy LJOSTabie 
OVer Ihe period assayed and in keepllg WIth IIlLS, lost e"Presslon CapacLty most quickly 
rMS RTt06 had a more moderale loss of genetIC slatllliTy which WaS rellected ,n a more moderale 
drop In Gag expresslOfl The twO recombLnanls exp,essirlg Gag from the k<JIG promoter. 
rMS RT t07 and rMSRTt08, did S<l at a lowe, level compared TO rMS RT10S and rMS RT106 and 
th,S leve l remalled faLrly cOrlstanl over l!1e growth period assayed (fig 3.4) Although these kalG 
recomb .. ams had low buT constant Gag expresslon levels, they had d'flerent patterns 0' genetic 
stability rMS:RT107 10SI genenc Siability quite soon dunng the assay period but thiS was not 
partnere d WITh a rapid loss 01 Gag expressloo. rMS.RT t 08 had 8 slower loss 01 geJ1f!tic slabl li ty 
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3.3.3. AN INVESTIGATION OF STABILITY AND EXPAESSION OF SHUTTLE 
VECTORS IN AECOMB1NANT M.smegmalis 
Genetic .tabillty: Inte!i1rative .huHIe vectors 
""~o-. 
'1_3.2 
Recomblnanl M.smflgmalis carryWl!i1 !he 1001 integrative shuttle WC!013 (pAT101 . pRT102, 
pfUl03 and pRT104) wara $ubCu!tur(!(l for atlOut 40 goneratlons_ AI so.tJe\lKures , lind 6 
(comos.pomlin!i110 generallons 16 and 33. raspectlwly) ganomoc DNA WIllI eldr&ClOO lrom eacn 
culture. The genomIC DNA was SWJe<:t<XIlo ,eslrlcllon enzyme djgesloon with XbaI and Cl/II and 
Soutt\efn hybfldizatlon using II gag gane probe. FIg.3.2 ~ a photOljfllpl'l Of !he ageft)M gel and a 
5C8II clthe r6!lulting lIu!orad. Tho ~Ignills oblalned lor each VOCIor W1!5 althe ellJl8Cled molecular 
weighl 10' bolt! subcu ~ur6!j (2kb for pRT101; 2.8kb lor pRT102: 1 .91kb lor pRT103 and 24i(D for 
pRT104). This Impjles lIlal !i1ross genetIC sl8b, ' ~y has IlEKIn mlllntalf19d 0_ 1I1e ganeratlons 
,os 
To determine the effect of growth phase on expression of Gag, the expression level in the 
recombinants carrying the episomal vectors was investigated during different phases of growth 
(early logarithmic, mid-logarithmic and late-logarithmic/stationary phase). The differences seen 
were not significant and would not have an effect on the results of the expression level study 
(data not shown). 
Growth at 37°C and 42°C to investigate the stress response of the recombinant 
M.smegmatls 
The hypothesis for this experiment was that the bacteria were being stressed by an accumulation 
of misfolded. denatured Gag protein. This stress results in a heat shock/stringent response that 
allows the bacteria to grow at 42°C. The implication is that the higher the expression level. the 
more the bacteria are stressed. leading to smaller colony sizes and survival at 42°C. The 
constructs in this study varied according to promoter and localization signal. The results from this 
experiment thus give an indication of the level of expression from each construct. Combined with 
the expression and stability data detalled above this experiment should give further insight into 
the differences between the constructs and confirm the results of the expression and stability 
studies. pCONEPI is an empty vector expressing only kanamycin resistance rN. Bourn. Division 
of Medical Virology. University of Cape Town). This was used as a control in the experiments and 
the colony size for M.smegmatis transformed with this vector was taken as "normal." 
This experiment was performed three times with the same result each time. Table 3.6 
summarizes the colony size differences for the rMS. The results can be summarized as follows: 
recombinants carrying the plasmid. pCONEPI. did not survive heat shock 
only recombinants carrying the episomal constructs survived heat shock, implying 
that those carrying integrative constructs were not as stressed. 
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based on the hypothesis of the experiment and the colony size differences. the 
comparative Gag expression levels were: 
o episomal vectors: highest RT105>RT106>RT108>=RT10710west 
o integrative vectors: highest RT101>RT102 and RT104>RT10310west 
the size or growth of the RT105 colonies was limited compared to the other rMS 
colonies. This implies. based on the experimental hypothesis that rMS:RT105 was 
producing the largest amount of Gag. 
Table 3.6. Colony size differences for recombinant M.smegmatis grown under nonnal (37°C) and heat shock 
(aoC) conditions. 
rMS: GROWTH at 37°C GROWTH at 42°C EXPRESSION LEVELS' 
RT101 large none 
RT102 large none 
RT103 large none 
RT1 04 large none 
RT105 minute minute 
RT106 small-medlum small 
RT107 medium-large small-medium 
RT108 medium-large small-medlum 
pCONEPI large none 










The results seen in this experiment were consistent with the data from the expression study. The 
Integrative constructs expressed Gag at a lower level than the episomal constructs. They were 
thus less stressed and unable to induce a stringent response that would have allowed survival at 
42°C. There was a stringent response in the recombinants carrying the episomal constructs and 
the colony sizes did correlate with of the expression levels. rMS:RT105 had the smallest colonies 
and the highest expression levels. rMS:RT106 had small-medium colonies and a more moderate 
expression level while the rMS:RT107 and RT108 had the largest colonies and the lowest 
expression levels. 
3.3.4. AN INVESTIGA"nON OF EXPRESSION OF GAG IN CYTOSOLIC VS 
MEMBRANE-ASSOCIATEDIINSOLUBLE PROTEIN FRACTIONS 
The data from the stability and expression studies in recombinant M.smegmatis are summarized 
in Table 3.7. As can be seen. the recombinants could be divided into 5 categories: 
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integrative low producers with high stability (RT101. 102, 103 and 104) 
episomal high producer with low stability (RT105) 
episomal moderate producer with moderate stability (RT106) 
episomal low producer with low stability (RT107) 
episomal low producers with high stability (RT108) 
Table 3.7. Summary of the recombinant M.smegmatls stability and expression data 
Shuttle Promoter Signal IntlEpi Genetic pM Colony Stress 
vector stablll!! levels Size reseonse 
RT101 hsp60 None Int High Low Large No 
RT102 hsp60 a-Ag Int High Low Large No 
RT103 hsp60 19kDa Int High Low Large No 
RT104 mtrA 19kDa Int High Low Large No 
RT105 18kDa a-Ag Epl Unstable High Minute Yes 
RT106 mtrA 19kDa Epi Moderate Moderate Small- Yes 
stablHty Medium 
RT107 katG a-Ag Epi Unstable Low Medium- Yes 
large 
RT108 katG 19kDa Epl High stability Low Medlum- Yes 
whichdro~ large 
The genetically unstable constructs were not selected for further study. The integrative constructs 
appear to be the most stable but were also the lowest Gag producers. For this reason and 
because episomal plasm Ids present more ease-of-use, the integrative constructs were also not 
used in rBCG studies. The medium stability/moderate producer, RT106 and the high stability/low 
producer, RT10S were introduced into BCG Tokyo and Pasteur. 
Since the 19kDa antigen signal sequence was designed to result in membrane-associated 
expression of Gag, the expression levels in rMS:RT106 and RT10S and rBCG:RT106 and RT10S 
(Tokyo and Pasteur) cytosollc and membrane fractions were compared. For each of the strains 
tested the percentage of p24 protein in the membranelinsoluble fraction of the RT106 
Mycobacteria, compared to that in the cytosol was the same (Table 3.S). Although the percentage 
of p24 for rMS:RT10S was the same for both fractions, rBCG:RT10S Tokyo had 4.Sx more p24 in 
the membrane/insoluble fraction than in the cytosolic fraction. rBCG:RT10S Pasteur did not 
express any p24 In the membrane/insoluble fraction. Overall, the expression of Gag in all cases 
was a very small percentage of the total protein. The highest level was seen in rBCG:RT106 
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Pasteur while the rBCG:RT108 Tokyo had the lowest expression levels, even though it had the 
biggest difference between p24 in the cytosol versus the cell surface. 
Table 3.B. Cytosollc vs membrane-associated expression of Gag In rMS and rBCG (Tokyo and Pasteur) 
sm 
'COI:cytosolic 776.6 178 107 16.5 1278 45.38 
otal protein in sample: cytosolic bag) 5 5 10 10 5 5 
p24 In cytosolic protein (ng) 1.16 0.27 0.16 0.025 1.9 0.068 
0.02 0.005 0.0016 0.00025 0.038 0.0014 
Ol:membrane 832.7 219.7 103 82.81 1171 Nop24 
otal protein in sample: membrane (j.lg) 5 5 10 10 5 
1.24 0.328 0.154 0.124 1.75 
24 In membrane rote!n % 0.02 0.007 0.0016 0.0012 0.035 
'COI: p24levels are reported In the form of a CutOff Index that is calculated by the Elecsys 2010 analyser using the readings from 
the negative and positive calibrators su~ied with the HIV type 1 (groups M and 0) p24 Ag test kit 
3.3.5. GAG EXPRESSION IN BALB/C MOUSE MACROPHAGES 
Before preclinical immunological testing of the rBCG vaccines in mice was undertaken, Gag 
expression in BALBlc mouse macrophages was investigated for the two recombinants, 
rBCG:RT106 and rBCG:RT108 (Tokyo). Expression of Gag from both recombinants was 
demonstrated successfully (Table 3.9). Unlike the culture expression work, the level of expression 
from rBCG:RT106 and rBCG:RT108 was not different after both 24 and 48 hours of infection. 
Table 3.9. Gag expression levels (± standard deviation) from rBCG:RT108 and rBCG:RT10Bln macrophages. 
24hr 48hr 
macrophages 0.33 ± 0.109 0.37 ± 0.051 
RT106 13.97 ± 0.154 9.49 ± 0.227 
RT108 11.88±0.312 6.13±0.222 
• COrrected COl indicates the Elecsys readout corrected for the amount of protein in each sample. 
The results represent the average of the Iysates from 6 separate infections. 
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3.4. DISCUSSION 
The approach taken with this project was to use the available resources to produce a suitable 
rBCG-HIV vaccine candidate. Medlmmune and Prof W. Jacobs Jr made E.colllMycobacterial 
shuttle vectors available for this purpose. Further shuttle vectors were constructed in our 
laboratory by modifying the ones already available. The strategy employed was to produce 
E.colilMycobactfirlum Gag shuttle vectors and test these in the model M.smegmatis system for 
stability of the constructs and production of Gag before selecting the most appropriate 
construct(s) for introduction into the BCG system and immunogenicity testing. 
3.4.1. FEATURES OF THE VECTORS 
Various HIV antigens have been expressed in rBCG previously (Stover st al., 1991; Aldovini and 
Young, 1991; Winter st a/., 1991; Fuerst fit al., 1992; Kameoka fit al., 1994; Wada st al., 1996; 
Kawahara fit al., 2002 and Chujoh fit al., 2002) but this is the first study to report the use of HIV-1 
subtype C Gag. Chujoh st al. (2002) also used a non-subtype B virus - subtype E HIV-1 epitopes 
were used to construct a V3-loop rBCG. Of the studies listed above, HIV-1 Gag was one of the 
heterologous antigens in the following: 
Stover fit al. (1991) and Fuerst fit al. (1992) expressed gag from the hsp60 promoter 
in both an episomal and an integrative vector (subtype B); 
Aldovini and Young (1991) used the hsp70 promoter and an episomal vector to 
express the gag gene (subtype B); and 
Wada st al. (1996) expressed a B-cell epitope of p17 under the control of the 
M.kansasii a-antigen promoter and secretion signal (subtype B). 
In this study. in addition to the pMV361 vector used by Stover fit al. (1991) and Fuerst fit al. 
(1992), a number of shuttle vectors not previously used to express HIV-1 Gag were employed. 
This was the first time the katG promoter was used to control expression of any heterlogous gene 
in rBCG. In addition, the mtrA and M.lfiprafi 18kOa promoters have not been used in the 
expression of the HIV-1 gag gene before. 
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Export or surface expression are desirable since it is thought that these features promote stability 
of the shuttle vectors by moving the heterologous antigen out of the bacterium and also enhance 
the immune response to the antigen by making it more readily accessible to presentation by MHC 
molecules (Stover at a/., 1993). Other groups have shown better immune responses to rBCG 
antigens that are exported or expressed on the surface of the bacterium (Stover at al., 1993; 
Langermann at al., 1994b; Bastos at al. 2002; Grode at al., 2002; Bao at al., 2003). Only Wada at 
al. (1996) expressed a Gag epitope fused to a secretion signal. In this study the fusion of GagC to 
both the a-antigen secretion signal and the 19kDa lipoprotein signal is described. pRT101, which 
was derived from pMV361 (Stover at al., 1991), was the only shuttle vector with features similar 
to any used previously for rBCG:Gag vaccines. 
While expression from the hsp60 promoter is constitutive, expression from the 18kDa promoter 
and the mtrA promoter is induced in macrophages. Expression from the katG promoter peaks 
during late exponential phase. The properties of the vectors were thought to be suffiCiently broad 
to ensure that there would be a suitable candidate identified for further study. 
The range of vectors used could be grouped In various ways: 
3 integrative vectors with the same promoter (hsp60) but different localization of the 
Gag protein product [viz. pRT101 (cytosolic), pRT102 (secreted) and pRT103 
(membrane associated)] that were all derived from pMV361. 
2 sets of 2 episomal vectors that have different promoters (M.lepraa 18kDa promoter 
vs katG promoter and mtrA promoter vs katG promoter) but localize the Gag product 
to the same place [viz. pRT106 and pRT108 (membrane associated) and pRT105 
and pRT107 (secreted)] 
2 episomal vectors with the same promoter (katG) but different localization [viz. 
pRT107 (secreted) and pRT108 (membrane associated)] 
2 vectors with the same promoter (mtrA) and signal sequence (membrane 
associated) but one was integrative (pRT104) and one was episomal (pRT106). 
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3.4.2. STABILITY AND EXPRESSION IN RECOMBINANT M.smegmatis 
The in vitro stability and expression of the shuttle vectors was studied in rMS with a view to using 
the data to decide which constructs would be suitable for further study in rBCG. Oas Gupta et al. 
(1998) reported that fast growing M.smegmatis recognizes mycobacterial promoters with 
efficiency comparable to the slower growing M.bovis BCG and M.tubarculosis. Their observations 
suggest that M. smegmatis is a suitable surrogate for analysis of gene expression. 
The induction of a good immune response against the foreign antigen expressed in rBCG usually 
goes hand-in-hand with a high expression level (Fuerst at al., 1991 and 1992; Himmelrich at al., 
2000). However, as mentioned before (section 3.3.3), high levels of a foreign antigen may result 
in a metabolic load that is disadvantageous to the bacterium. Partly for this reason, the constructs 
are often unstable and genetic rearrangements that negate expression of the foreign gene are 
more common and more necessary in higher expressers. Another consideration is that these 
vaccines are intended for eventual general distribution to a large population. In order to scale-up 
the production of the rBCG from a laboratory-level culture to the volumes required for large-scale 
production of the vaccine, the rBCG would need to be stable over numerous generations and 
subcultures. A successful rBCG vaccine would balance sufficient expression with good stability. It 
was important for the stability of the constructs used in this study to be measured in order to 
assist in deciding which rBCGs were suitable for immunogenicity experiments. The experiments 
were designed to first investigate the genetic stability of the constructs in recombinant 
M.smegmat;s, then to determine what effect the stability had on the expression levels of Gag in 
these recombinants. The heat shock stress response in the recombinants was also tested to 
further establish the link between expression levels and stability. The data from these 
experiments were used to select the constructs that would be introduced into BCG for 
immunogenicity studies. 
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The stability of the constructs was studied by monitoring genetic rearrangement of shuttle vectors 
in the rMS over time. Recombinant M.smegmatis carrying integrative vectors were highly stable 
for the entire period assayed. This was similar to results in other studies showing Increased 
stability for integrative shuttle vectors when compared to episomal ones (Mederle et al., 2002). 
However, the recombinants carrying the episomal vectors were far less stable. The recombinant 
carrying pRT105 showed instability most rapidly. The two vectors expressing Gag in combination 
with the 19kDa lipoprotein signal were the most stable episomal vector recombinants. rMS:RT108 
was able to retain 90% plasmid integrity after -20 generations, while rMS:RT106 retained 60% 
integrity. Loss of stability was shown to result from deletions encompassing the promoter/signal 
sequence region and the gag gene. These results compare favourably with other studies where in 
v;tro stability was investigated. Horwitz et al. (2000) found their episomal vector expressing a 
Mycobacterial protein to be highly stable, while other groups report more instability and genetic 
rearrangements in their episomal vectors (Kumar et al., 1998; Medeiros et al., 2002; AI-Zarouni 
and Dale, 2002 and see section 3.1.4). 
One would expect the genetic stability to be mirrored in the expression levels: the higher the 
stability, the better the expression level will be maintained and the more rapid the accumUlation of 
deletions, the more rapid the drop in expression. For the recombinants carrying the integrative 
constructs, the results seen in genetic stability experiment were predictive of the results in the 
experiment tracking the expression level changes over time. The integrative constructs expressed 
at a lower level compared to the episomal constructs and this level was fairly constant over the 
assay period. The recombinant carrying pRT101 was the only integrative rMS that expressed at a 
level approaching the level of any of the episomal vectors. For this reason, no doubt, the 
integrative recombinants were also more stable. Since the hsp60-driven rMS:RT101 differs from 
rMS:RT102 and rMS:RT103 by not having a signal sequence fused to the gag gene, it is possible 
that expression of Gag from the latter recombinants was lower because of the presence of the 
signal peptides. Expression from mtrA-driven rMS:RT104, which had a 19kDa lipoprotein fusion, 
was equivalent to the other integrative recombinants carrying fusions. 
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Since the integrative constructs were only present at 1 copy per bacterium whereas the episomal 
constructs were present at 5 copies per cell, one would expect a difference in expression level. 
rMS:RT105 expressed at a high level initially but rapid accumulation of deletions lead to a rapid 
drop in expression level. For rMS:RT106, the higher genetic stability yielded a more moderate 
loss of expression. These recombinants had expression profiles that matched their genetic 
stability profiles. However, the expression data for the two katG-based recombinants did not 
match the genetic stability data. Although there was an accumulation of deletions (rapid for 
rMS:RT107 and slow for rMS:RT108), the expression of Gag was at low but consistent levels. 
Smaller plasm ids are taken up more readily by competent cells and are more readily extracted by 
the alkaline lysis method than larger DNA molecules that are sheared more easily (Maniatis, 
1982). Since only 10-15 colonies were selected for plasmid extraction in the genetic stability 
study, it is conceivable that a higher percentage of the colonies contained plasm ids with 
deletions. The expression levels give a clearer indication of the construct stability because they 
were performed on the entire culture rather than a sample. 
An experiment in rMS was designed to establish the influence the expression level of Gag from 
the different constructs had on the response to heat stress of the recombinants. Low-level 
expression would produce a low metabolic load and recombinants would not be under stress, 
while high-level expression would result in stress allowing for the recombinants to grow at the 
higher incubation temperature of 42°C. Colony size was also hypothesized to be an indicator of 
metabolic stress with the hypothesis that a high expression level will result in high metabolic load 
and smaller colonies and vice versa. It was a crude evaluation of the differences between the 
constructs but it yielded interesting results. 
The hsp60 promoter in the integrative constructs did not produce Gag at a level high enough to 
place a metabolic stress on the recombinants and thus no colonies were seen at 42°C. Further 
evidence for the low expression levels lies in the fact that the hsp60 integrative constructs 
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produced colonies (at 37°C) of a size almost equal to that of the pCONEPI recombinants (control 
for "normal" size). The same result was obtained for the integrative construct expressing Gag 
from the mtrA promoter. This was expected as the integrative constructs did produce low levels of 
p24 when assayed over time. 
The episomal constructs gave rise to a different scenario. In all cases, production of Gag was at 
a level sufficient to impart a metabolic load on the recombinants to such an extent that they 
underwent a stringent response and were able to grow at 42°C. The higher the load, the more the 
recombinants struggled, ie. the smaller the colonies, implying that the expression of Gag was 
higher. Based on the sizes of the colonies, the constructs expressing Gag from the katG promoter 
did so at a level almost equivalent to expression in the integrative constructs but still high enough 
to induce the stringent response. However, the mtrA and 18kDa promoters were producing Gag 
at the highest level yielding the smallest colonies. Again, these results support the experimental 
hypothesis since the higher expressers (as shown over time in the p24 assay) were also the 
constructs that induced the most metabolic stress as seen by colony size and heat shock 
survival. 
What could be concluded from the experiments was that the recombinants carrying the episomal 
shuttle vectors were expressing Gag at the highest level; rMS:RT1 05 and rMS:RT1 06 being the 
best expressers. Although the integrative constructs were stable, they also produced Gag at the 
lowest level. In addition, episomal plasmids are practically easier to use and and most studies in 
rBCG utilize episomal vectors (see section 1.B.3). However, Mederle et a/. (2002) were able to 
express an SIV gag gene to the same level from an integrative construct as the level from an 
episomal one. This is not the norm, however, and the results of this study were similar to what is 
usually seen. The medium stability/moderate producer, RT106 and high stability/low producer, 
RT108 were thus selected for use in further experiments. 
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3.4.3. EXPRESSION OF GAG IN rBCG 
pRT106 and pRT10B were introduced into BCG Tokyo and Pasteur. Before commencing 
immunogenicity testing, the expression of Gag from these rBCG was evaluated in culture and in 
infected macrophages. The expression in culture was tested in the cytosolic and the membrane 
fractions because the 19kDa lipoprotein signal is meant to export the Gag antigen to the 
membrane of the rBCG. The RT106-containing recombinants (M.smegmatis and BCG) had the 
same percentage of p24 protein in both fractions. This indicates that there was some transport to 
the cell surface but that it was not efficient. The same result was seen for rMS:RT10B, however, 
rBCG:RT10B (Tokyo) had a higher percentage of p24 in the membrane/insoluble fraction implying 
that transport was more efficient in this recombinant. Gag expression levels only fonned a small 
percentage of the total protein. Other work has also shown that viral antigens are not expressed 
as well in BCG as bacterial antigens (AJdovini and Young, 1991; Winter et al. 1991 and Mederle 
et al., 2002); however, the expression levels in those studies were all better than those achieved 
in this study. In both rBCG Tokyo and Pasteur, RT106 produced more Gag than RT10B, as was 
seen in the rMS experiments. 
Expression of Gag from rBCG:RT106 and RT10B Tokyo in macrophages was investigated as a 
final test before preclinical immunological studies were undertaken. If the rBCG were unable to 
express Gag in a macrophage infection model, there would be little chance of expression in an in 
vivo mouse system. However, expression was successfully demonstrated for both recombinants. 
Unlike the other expression studies where rBCG:RT106 was found to express Gag at a higher 
level, in the macrophages, expression from the katG promoter (rBCG:RT10B) was the same as 
expression from the mtrA promoter (rBCG:RT106) after both 24 and 4B hours of infection. Based 
on the results shown in this chapter, further immunological testing of the rBCG:RT106 and 
rBCG:RT10B vaccines was undertaken. 
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CHAPTER 4 
IMMUNOGENICITY TESTING OF rBCG:GAG VACCINE 
CANDIDATES 
4.1. INTRODUCTION 
In this chapter immunogenicity testing of two different rBCG:Gag is described. Based on the 
results of the genetic stability and expression studies in culture and in macrophages (Chapter 3), 
a medium stability/high-moderate producer (rBCG:RT106) and a highly stable/low producer 
(rBCG:RT108) were selected for this testing. Both vectors express the Gag gene fused to the 
19kDa localization signal, while rBCG:RT106 drives expression of Gag from the mtrA promoter 
and rBCG:RT108 from the katG promoter. 
The BALB/c mouse model is the most frequently used model for initial immunogenicity testing of 
rBCG vaccines (section 1.B.3). This model was chosen for the immunogenicity studies of rBCG 
using three different vaccination strategies. rBCG vaccine strategies have made use of multiple 
inoculations of the rBCG in order to elicit a stronger response (Aldovini and Young, 1991; Stover 
at al., 1993; Abdelhak at al., 1995; Fennelly at al., 1995; Wada st al., 1996; Kremer at al., 1996, 
1998; Abomoelak at al., 1999; Mederle at al., 2002 and Biet st al., 2003). In light of these studies 
the initial strategy employed in this study was five consecutive rBCG inoculations. 
A single rBCG inoculation and, although it would obviously be advantageous to have a single 
vaccine for HIV, a DNA prime followed by an rBCG boost strategy was also attempted. Prime-
boost strategies with different vaccines have been proven to elicit stronger and broader immune 
responses (eg. Hanke at al., 1999; Allen at al. 2000; Casimiro at al., 2002 and Leung at al., 
2004). Mederle at al. (2002) demonstrated that rBCG expressing SIV Gag and Nef provided an 
efficient prime for a recombinant SIV Gag protein boost - CD4 IFN-y production was enhanced 
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using this rBCG prime:protein boost regimen. In contrast, Martin et a/. (2001) performed a DNA 
vaccine prime followed by a rBCG boost using the M.avium 35kDa antigen (and vice versa) and 
found that there was no increase in IFN-y production compared to the application of either 
vaccine alone. 
The Tokyo and Pasteur substrains were chosen for the immunogenicity studies since they were 
used in the majority of rBCG studies in the literature. In addition, the Tokyo substrain was the one 
in use in South Africa at the time the study was first started and the Pasteur substrain is the 
standard BCG vaccine strain. The strategy using five rBCG inoculations studied IFN-y production 
in the draining lymph node cells and the generation anti-p24 antibodies in the sera of mice 
inoculated with either rBCG:RT106 or rBCG:RT108 (Tokyo). The single inoculation and prime-
boost experiments investigated the production of different cytokines in the splenocytes of mice 
inoculated with rBCG:RT106 (Pasteur) by means of ELiSPOT assays and cytokine cytometric 
bead arrays. The sera of these mice were also tested for the generation of antibodies against 
p24. 
4.2. METHODS 
4.2.1. PREPARATION OF rBCG VACCINE STOCKS 
rBCG:RT106, rBCG:RT108 (Tokyo and Pasteur) and rBCG:119L 1e (Pasteur) were grown in 
100ml Sauton's medium at 37°C on a roller until mid-logarithmic phase (00600 = 0.6-0.7). The 
cultures were then harvested by centrifugation at 3000rpm for 20 min in a benchtop centrifuge 
(Eppendorf Centrifuge 5702, Eppendorf, Hamburg, Germany). The supernatants were removed 
and the pellets were resuspended in a volume of resuspension medium (Appendix A) to give an 
00600 = 10. This yielded a concentration of 1 x1 09cfu/ml which were checked by plating dilutions 
on Middlebrooks 7H10 media supplemented with OADC and containing kanamycin (15IJg/ml). 
The genetic stability of the vaccine stocks was determined by restriction enzyme analysis of 
plasmid DNA extracted from the stocks. Before aliquotting the vaccine stock in 200IJI, for storage 
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Five mice out of each group were sacrificed 8 weeks and 12 weeks after the final inoculation and 
spleens were removed. Blood was collected before inoculation and at each sacrifice. Serum was 
stored at -20°C. 
4.2.5. PREPARATION OF MOUSE CELLS 
A suspension of cells in R10 medium (RPMI-1640 medium with Glutamax-1 containing 10% 
foetal bovine serum, 100units/mL Penicillin-G and 100 ~g/mL Streptomycin) was prepared from 
the harvested organs (spleens or lymph nodes). The suspension was purified further using a 
Iympholyte M (Cedarlane Laboratories Ltd, Ontario, Canada) gradient after which an enriched T 
cell suspension was prepared by removing the B cells using B220 magnetic beads (Dynal, Oslo, 
Norway) according to manufacturer's instructions. T cells were resuspended at 5x106 cells/ml in 
R10. 
4.2.6. IFN-y ELISA 
Gag T cell stimulation prior to IFN-y ELISA 
T cells (0.5x106) were cultured (37°C, 5% CO2) in duplicate in a final volume of 200 ~I containing 
50 ~I mitomycin C-treated narve splenocytes (1x107 cells/ml) with the peptides listed in Table 4.1 
as stimuli. Culture supematants were collected at 48h and 72h and stored at -20°C before 
quantification of IFN-y as a measure of T cell activation by the stimuli. Unstimulated splenocytes 
were also cultured as negative controls. 
Table 4.1. Peptldes used for T cell stimulation prior to the IFN'1 ELISA. 
PEPTIDE DESCRIPTION FINAL CONC In ASSAY 
ConAl Non-speclflc +ve control 111g/ml 
AMQM' CDB p24 peptide 2t.tg/ml 
MRC t' CD4 p24 peptide 211g/ml 
MRC 13b CD4 p24 peptide 2t.tg/ml 
MRC 17b CD4 p24 peptide 2f.!,g/ml 







The AMQM peptide (Mata st al., 1998) was altered to reflect HIV-1 subtype C sequence (altered 
bases underlined in the table). The MRC peptides (Mata st al., 2001) were used as published 
(HIV-1 subtype B sequence). 
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at -Boec, the resuspension was passed through a syringe needle (21 gauge) 5-10 times to break 
up any clumps. Prior to inoculation, appropriate dilutions of the rBCG were made in resuspension 
medium and passed through a syringe needle (21 gauge) 5-10 times to break up any clumps. 
rBCG:119L 1e is equivalent to rBCG:RT106 except that an HPV-16 L 1 gene is expressed from the 
mtrA promoter rather than the gag gene. Vaccine stocks of this rBCG were prepared as 
described for rBCG:RT106 and rBCG:RT10B. This rBCG was used a negative control in the 
ELISPOT and CBA experiments (see section 4.2.4) 
4.2.2. HIV ANTIGEN PRODUCTION 
Bacu!ovirus-derived recombinant HIV-1 p24 (Quality Biological, Inc; MD, USA) and Gag VLPs 
produced using the Bac-to-Bac® Expression System (Invitrogen. CA, USA; Jaffray et al., 2004) 
were used in various assays. The Gag VLPs were kindly provided by Dr. A. Jaffray (Department 
of Molecular and Cell Biology, University of Cape Town. South Africa). 
In addition, subtype C p24 was produced in E.co!i. The p24 gene from pRT001 (see section 
3.3.1.) was cloned into pProEX HTb (GibcoBRL Life Technologies, CA, USA) and expressed with 
a histidine tag in E. coli DH5a cells. The pProEX HTb clone carrying p24 was kindly supplied by 
Dr. F. Tanzer (Department of Molecular and Cell Biology, University of Cape Town. South Africa). 
The recombinant p24 protein was column-purified over Nickel-Nitrilotrlacetic acid resin (Qiagen, 
CA. USA). following manufacturer's instructions. 
4.2.3. PREPARATION OF BCG LYSATE 
Wild-type BCG Pasteur was grown until late logarithmic phase and harvested at 3000rpm in a 
benchtop centrifuge for 20 min. The pellet was resuspended in PBS and centrifuged as before. 
This washing step was repeated and the pellet was resuspended in 4ml PBS. The suspension 
was then divided Into 2 screw-cap tubes containing zirconian silicon beads. The tubes were 
placed in a FastPrep FP120 bead beater (Bio 101 Systems, CA, USA) and subjected to four 30 
124 
sec shakes at speed 6. Tubes were placed on ice for 3 min between each shake. The Iysates 
were clarified by centrifugation at 10000rpm in a mlcrofuge. The supernatant containing the 
protein was removed and the remaining debris was removed by further centrifugation. The 
Iysates were stored at -20°C. 
4.2.4. INOCULATION OF MICE 
Mice were housed in the University of Cape Town Animal Unit. All animal inoculations, bleeding 
and other handling were performed by Mr. R. Lucas, Ms. M. Rheeder and Ms. E. Janse van 
Rensburg (South African AIDS Vaccine Initiative, University of Cape Town, South Africa). Ethics 
approval for the experiments was obtained from the University of Cape Town Research Ethics 
Committee (Approval Number 01/041). 
For the IFN-y ELISA experiments, female Balb/c mice (5-6 weeks old) in groups of 10 were given 
5 subcutaneous inoculations of either rBCG:RT106 or rBCG:RT108 (1x107 cfu; Tokyo) in the 
back of the neck. One group of mice was not inoculated and served as a negative control group. 
The inoculations were at monthly intervals, the mice were sacrificed a month after the final 
inoculation and draining lymph nodes were removed. Blood was collected 2 weeks after the 3n:l 
and 4th inoculation and at sacrifice. Serum was stored at -20°C. 
For further experiments, female Balb/c mice (5-6 weeks old) in groups of 10 were given either: 
one intraperitoneal inoculation of either rBCG:RT106 or rBCG:119L 1e (Pasteur) 
at 1x103ctu per inoculum or 1x105cfu per inoculum or 
one intramuscular inoculation of pTHGagC (100J,lg) followed a month later by 
one intraperitoneal inoculation of either rBCG:RT106 or rBCG:119L 1e (Pasteur) 
at 1x103cfu per inoculum or 1x105cfu per inoculum. 
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IFN-y ELISA 
IFN-y production during stimulation was determined by an IFN-y specific ELISA using pairs of 
speCific mAb (Pharmingen, CA, USA) according to the manufacturer's instructions. IFN-y 
concentration in individual samples was measured against a supplied rIFN-y standard. 
4.2.7.IFN-y AND IL-4 ELISPOT ASSAY 
The ELiSPOT assays were performed on cells from mice that were inoculated with one dose of 
rBCG Pasteur or mice that were primed with a dose of DNA vaccine (pTHGagC; van Harmelen at 
a/., 2003) and then boosted with one dose of rBCG Pasteur. 
T cell plating and stimulation 
Ninety-six well ELiSPOT plates from the ELiSPOT Set kit (BD Biosciences, San Diego, USA) 
were coated with 100IJ.I of either purified anti-mouse IFN-y or purified anti-mouse IL-4 capture 
antibody supplied with the kit. The capture antibodies were diluted 1 :200 in PBS. The plates were 
incubated at 4°C overnight. After washing with 200IJ.1 R10 (Appendix A) per well, the plates were 
then blocked with R10 for 2 hr at room temperature. Peptides were diluted to the required working 
concentrations and then plated in triplicate (100IJl/well). The splenocytes were added at a 
concentration of 500 000 cells in 100IJ.I per well. For the IFN-y plates, 1.6IJIIL-2 was added to the 
1001J.1 of the cells that were incubated with CD8 peptldes (see Table 4.1). The plates were 
covered in foil and incubated at 37°C. 5% CO2 for 22-24 hr (IFN-y) or 46-48 hr (IL-4). 
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Peptide. 
Table 4.2. Peptldea used In the ELiSPOT assay. 
PEPnDE DESCRIPnON FINAL CONC In ASSAY SEQUENCE 
ConAl Non-specific +ve control 1f,lg/ml NlA 
Irrelb -ve control 2f,lglml TYSTVASSL 
AMOMb CDS p24 peptide 2f,lg/m1 AMOMLKQTI 
Gag CD4 2b CD4 p24 peptide 2f.lg/ml VHQAISPRTLNAWVKV!EEL 
Gag CD413b CD4 p24 peptide 2f.lg/ml NPPIPVGBIYKRWIILGLNK 
IL-2c Costimulatory signal O.01f.lg/mi N/A 
BCG Iysated +ve control 5f.lg/ml N/A 
8= Sigma, MO, USA; b = Bachem. Bubendorf. Switzer1and; c = R&D Systems, MN, USA; d = this study 
The CD8 and CD4 p24 peptldes are recognized by BALB/c mice (Mata et a/., 1998 and 2001) 
and the sequences were altered to reflect HIV-1 subtype C sequence (altered bases underlined in 
table). 
ELiSPOT plate development 
The plate development was performed using reagents supplied with the ELiSPOT Set kit and 
following the manufacturer's protocol. After discarding the cell/peptide suspension, the wells were 
washed twice with 200111 of deionized water per well with a soak of 3-5 minutes between washes. 
The plates were washed thrice with PBS containing 0.3% Tween-20 using a ELx50 Auto Strip 
Washer (Bio-Tek Instruments, Inc; VT, USA). The detection antibody was diluted in PBS 
containing 10% FBS and 100111 were added per well. The plates were incubated at room 
temperature for 2 hr. After 3 washes with PBS containing 0.3% Tween-20, avidln-horseradish 
peroxidase was diluted in PBS containing 10% FBS and 100111 were added per well. A 1 hr 
Incubation at room temperature followed. The plates were washed as before and then a further 3 
washes were performed using PBS. Nova Red Substrate solution (Vector Laboratories, CA, USA) 
was used according to the manufacturer's Instructions to develop the spots. The spot 
development was monitored for 5-12 minutes to avoid high background. Washing the wells with 
deionized water stopped the substrate reaction. The plate was allowed to air-dry at room 
temperature ovemlght before counting the spots. 
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ELiSPOT plate counting 
An ImmunoSpot (Cellular Technology Ltd, Cleveland, Ohio) automated plate analyser together 
with ImmunoSpot Version 3.0 software was used to count the spots in each well. Mean 
background spots in the absence of peptide were subtracted from the mean spot value in the 
presence of peptide and data are reported as the net spot forming unit per million cells (sfuJ106 
cells) +/- the standard deviation. 
4.2.8. MOUSE Th1ITh 2 CYTOKINE CYTOMETRIC BEAD ARRAY (CBA) 
Mouse splenocytes from the 8 and 12 week sacrifice time points were prepared as described in 
section 4.2.4. The cells were stimulated with the peptides listed In Table 4.1 for 48 hours. 
Cytokines (IFN-y, TNF-a, IL-4 and IL-5) released during the stimulation were measured using a 
Mouse Th1fTh2 cytoklne cytometric bead array (CBA; BD Biosciences, San Diego, USA) 
following the manufacturer's instructions. 
4.2.9. p24 ANTIBODY ELISA 
Maxisorp C96 plates (Nalge-Nunc International, Denmark) were coated overnight at 4°C with 
SOlll/well of Baculovirus rp24 antigen (5 Ilglml in carbonate bicarbonate buffer pH 9.6; Quality 
Biological, Inc, MD, USA). Plates were washed 3 times with PBS containing 0.3% Tween-20 and 
once with 200lli of blocking buffer (PBS containing 0.3% Tween-20, 1 % goat serum, 2% fat free 
milk powder) then blocked In blocking buffer (4°C overnight). Pooled mouse sera was diluted 1:50 
in dilution buffer (PBS containing 1% fat free milk powder, 1% goat serum), 1 00 III was added per 
well and the plates were incubated at 4°C overnight. Plates were washed 6 times in blocking 
buffer and then incubated at 37°C for 1.5 h with 100lli blotinylated goat-anti-mouse IgG (ICN 
Biomedicals, CA, USA; diluted 1 :2000 in dilution buffer). Following this plates were washed 5 
times with wash buffer (PBS containing 0.3% Tween) and 50 III horseradish peroxldase-
streptavidin conjugate (4llg/ml wash buffer) was added to each well. After incubation for one hour 
at 37°C, the plates were washed with wash buffer and developed with 50 III per well para nitro 
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phenyl ph05phate. The reactIOn was alloweel tl'l eontmue lor to minutet belore II'Ie optICal o.ns~y 
at 4050m _ read 
4.2.10. WESTERN BLOT OF MOUSE SERUM 
For e Hlect>on of \tie mouse sera. !he presence of gag antibod_ was confirmed .... lng the New 
LAV Blot 1 kit (&o.Rad 18borBtones. CA. USA) foHowII"rV manulac!urer', Inslroellon, 
4.3. RE5UL 15 
4.3.1. IFN-y PRODUCTION BY LYMPHOCYTES FROM MICE THAT 
RECEIVED FIVE rBCG TOKYO INOCULATIONS 
The abll,ty I'll rBCGRT100 end ,BCG RT1 08 in the Tl'lkyo str8i~ tl'l indllQl Ga9 specitk: T cel l' 
aller multiple inoeulallonl WIll Invesl;gated In BALBlc mice. Mice received fi~e sutlcuta~eollS 
inoculation, I'll rBCG RT106 or rBCG RT108 al IO'du. Twe~ly-eoghl days after Ihe lasl 
inoculation wllh rBCG, T calls MfVllSled Irom \he draining Iymrm nodes wttre stomuleted wotn 
various G3g·s()eei11c ~ptjde., rp24 or Gag VlPs for 2·3 days. The Gag CDS (AMOMLKDTI) end 
CD4 (MRC 2. 13 end 11) ~Pllde. did nolll,mulete a hOg/llevet I'If IFN·y production (Tsble 4 3) 
HOW~IV", IFN-y product,on by T ceUs iTom ,llOClAaled ml(:e was induced try rp24 and Gag VLP 
stimulallOn In 9_al. IFN-y prodUCllOI'I was """her aile< 3 daY!ll 01 stimulation and production 
from T can. I'll mice Inoculaled WIth ,ecG RT100 wa, approximately !Wice I118t of T cells !tOOl 
rSCG RT108 Inoc:ulaled nuee. The produetlon of IFN.y by T eels from i,.."unized mice or oon· 
imTIunozed ml(:fl cuIIured wMOI.II Gag prOleln _ minimal (Table. l) 
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4.3.2. p24 ANTIBODY ELISA ON SERA FROM MICE THAT RECEIVED FIVE 
rBCG TOKYO INOCULATIONS 
The humoral response 10 5 lnocutsllons of .BeG RTHlG or IBCG RT108 (Tok~) was also 
;,w8s1,geted The ~v~s 01 an~·p24 antibodies were 148 fold or 2 7 laid above the background 
level of these antibodies In n8r~ m>ce, respeclMlI~ (Fig 4 tAl Minimal antibody production 10 
Gag could be detected for e,lher of the two rBeG 0,]01 to /I 5"' Inocul"tIOn Western blaHing 
coofi!Tl1!td the presence 01 p24 antibodies on the sera lrom mK:e given 5 iooc<.tlations of 
reCG.RTl06 but was nOI sens,ttve enough to confirm the lower level 01 BIltlbodies In the sera 
from the mICe that received ,8CG-RTIoa (F~ 4 1 B) 
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&noe rBCG,RTl06 prOduced low .... amounts of IFN.., as measuo-ed by 11m ELISA and also lower 
IevIItS d ... ,i..p2. /WltibodlflS !han raCG RTl06. further mll'll.ll'109flliClty testong was performed 
US,"" only rBCG RTl06 An WnmllrllZRloon 'egomen thai ilvolves r .... '" coosecutJve lI'lCloCdallOl1S 
would not 1)11 prac!JCally feasible, so '" sngle YlICCnallDn approacl'l was auempled "~l8ay. The 
'" 
~~ 
avaJab~ity of "'~_. mae ..ensllIve IISseys (ELISPOT and eSA) also meanlthal ltIe vacclne· 
inOuce<J immune r",sponse eoule! I)e more aeeuretely tested 
4.3.3. IFN.,. AND Il4 ELISPOT ON SPLENOCYTES FROM MICE RECEIVING 
rBCG PASTEUR 
Thf! B.ISPOT e.penmenl W3S e!e,.;gneo to teSI .....nettle. mIC\! inoculated Wllh the ,BCG RTl06 
YeCClne caldldate "Nefll a~ to mount a G8g·spec,rc c:eII-medoated "'mune rt!sponse 8 and 12 
_ks after InocuIaIIon Thf! produe100n (II IfN 'l' afNI Il4 by mouse splenocytes in response 10 
slft1uialJOn willi a Gag C08 pept~ lind Gag CO<I peplKIe$ was ,"",stigaled_ COnA MlO BCG 
Iysete were posillvtl controls TIle splenoeytet, ""' ... obI.aine<i "om IPJUPS of mICe that received 
elth« one lnoeul81ioo 01 .BCG.RTl06 or a prim,nog vaecloetoon with e DNA vaccine (pTHG&gC1 
IoIIowe<I by en rBCG RTl06 boost. Mice inoeulated with rBCG ""pre$Sing \he Hpv·16 L 1 gene 
__ uled el e negalive eonlrol ln these experiments. 
In 1111 groups 01 moe. lor boIh slng~ inoeulanon and prlfTltt-booSt ",.perlments, the background 
numbef 01 .pots Kl response 10 !ill/l1ulaloon Wllh lin n leYlllll peptide or ebsenee of p"'pbdt! _,e 
equ,veienl &ndiow and hBv$ been subtrBcled from !lie ~s obIaoned on .esponse to the $pfJCific 
PIII)lidM, BGe Iy$ale and conA togel net spoIs 1* m,lI iOn splenoeylet 
RHporoH to a s ingle rBeG vsccin"ioro 
A III'lgIe LolocutaliOn of rSCG (RTI 06 and I t 9L1 e) al both do .. s yoIided splenocytes that 
produced tfN-7 ana Il4 in response III the nIXHpecilk; conA Itomulul (f ig 42). Both 
.BCG RTl06 end ,BCG t 19l Ie were able to Induce BCG·spec lfic: .plenoeyte production oIlfN.y 
and IL4 (FIg 4 2) A lergor IfN.., response was generated In responn 10 BCG·I)'$ate stimulat IOn 
Indcatong thai the response f5 predominantly 1111 In reture 
In COIIIrasI . the ~ngle inocullll ,OIl aI rSCG .RTIO( III the dO$lls admil'llstered was insuf1ielenc 10 
\YI!flI 110 IFN-r or Il'" producing cells wflen splenoeyces wefe Shmul8led Wllh the G ag C08 
(AMOM. Tllble. 2) and CQ.4 pepldes (CO . 2 In:! 13. Table . 2) 31 !lOth e and 12 welcs !lOS!' 
lIIOCuiaIion (between 0 and 10 shM'millOO splenocyles) Forlhls reason. I pTHGagC ONA vaccine 
pnme fOllowed by an IBCG RTIDe IloOSI was ned In Btl aIIen1pr 10 generate Gag-5peCJf1C 
r@SpIln$l!S ,n Ihe mice 
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-
• • ---- -._L_...,' _ ... OOOO, _ __ .. -..... --~-- -• • 
i - I_ 
i ! - ,-j - -
• • l ..d-'.L -.. ,,,,, .. -
• gpl~ op2 . 01'3 E1<,1p04 
,,,,.'.2. IFN...,. and IL'" EUSPOT ... _ .... to ConA ~"" BeG .tlmulation I an<! 12. _ks aile< tha ling .... BCQ 
Inocul8lion. 
Respon. es w e sr.own in ' po! It><"..ng lJflu /mdl,OI'T coli, Th .. not , 1,.rIC' cells Wlf. menu,..:j ,n UopllclII& e ng ,hl_. 
' '''pMSfO ' s!anaa,a d"",stlGn .,e l hoo<>n Ino<:<JI,UOI'T I YP 1 : ,BeG RT ITJe ( l a'clu ~ gp 2 • ,BeG RTITJe (1 O'dIJ~ 9P 3 • 
reCG 11 9L H, (Io'c!u). gp ~ ~ . BeG 119L '. ( IC' clu) 
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Response 10 a pTHGagC DNA vlICclna prima l ollowad by a rBCG boo.1 
A DNA prIme folklwed by a $O'1g le boost with rSCG: ATl06 (groupa 1 and 2) or rBCG.II91..10 
(groupS 3 and 4) wa$ al$o able 10 gonerale splenOCylH prodUCing DOlh IFN-y end IL-4 io Ihe mico 
i'l rasponSfi 10 conA 8Ild BCG Jy$lue stImulation (F~ 4,3.). This response was also predominantly 
TIll in mllule since more IFN-y was produced In response 10 boIh sllmuji. 
BoIh IFN-y and IL-4 po-oducing splenocyles were delected In all 5 groUjlI 01 mice (8 and 12 weeks 
post-~ulal","1 alto! sUmulaloon wrth tha Gag-spec: lhc pep!ides (Fig 44 ), In general, a larger 
response was observed aller Sbmllla1l0n wrlh ItIe Gag coa peptide than aHer stimulation wi1h the 
CD4 pephde • . 
When comparing the Gag-lIPOCrtoe productoon 01 IFN-y w>d 11.-4 generated by the spienoeytO$ 01 
racG-boosted moe. 10 Ihe fespon_ genereled by !he spIenocy19S 01 posl1M:1 control mtce 
flOCUlated WIlh pTHGagC only 10.0141 5). ~ W8$ clear thai tha rGSpOr'IS(Ilo !he DNA primo had 
6mO'1~ .1181 raCG tIOOSting (Fig 4 4.) , ~ was parueularty 8VI(\Or1l ~ !he fesp0ns8 10 COB 
peptide st.,"lIIaloon The IFN-y and IL-4 prCKt.Jct1Ofl alter the rBCG ATl06 (groups 1 and 2) boosts 
was not slgmfleanlly dollerent to me plOducttof1 aflel' the rBCGll9-L Ie (gro~ 3 aod 4) boosts 
(FIg 4 4.). 
4.3.4. CYTOKINE PRODUCTION FROM SPlENOCYTES 8 AND 12 WEEKS 
AFTER pTHGag PRIME·rBCG BOOST 
Production 01 IFN-y, TNF-u. IL·4 and IL·S by the sp~yles 01 mIce primed with a DNA V3CC11l(I 
(pTHGagC) and boosted with raCG expressIng Gag or HPV-1S L1 W6re lI"lVosll98ted uSing a 
cytOmotric bENld assay Thasa mICe were the sama as avalualad Tn !he EliSPOT assay alter 
receiving II pTHGagC prime loIIowad by a ,BeG boost. Tho prodllclion 01 these Cytok"H wall 
me85~red toOowlng 48 no~r $tcm~ latIOl1 In cu~ ufe wom a Gag CDS peptide or two Gag CD4 
peptide! The backg'ol.l'1d cytolme PflXlt.lCtlOl1 I'l res.ponse to an Iffa""'ant peptide and C\lh~re 
medium was also tlelermined. These bacllground responses were vel)' low atld equlvalenl and 
_re sublraCled from the data presented in fig. " 5 .... ·F 11m! fig "6.A·F 
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Fig .oJ .). IFN..,. and IL'" ELiSPOT ,...pon .... lo ConA a!>d BeG .tirnullllion 8 and 12 weeks afte, I .... ,BeG I>oosL 
Rnpon ..... T. sl>own In 5pol fom""l1 un~s/m~lon c<!IIs TI'J!! neI "' .... 10· eells _e mea ..... ed in t"plicate and I .......... "'9'0 
r ... ponse • standard ~eviat,,>n ar~ stIown All S IIroup. rec&lV.:l lOOjIg 01 plHGaIlC, tI"oIf1 28 ""Y1' IlIIer liP 1 = 
,BCGRl1Of1 (HYcful. liP ;> = rBCG RTl06 {IO'clul. gp 3 '" rOCG 1191..1. {10'du~ 'BCG I 19L1,. ( l O'clul. 9P 5 ~ 
'''sus"","s"", med ium 
N",. tl>a1.l0< liP J _ 8 ELlSf'Oll,*e _" ,nsuffic",nl '~I"I<> po!rform 100 assa~ 10< bOll> IFN" aMll"'. so onlV IFN.y 











.... .. ..,.......,t • ..-.. ""'~ •• ".,.,.. 
'". -_. 
._ .......... ,.UI'O .......... ~ 




-~~.  .• ---
l 
• 
I" , ,. 
, I 




• " ... ..,. ., 
Fig .• .•. lF N..,. ~nd !l--4 EUSPOT .espotl5eS 10 0'"9 CD8 ~nd C~ anligens 'and 12 weelI.s atter the ,BeG boost. 
R~~es are $rI<Iwr'I on spool """""9 ",u''m;~on ceH. The net .1u11O'~. we<e m ....... "" In IrJplocrte ano Ihe average 
,esl'O"$8 • stal><lo 'O o"",,",on 8,e ~ All 5 g'oops ,ecer.ed lOOpg 01 pTHGagC, th .... 21! <lays 1",...- 91' , = 
,BCG RT106 (10'cfll). gp 2 = ,BCG RT106 IIO'cluJ, liP 3 ~ ,SCG 119l..1<> (Hr'cfu~ ,BCG 119Ll e (,o'c"'J, 91' 5 : 
resuopen.lOn med,,,", 
Notelha! 1(1, gp 3 weel< 8 EliSPOT U.eI" were InsUI'll",,,,,t c ... 1510 p(!norm the ..... y fo< bOth IF/II-y and IL-4 .0 only IFN-~ 
EUSf'OT was peo1Ofmed 
A.$ v.own 1'1 fig 4.5.A_F, ,I Lhe 8 wee~s hme POInI. Lhe producl'O<l of IFN1'. TNF .... , IL-4 and IL-5 
by splenocyles frem mice lnoculaled 'MIl! pTHGagC dllring stlmlliatton Will! Lhe Gag coe. COol 
(MRC-2) and CD4 (MRC-13) pepHdes was gen"'ell y -.creased after a boos!er inoculallon of both 
doses of !SCG RTl 06 when compared to tne eq ..... aleni doses of !SCG.l I (Table" 3). However, 
alII". lime po"'t. e dose of IO' du boo$led this cyloI<l'Ie production more IIIan a boost with , 
dose of 10"dll Although there is a dear boosllo lIle response WI1h !SCG RTl06 admiruslr~hOn 
oompared to !SCG_L I . rBCG bOCItt appea ... to flJppre$1 lIle anbgen.$peCIIiC eytOkne proouctIOn 
from Ihe Gag-specific cells ",,,,,..:11(\ 11'1 'esponse 10 II pTHGagC onocutation_ Ttus emphasizes 
I'If! pr8CIocal necessHy 10 lI'Ic1uoe a negatIVe CQ'ttroi V8CCII'Iaticon as pan of !he !SCG IflShr>g. MM:e 
\he boosl would root na~ been recognl2:ed ~ It we. on~ compared 10 tile respOnse to !he 
pTHG&gC vaccine This was partICUlarly evioent In the C04 IfN-l and TNF .... produchon afler 
IIImllialion with COol 2 and CD4 13 (Fog 45 C.O) 
At ,hewn In fig 4 6.A-F . at Ihe 12 wellks lime fXMnt. 1hIJ prodUC\Jon of the cytoklnes by mOlJH 
lpIenocytes was also Increased in genef81 after a r8CG;RTl06 boostlJr noruetico wILen 
compared to a boost with rBCG Ll (Table 43) The response atIo appeaa 10 be tme dependent 
M1ee the amOUl'll 01 c'{ll>l!one ~ at 12 weeki were Iowef II'I8n at e week$ However. !he 
antogen.speclflC cylokille response from !he Gag.soeofoe CeDI wes &gaII'I suppressed by 
8dt1'Wuftralion 01 rBCG &ince Lhe produoc1ion of COS IfN-y ,lid TN f .... al -r as CD4 IL4 and IL-
5 was hlgheltln splenoeylell from rna Iilat rooet...ed only pTHQagC (Fig" 6 A. B. E and Fl. In 
general. at W!II teen al 8 wee~s, the cylokone prodlJClion from Lhe Iplenoeytes of mief! lIlat 
reeel\'ed Lhe 10' dll ,BCG RT106 inoc,!lal'on Wl" higher Ihln the prodllCtion from the 
fIIllenoeytes from oLher groups H0W9ver. only IFN-l prod\.IC\fon after COol 2 allmulalion was 
enhanced to e level ebove Lhe pTHGagC lev~ (Fig 4.6 C) iJIld Lhe prodl,lCllon of TNF .... after C04 
13 $Iimutel lon Wei boosted more eltedllo'tlly by the ,BeG RTl06 10' efu 'onoculalion (Ftg 4 6 0.). 
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Fig .(.5. Cytokine ptodllClion f,om mouoe &plenocytes to Gag CD3 and CIM anligens measured by cytomel Jic 
bio~ assay B _ •• n", !he ,BOO~!. 
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These data highlight the lact that thfl mllrllory rasponse to lhfl Gag pe01iOe S1imulatlon was also 
Pf&domlOantiya Thl response (u mllasured by C8A) as was SO&n In the 1I1111al raspor1se If1 tile 
ex vivo ELiSPOT dala above. 
4.3.5. p24 ANTIBODY ELISA ON SERA FROM MICE RECEIVING rBCG 
PASTEUR 
Sera taken Irom mice batore inoculation and al each sacr~icIl _II subjoc1ed 10 an ELISA 
desigl"llld to dIIllIOTIn(I IhIt prllSllOCfl 01 anll·p24 antilxKies. The mICe receiY'lOg DOly one .SCG 
InOCUlation )'IIlkl&d no an~bodles 10 p,24 (<isla nol shown). The mice receIVing lhe DNA ptim&-
I8CG boosl lid produce !Inlibod"lfI~ 10 p,24 tII.I1 !he diflllrllr.c!ls In lewl batween the groups, 01 
bOOSled micll \ll9fe low ThIt Inllbo<1y productIOn III !he b005l9d mlCll was :;milar 10 \he 
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4.4. DISCUSSION 
Surprisingly. despite numefOUS ,BeG sluClIeS employing HIV·' antigens (Stover ellJl.. 1991; 
AklCNInI and Yoong. 1991, Wonter et 61 .. 1991 , Fuerst a l 81., 1992, Kameoka a l ()/, . 1994; Wad" at 
81., 1996; Kawahara e/ III .. 2002; Chujoh 81 aI .• 2002 and Someya et a/. , 2004), only two of Ihesa 
have investigated lne immunogenicrty of HIV· ' Gag expressed In raCG (Aldovinl an<.! Yoong. 
1991 and Wade "I aI .. (996). In the lirsl, the hsp70 promoter was used Iu drive expressIOn 01 " 
subtype a gag. pol and /mv genes on an 8f/lsomal vector in raCG. Mice inoculated with !he Gag 
and Env expreSSIng ,BeG had lOW but dele<:labla levois of IgG anlibod~ aga inst p24, p17 and 
9PI60 Spleno<::ytes from mica inoculated WIth Gag expressing (BCG produced subs !an Hal levels 
'" 
of IFN-y and IL-2 when stimulated with Gag peptides after 4 day in vitro culture and, in addition, 
were able to lyse P815 cells pulsed with Gag peptides. In the second study, Wada at a/. (1996) 
demonstrated that high titres of antibodies to a B-cell epitope of HIV-1 p17 fused to the a-antigen 
from M.kansasii were produced in 3 of 7 mice inoculated with the rBCG. This study demonstrated 
both cellular and humoral immunogenicity in the mouse model using rBCG:RT106, and 
rBCG:RT108 (Tokyo), which express Gag at high and low levels, respectively. 
Although it has been shown that the BCG Pasteur substrain induces better immune responses 
than the BCG Tokyo substrain (Lagranderie et a/ .• 1996), numerous studies have been performed 
successfully using the Tokyo substrain (eg. Kameoka at a/ .• 1994; Honda at a/., 1995; Wada at 
al., 1996; Hiroi et a/., 2001; Chujoh at a/., 2002 and Kawahara et a/., 2002). In addition, the Tokyo 
substrain was the one used for BCG vaccination in South Africa at the time this study was 
undertaken. For these reasons, rBCG:RT106 and rBCG:RT108 Tokyo initially were tested for 
immunogenicity in the mouse model. 
Mice receiving 5 inoculations of either rBCG:RT106 or rBCG:RT108 (Tokyo) at 107cfu generated 
Gag-specific T cells that were able to produce IFN-y when stimulated with rp24 or Gag VLPs. In 
addition, anti-p24 antibodies were generated. The other Gag-specific peptides used in this ELISA 
did not stimulate IFN-y production. Although the Gag-specific peptldes have been shown to be 
recognized by mice, they represent individual epitopes. The rp24 and Gag VLPs, on the other 
hand, consist of all the possible Gag-specific epitopes. It is thus more likely that the mouse T cells 
which were Gag-specific would be more easily stimulated by the wider range of epitopes 
presented by the recombinant protein or VLPs. 
Better IFN-y production and anti-p24 antibody levels were eliCited by rBCG:RT106 vaccination 
than rBCG:RT108 and as mentioned above, the Pasteur substrain has been shown to induce 
better immune responses than the Tokyo substrain. rBCG:RT106 (Pasteur) was tested further. 
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Additionally. newer, more sensitive assays were available for measuring vaccine-induced 
responses in the mice, and these ELiSPOT and CBA assays were used in the testing. 
Since a five-inoculation regimen is practically unfeasible, a single inoculation of rBCG:RT106 
(Pasteur) at two different doses was attempted. This inoculation induced BCG-specific IFN-y and 
IL-4 responses in vaccinated mice. However. no Gag-specific IFN-y or IL-4 producing cells could 
be detected in the mouse splenocytes in an ELiSPOT assay. In addition, no anti-p24 antibodies 
were detected by ELISA in the mouse sera. Since prime-boost regimens have been successfully 
used to broaden and strengthen immune responses. a DNA prime-rBCG boost was attempted 
next. 
A pTHGagC prime followed by an rBCG:RT106 or rBCG:119L 1e (Pasteur) boost, at two different 
doses, was performed. An ELiSPOT assay indicated that BCG-specific IFN-y and IL-4 producing 
cells could be detected in all groups of mice receiving the rBCG boost. IFN-y and IL-4 were 
produced after Gag-specific peptide stimulation (particularly with the Gag CD8 peptide) in all 
groups of mice. However. there was no significant difference in IFN-y responses when comparing 
rBCG:RT106 boosted mice to rBCG:119L 1e boosted mice. In general, the cellular response as 
measured by ELiSPOT after rBCG boosting (Gag and L 1) was reduced in comparison to the 
response in mice receiving DNA-Gag only. The cellular response to the DNA Gag vaccine was 
reduced when mice are inoculated with wild-type BCG. This suppressive effect could also have 
masked any boosting effect the rBCG vaccination might have had and highlights the importance 
of negative controls when testing rBCG-generated immune responses in mice. In addition, it has 
been shown in other studies that administration of BCG can have a suppressive effect on the 
generation of T cell responses to non-BCG antigens (Dudani et al., 2002 and Smith et al., 2002). 
A cytometric bead assay was used to investigate the production of different cytokines in response 
to Gag CD8 and CD4 peptide stimulation. When the assay was performed 8 weeks after the mice 
received the rBCG boosters, it was shown that both CD8 and CD4 peptides elicited Gag-specific 
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IFN-a and TNF-a production. IL-4 and IL-5 were produced on stimulation with CD4 peptides. 
Higher levels of CD4 Gag-specific TNF-a, IL-4 and IL-5 were produced in the splenocytes of mice 
that received both the pTHGagC DNA vaccine prime followed by the rBCG:RT106 when 
compared to that produced in splenocytes from mice receiving only the pTHGagC DNA vaccine 
or those mice boosted with rBCG: 119L 1 e. The rBCG:RT106 vaccine was thus shown to be an 
effective Gag-specific CD8 and CD4 boost for the DNA prime. The cytokine production was 
boosted more effectively with a 103Cfu dose of rBCG:RT106 than a 105cfu dose. At 12 weeks, the 
Gag-specific production of cytokines was at a lower level than at 8 weeks. This indicates the 
importance of determining the timing of the peak response when measuring the vaccine-elicited 
immunogenlcity. The rBCG:RT106 vaccination again boosted the response to the pTHGagC 
prime compared to the rBCG: 119L 1 e boost. 
The ELiSPOT data point to a predominantly Th1 response after rBCG:RT106 boosting implying 
that the ex vivo response as seen by ELiSPOT assays was a Th1 response. The memory 
response which is measured by CBAwas also shown to be a predominantly Th1 response. 
This study was the first demonstration of cellular and humoral immune responses in mice to 
rBCG expressing a subtype C gag gene. The rBCG:RT106 vaccine was able to stimulate better 
cellular and humoral responses than rBCG:RT108. This implies that an initial high level of Gag 
expression. which may drop off gradually as the effects of construct Instability become apparent 
(rBCG:RT106) resulted in better immune responses in the mice than a lower level of Gag 
expression that is maintained (rBCG:RT108). Mederle et al. (2002) also reported that an initial 
high level of Gag expression in the rBCG was critical for the induction of cellular immune 
responses. 
The immunogenicity of rBCG:RT106 and rBCG:RT108 was also demonstrated In the baboon 
model In studies performed by Dr G.K. Chege in our laboratory (Appendix E). Dr Chege was able 
to show clearly that both rBCG:Gag constructs induced Gag-specific cellular immune responses 
145 
in the immunised baboons using an ELISPOT assay with pools of Gag peptides (Fig. E.1.). These 
responses were weak but they were efficiently boosted by Gag VLPs which were administered 
one year after the last rBCG immunization. An ELISA performed on the baboon sera showed that 
weak humoral response was detected in 1 of 4 immunised baboons after immunisation with 
rBCG:Gag (Table E.1.). However, antibodies against p24 were detected in all the rBCG:Gag 
immunised animals after the 1s1 Gag VLP boost, whereas they were only detectable in the 
rBCG:L 1-primed baboons after a Gag 2nd VLP boost. The rBCG:Gag vaccine induced weak 
humoral and cellular responses in the immunised animals but a single VLP immunisation was 
enough to give them a strong boost. Masemola at al. (2004) have identified and characterized 
epitopic regions across the Gag protein have in subtype C HIV-1-infected people in Southern 
Africa. Dr Chege found that several of these regions of Gag were also targeted by PBMC from 
Gag-immunized baboons. 
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CHAPTER 5: CONCLUSIONS 
This project is part of the efforts of the South African AIDS Vaccine Initiative group working at the 
University of Cape Town to develop an affordable and effective HIV~1 subtype C vaccine for South 
Africa. The group has a number of candidate vaccines in various stages of development and the work 
presented here is the initial foray into the use of recombinant BCG technology as a likely candidate. 
Since this was a first generation HIV-1 vaccine. the gene chosen for the rBCG vaccine was the gag 
gene. The Gag protein is one of the more conserved HIV-1 proteins and many reports have 
documented Gag-specific CTL responses in small animals. non-human primates and humans. Also, 
many other first generation CTL vaccines have been Gag-based. 
The selection of the isolate for use in the Gag vaccine was made from a group of recently transmitted 
viruses so that it would be as close to the currently circulating strains as possible. Subtype C HIV~1 
predominates in South Africa and all the viruses in the study were found to be subtype C. A Gag C 
consensus sequence was derived from all the sequences in the study and the vaccine strain isolate 
was chosen on the basis of its close relation to the consensus sequence. Du422 was selected since it 
was 98.7% similar to the consensus. Updated analyses performed at the time of writing, indicated that 
Du422 was a good choice as a regional Gag vaccine strain because it has not lost relevance since the 
original selection process - using a larger database of sequences and a current consensus sequence 
did not alter the fact that it is most closely related to the consensus. It was also shown to be 96% 
similar to the derived ancestral sequence and 97% similar to the derived consensus sequences for the 
whole of subtype C. Further, it was shown that Du422 was an appropriate choice for immunological 
reasons since it contains peptides recognised by southern African individuals that are infected with 
subtype C HIV-1. 
Since vaccine projects are long term efforts, the final outcome of which are only seen many years after 
the project commences, it is of great importance that proper care be taken when selecting the gene 
that will be used in the candidate. The fact that the samples used to make the selection at the start of 
this project were taken in 1999 meant that there was a possibility that the phylogeny of the South 
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African epidemic would evolve to make the choice of Du422 less optimal and the vaccine candidates 
less useful. However, analysis using updated datasets proved that Du422 has not lost relevance and 
that it was a good choice of Gag vaccine strain for the southern African region. The Du422 gag gene 
has been used in other SAAVI HIV-1 vaccine candidates including recombinant Salmonella vaccines, 
DNA vaccines (van Harmelen et al., 2003) and protein subunit vaccines (Jaffray et al., 2004). The 
gene has also been incorporated in a Venezuelan equine encephalitis VRP vaccine and an AAV 
vaccine that are currently being evaluated in clinical trials (http://www.hvtn.orgltrials and 
http://www.iavirep.org/trialsdb). The VRPOu422 candidate was the first HIV-1 vaccine to enter phase I 
trials in South Africa and the AAV candidate will be entering trials here in 2005. 
BCG, the tuberculosis vaccine, has a number of advantages associated with its use, including the fact 
that it is already in widespread use globally, it is safe, oral administration is possible, it has proven 
adjuvant potential and the capacity exists to manufacture the vaccine locally and inexpensively. 
However, there are practical limitations involved in working with BCG: it is a slow-growing organism 
that takes up to 2 weeks to grow in liquid culture and 3-4 weeks on solid media; the shuttle vectors 
used in rBCG technology are often genetically unstable and expression levels of the heterologous 
protein vary widely; monitoring the immune response to the heterologous protein is often difficult. 
In this study, the Du422 gag gene was cloned in 8 E. coli/Mycobacterium shuttle vectors that either 
integrated into the Mycobacterium genome or were maintained episomally. These vectors also differed 
with respect to the promoters used to drive expression of Gag (hsp60, M. leprae 18kDa, mtrA or katG) 
and the localization signals (a-antigen or 19kDa signals) fused to the gag gene. In order to determine 
which of the 8 shuttle vectors were the best candidates for use in an rBCG-HIV vaccine, the genetic 
stability and Gag expression levels were compared in vitro. A stable vaccine with high expression 
levels is important not only to ensure a good immune response in vaccinees but also for future scale-
up of the vaccine candidate from laboratory to population level doses. 
The genetic stability of the constructs was studied in recombinant M. smegma tis (rMS) by monitOring 
genetic rearrangement over time. rMS integrative vectors were found to be highly stable while the 
recombinants carrying the episomal vectors were less stable. rMS:RT105 (18kDa, a-antigen) 
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demonstrated rapid instability, Gag expression in combination with the 19kDa lipoprotein signal 
(rMS:RT106 and RT1 08) was more stable. Deletions that encompassed the promoter/signal sequence 
region and the gag gene were the source of the genetic instability. 
Comparison of the expression levels was also performed in rMS by measuring the p24 levels in 
cultures over time. The integrative constructs did not produce Gag at a high level and higher 
expression levels were observed for the episomal constructs. The katG promoter induced the lower 
expression levels for the episomal constructs than the mtrA and 18kDa promoters which were 
producing Gag at the highest level. The stability of the constructs appeared to be linked to the 
expression levels with the higher expressing episomal constructs being more unstable than the 
integrative ones. 
The use of colony-size comparisons on solid media and the indirect metabolic load measurement 
using differential growth at 42°C and 37°C was also used to compare the 8 recombinants. Importantly, 
results from this experiment were shown to support the data from the more accurate measurements of 
genetiC stability and p24 levels in rMS cultures. Larger colony sizes were seen in the lower expressing 
integrative constructs, with colony size decreasing as expression levels increased. Accumulation of 
misfolded or denatured Gag was hypothesized to create a metabolic load on the bacteria that would 
trigger the stress response and allow growth at 42°C. Again, the lower expressing integrative 
constructs did not experience a metabolic load high enough to trigger the heat shock response, while 
the higher expressing episomals were able to grow at 42°C. This provides a useful initial screening 
method for testing the utility of candidate shuttle vectors that is less labour-intensive and quicker than 
the conventional method of measuring expression levels directly. 
pRT106 (episomal, moderate expression, medium stability) and pRT108 (episomal, low expression, 
high stability) were selected for further investigations in rBCG since they were thought to combine the 
best mix of stability and expression level as well as practical ease-of-use (episomal). The expression 
of Gag from rBCG:RT106 and rBCG:RT108 (Tokyo and Pasteur) was evaluated in culture and in 
infected macrophages. Export of the Gag antigen to the membrane of the rBCG by the 19kDa 
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lipoprotein signal was not efficient and Gag was only expressed to a small percentage of the total BCG 
protein. As was seen in the rMS experiments, RT106 produced more Gag than RT108 in both rBCG 
Tokyo and Pasteur. Expression was successfully demonstrated for both recombinants in infected 
macrophages but in this case expression from the katG promoter (rBCG:RT108) was at the same level 
as expression from the mtrA promoter (rBCG:RT106) after both 24 and 48 hours of infection. 
Immunological testing of the rBCG:RT106 and rBCG:RT108 vaccines was undertaken in the BALB/c 
mouse model. 
Mice receiving 5 inoculations of either rBCG:RT106 or rBCG:RT108 (Tokyo) at 107cfu generated Gag-
specific T cells that were able to produce IFN-y when stimulated with rp24 or Gag VLPs. These mice 
were also able to generate anti-p24 antibodies. 
rBCG:RT106 (Pasteur) was tested at two different doses as a single inoculation or as a booster 
inoculation following a DNAGag prime. After a single inoculation, BCG-specific but not Gag-specific IFN-
y and IL-4 responses were induced in vaccinated mice as measured by ELISPOT. In addition, no anti-
p24 antibodies were detected by ELISA in the mouse sera. The DN~g prime was able to elicit Gag-
specific IFN-y and IL-4 responses (ELISPOT) and anti-p24 antibodies but these responses were not 
enhanced by the rBCG:RT106 boost even when compared to rBCG:119L1e boosted mice. As has 
been shown in other studies (Dudani et al., 2002 and Smith et al., 2002), the cellular response 
boosting with rBCG was suppressed in comparison to the response in mice receiving DNA-Gag only 
making it difficult to conclude whether there was no boosting effect or if this was masked. 
This ex vivo response was not mirrored in the memory or recall response seen in a CBA measuring 
CD8 and CD4 cytokine production in the mice than had received the DN~g prime and rBCG:RT106 
boost. The memory response demonstrated that rBCG:RT106 was an effective Gag-specific boost for 
the DNA prime. Gag-specific IFN-a, TNF-a, IL-4 and IL-5 were produced in the splenocytes of the 
vaccinated mice after 2 days of stimulation. There was a clear boosting effect seen particularly in the 
production of CD4 Gag-specific TNF-a, IL-4 and IL-5 in the splenocytes of mice that received both the 
DN~g prime followed by the rBCG:RT106 in comparison to mice receiving only the DNA vaccine or 
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mice boosted with rBCG:119L1e. This boost was shown to be time specific and dose dependent 
However, the assay again demonstrated that the rBCG vaccination had a suppressive effect on the 
overall response. Another finding was that both the ex vivo response and the memory response were 
predominantly Th1 responses. Since the CBA indicates the type of response (memory) one would 
expect in vaccinees upon challenge, it is a more informative result. 
These data were the first demonstration of cellular and humoral immune responses in mice to rBCG 
expressing a subtype C gag gene. rBCG:RT106 yielded better cellular and humoral responses than 
rBCG:RT10S. This implies that a higher initial level of Gag expression which waned as the effects of 
genetic instability became more pronounced was more effective than a lower level of expression that is 
maintained. These data also provide insight into the usefulness of the mouse model when studying 
responses to rBCG vaccine candidates. Since BCG tends to suppress the responses to non-BCG 
antigens in the mouse model, it is not well-suited to immunogenicity testing of rBCG candidates. As 
mentioned in section 4.4, work in our laboratory by Dr G.K. Chege has demonstrated that despite the 
difficulty in measuring the responses elicited by rBCG:RT106 and rBCG:RT10S in mice, good Gag-
specific cellular immune responses could be induced in the baboon model. 
In conclusion, Du422, a Gag vaccine strain highly suited to the southern African region was 
selected. The gag gene from this strain was cloned in E. coli/Mycobacterium shuttle vectors. The 
genetic stability and Gag expression levels of these shuttle vectors were evaluated in vitro in M. 
smegmatis and BCG. Cellular and humoral immune responses were demonstrated in the mouse 
model using rBCG:Gag subtype C vaccines. This study provides a good basis for the HIV-1 
subtype C rBCG vaccine candidate being developed by the UCT SAAVI group. It demonstrates 
that it is possible to generate an immune response to HIV-1 subtype C antigens expressed in 
rBCG. These vaccines may be useful in prime-boost modalities as shown in recent work by Dr 
Chege (section 4.4). Improvements in the expression level and construct stability are being 
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APPENDIX A: MEDIA, BUFFERS AND SOLUTIONS 
A.1. MEDIA 
Note: volumes were adjusted with distilled water unless otherwise indicated. 
2XYTMedium 








Broth (11): 4.7g Middlebrook's 7H9 
450111 Tween-80 
2.5ml 80% glycerol 
dH20 to 900ml 
Autoclave 
Add 100ml O-ADC 
Agar (11): 199 of Middlebrook's 7H10 
5ml glycerol 
dH20 to 900ml 
Mix thoroughly; boil for 1 min to dissolve fully; autoclave 
Add 100ml of O-ADC (State Vaccine Institute, SA) 
Sauton's Medium 




0.05g ferric ammonium citrate 
2.0g citric acid 
0.1mI1% ZnS04 
2.5ml 10% (w/v) tyloxapol 
pH to 7 with 2N KOH 
Autoclave. 
Resuspension medium for rBCG vaccine stocks 





R10 cell culture medium 
RPMI-1640 medium with Glutamax-1 containing 10% foetal bovine serum (FSS), 100units/mL 
Penicillin-G and 100 Ilg/mL Streptomycin 
A.2. BUFFERS AND SOLUTIONS 
Note: volumes were adjusted with distilled water unless otherwise indicated and all 





Mix in a ratio of 24: 1 
CTAB/NaCI 
Dissolve 4.1 9 NaCI in 80ml dH20 and slowly add 10g CTAS. 
Heat at 65"C to dissolve and adjust the volume to 1 OOml. 
Store at RT for no longer than 6 months. 
O.SM EOTA (SOOml) 
Dissolve 93.95g EDTA in 400ml dH20 by stirring vigorously. 
Adjust the pH to 8.0 with NaOH pellets (-10g). 
Autoclave. 
1M HCI (11) 
86.2ml HCI 
SM Potassium acetate (100ml) 
49.1 9 Potassium acetate 
Store at 4 "C. 
10% SOS 
10g SDS 
Heat to about 80"C to dissolve. 
Add a few drops of HCI to adjust pH to 7.2 
SM Sodium chloride/NaCI (100ml) 
29.22g NaCI 
Autoclave. 
10N Sodium hydroxide/NaOH (100ml) 
40g NaOH 
Store in a plastic container 
1 M Tris-CI (100ml) 
121.1g Tris 
Adjust pH to require level with concentrated HCI. 
Autoclave. 
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Tris-EDT AlTE buffer 
100mM Tris-CI (pH 8.0) 
1mM EDTA (pH 8.0) 
Autoclave 
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APPENDIX B: GENERAL MOLECULAR BIOLOGY PROTOCOLS 
B.1. TRANSFORMATION STUDIES 
Preparation of competent E.coli cells 
E.coli cells were made competent by a CaCl2-shock procedure based on the method described 
by Dagert and Ehrlich (1979). A single colony of the bacterium was inoculated into 5ml of 2x YT 
broth (Appendix A) and grown at 37°C overnight with shaking. This starter culture was diluted 
1/100 in 100ml of 2x YT broth and cultured to early logarithmic phase (ODsoo 0.2 to 0.4). The cells 
were harvested by centrifugation at SOOOrpm for 5 min at 4°C in a Beckman Model J2-21 
centrifuge. Cells were kept at 4°C during all subsequent procedures. Cells were resuspended in 
SOml ice-cold 0.1 M CaCI2 (Appendix A) and kept on ice for 1 hr. They were harvested as before 
and resuspended in 10ml ice-cold 0.1 M CaCI2• thereby inducing the transient state of 
competence. Ice-cold, sterile glycerol was added to the cells to a final concentration of 10% (v/v), 
mixed and held on ice for 30 min. Aliquots of the competent cells were stored at -80°C. 
Transformation 
Aliquots of competent cells were thawed on ice before addition of DNA. The tube was then held 
on ice for a further 20-30 min before heat shocking at 42°C for 2 min. 0.9ml of 2x YT broth was 
added to the tube and the cells incubated at 37°C for 1 hr. Transformation mixes were plated 
onto appropriate selective media and incubated at 37°C overnight. 
B.2. RESTRICTION ENDONUCLEASE DIGESTION 
DNA was digested with enzymes and buffers supplied by Roche (Basel, Switzerland). The 
appropriate buffers were used at 1x concentration with 0.5-1 U of enzyme in a total volume of 20111 
(made up with deionized water). All digests were performed at 37°C for 1-2 hr, except for 
genomic DNA digests, which were allowed to continue overnight. Digests with multiple enzymes 
were performed simultaneously using compatible buffers. 
B.3. DNA SEQUENCING 
All DNA sequencing was performed using a capillary system and Big Dye terminators on an 
automated DNA sequencer (ABIPRISM 3100 Sequencer; Applied Biosystems; Perkin Elmer; CA, 
USA). The sequencing was perfomed at the University of Stellenbosch (RSA). 
B.4. LIGATION 
Vector and insert DNA with compatible ends were ligated in volumes of 20lli. The insert:vector 
ratio in the ligation mix was 3:1 by weight. T4 DNA ligase (Roche, Basel, Switzerland) was used 
(2.5U/reaction) in 1x ligation buffer (Roche. Basel. Switzerland) and deionized water. Ligations 
185 
were performed at 16°C overnight. Control ligations testing ligase activity and levels of 
undigested vector and insert DNA were performed in parallel. 
B.S. GENOMIC DNA EXTRACTION FROM MYCOBACTERIA 
Genomic DNA was extracted following the method of Ausubel et al. (1987). Briefly, 5ml 
Mycobacterial cultures were harvested in a microfuge at 12000g for 2 min. The supernatant was 
discarded and the pellet resuspended in 500~1 TE buffer (Appendix A). The cells were lysed by 
the addition of 50~1 of lysozyme (10mg/ml) and incubation at 37°C for 1 hr. Further lysis and 
digestion of cellular proteins were achieved by the addition of 70".LI of 1 0% SDS (Appendix A) and 
3111 of proteinase K (20mg/ml). The suspension was mixed and incubated at 65°C for 10 min. To 
precipitate the cellular debris, 100lli of 5M NaCI (Appendix A) and 80111 of CTAB/NaCI (Appendix 
A) were added, mixed in thoroughly and incubated at 65°C for a further 10 min. An equal volume 
of chloroform/isoamyl alcohol (Appendix A) was added, the tubes were vortexed and centrifuged 
for 5 min at 12000g. The aqueous phase was transferred to a new tube and the DNA was 
preCipitated with 0.6x volume of isopropanol at -80°C for 1 hr. The DNA was collected by 
centrifugation at 12000g for 15 min. The DNA pellets were washed with 70% ethanol, air-dried 
and resuspended in 20111 of TE buffer. 
B.6. SOUTHERN TRANSFER 
DNA was transferred from agarose gels to Hybond™-N membranes (Amersham International, 
UK) using a mono-directional transfer based on the method of Smith and Summers (1980). 
Before the transfer was performed, the gel was soaked twice in 2-3 gel volumes of 0.25M HCI 
(Appendix A) for 15 min at room temperature. It was then soaked twice in 2-3 gel volumes of 
1.5M NaCI, 0.5M NaOH at room temperature for 15 min. Finally, it was neutralized by soaking it 
once in 2-3 gel volumes of 0.5M Tris pH7.2, 1.5M NaCI, 1mM EDTA at room temperature for 30 
min. Between each step and after neutralization, the gel was rinsed with water. On completion of 
the pretransfer treatment, DNA was transferred from the gel to the membrane. The gel was 
placed face down on a flat surface covered in a sheet of foil. A piece of Hybond™-N membrane 
was cut to size and layered onto the gel, ensuring that no air bubbles were trapped beneath it. 
Three pieces of Whatmans No.1 filter paper were soaked in neutralization solution and layered on 
the Hybond™-N. About 50mm of dry paper towel was placed on the filter paper, followed by a 
piece of Perspex and brick to compress the sandwich. Transfer was allowed to continue for 3 hr. 
The different materials were removed and the membrane was peeled off. The DNA was then 
fixed to the the membrane by UV cross-linking at 254nm in a UV Cross-linker (Hoefer Scientific 
Instruments, CA, USA) for 30 secs. 
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B.7. PLASMID EXTRACTION 
Small-scale plasmid extraction was performed on Sml cultures of putative recombinants. Two 
milliliters of each culture was pelleted at 14000rpm in a microfuge. Pellets were resuspended in 
0.2ml of Solution I (2SmM Tris-HCI pH8.0; SOmM EDTA, 1% w/v glucose). After resuspension, 
O.4ml of Solution II (0.2N NaOH; 1 % w/v SDS) was added; the tubes inverted to mix thoroughly 
and held on ice for S min. Pre-cooled Solution III (SM potassium acetate; 3M glacial acetic acid)-
03ml - was added and the tubes were kept on ice for a further S min. The precipitates were 
centrifuged at 14000rpm for 10 min; the supernatants were removed and centrifuged as before to 
further clarify them. The plasmid DNA was precipitated from the supernatants with 100% ethanol, 
washed with 70% ethanol, air-dried and resuspended in 20-S0~1 of TE buffer. 
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APPENDIX C: DNA SEQUENCES 






































Flg.C.1. SeqIJences of the gag gene cloned Into pRT001 and pRT002 
The restriction enzyme sites at the ends are underlined. The start and stop codons are indicated 
in bold. 
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pRT1 01: _"eo promoter + fIIII1 gene 
XbaI 
TCTAGACGGTGACCACAACGACGCGCCCGCTTTGATCGGGGACGTCTGCGGCCGACCATTTACGGGTCTTGTTGTCGTTGGCGGTCATGGGCCGAACATACTCACCCGGA 
-35 -10 tee 
TCGGAGGGCCGAGGACAAGGTCGAACGAGGGGCATGACCCGGTGCGGGGCTTCTTGCACTCGGCATAGGCGAGTGCTAAGAATAACGTTGGCACTCGCGACCGGTGAGTC 
GTAGGTCGGGACGGTGAGGCCAGGCCCGTCGTCGCAGCGAGTGGCAGCGAGGACAACTTGAGCCGTCCGTCGCGGGCACTGCGCCCGGCCAGCGTAAGTAGCGGGGTTGC 






pRT102: _peo promoter + u-antlgen signal + ,." gene 





Whole alpha antigen gene 
TTGGGGACGCCGATTGATGI,TCGGCACGGCAGCGGCTGTAGTCCTTCCGGj I CGCGGGCGGGCACAACGCCGTGTTCAACTTCCCGCCCAACGGCACGCACAGCTGGGAG 
BooRI gag 
TACTGGGGCGCTCAGCTCAACGCCATGAAGGGTGACCTGCAGAGTTCGTTAGGCGCGGATCC~GGGTGCGAGGCGTCAATATTFAGAGGGGA~AAATTAGAT 
M I GAACCCTTAACTTCCCTCIlAATC,A,CTCTTTGGCAGCGACCCCTTGTCTCAATAAAAGTAGGGGGCCAGACAAGGGAGGCTCTCTTAGACACAGGAGCAGATGATACA 
SalI HindIII 
GTATT~CTGCAGGCATGCAAGCTT 
FIg.C.1. DNA .. quences of the promoters, signal sequences and the gill gene for the different shuttle vectors 
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pRT103: hapeo promoter + 18kDa signal sequence + gllfl gene 


















RBS NdeI TSC 
~GC~G~CGCCCGTGTGGTGCGCC~GTTTTGTCCCG~TGTGGTG~C~CC~TaGAC~AAGCGTGGACTGACGGTCGCGGTAGCCGGAGCCGCCATTCTGGTCGC 






Flg.C.2. DNA sequences of the promoters, signal sequene .. and the gllfl gene for the different shuttle vectors, continued 
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pRT1OS: M./epru18kDa promoter + a. ... ntlg.n IlgnalHquence + 11118 gene 
XbaI 
TCTAG~TAGCCCGCAGCGTTCATAGAGCCGCAGCGACGGCACCGGG~CGCCGGAAAGTTCGGCCGCTACCGATGATGTCGTATACGCTGCGTTGCAGTGCCGACGTAC 
-35 -10 taa 
CCGTGCCGGCACTA~TCGGTCATGAGC~TCTCCTCAGCTGTTCAGACAG~CTTGTCTATCAC~CTTGCATC~TATATCGACCAGTGCTATATCAAATCTATG 
RBS NdeI TSC 
TAGTCAGG~CAGCTATATAGTTATAGTTTGTCA~CAGATTGGAGTGCaAaGTGACCA~CCACAGACGTGAGCCGAAAGATTCGAGCTTGGGGACGCCGATT 






















FIg.C.2. DNA sequ.ncel of the promotel'l, Ilgnal sequ.nc .. and th.,1. g.n. for the different Ihuttl. v.ctOI'l, continued 
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-35 -10 tee 
CATAACGGCTTCCTGTTG~CGAGGCGGAGGTCATCTACTGGGGTCTATGTCCTGATTGTTCGATATCCGACACTTCGCGATCACATCCGTGATCACAGCCCGATAACAC 












-35 -10 tee 
CATAACGGCTTCCTGTTGGACGAGGCGGAGGTCATCTACTGGGGTCTATGTCCTGATTGTTCGATATCCGACACTTCGCGATCACATCCGTGATCACAGCCCGATAACAC 
RBS NdeI TSC 19kDa signal 
CAACTCCT~~TCCATATGMGCGTGGACTGACGGTCGCGGTAGCCGGAGCCGCCATTCTGGTCGCAGGTCTTTCCGGATGTTCMGCMCMGTCGACTACAGGA 
ApaI gag 
AGCGGT GA GACCACGACCGCGGCAGGCACGACGGCMGCCCCGGCGGT~CATGGGTGCGAGAGCGTCM T,~ TT MGAGGGGlV'\NV\ TT AGA T AI I GMCCC TT MC 
ClaI 
TTCCCTCAAATCACTCTTTGGC}\GCGr~CCCCTTGTCTCMTAAAAGTAGGGGGCCAGACAAGGGAGGCTCTCTTAGACACAGGAGCAGATGATACAGTATTATCGAT 
Flg.C.2. DNA .. quences of the promotera, signal sequences and the fllIfI gene for the different shuttle vectora, continued 
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